Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Mar. 31, 2017	May 22, 2017	Sep. 30, 2016
DEI [Abstract]
Entity Registrant Name	STERIS plc
Entity Central Index Key	0001624899
Document Type	10-K
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		85,022,711
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$ 6,140,340,935
Entity Voluntary Filers	No

CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2017

Mar. 31, 2016

Statement of Financial Position [Abstract]

Allowance for Doubtful Accounts Receivable, Current

$ 10,357

$ 11,185

^[1]

Current assets:

Cash and cash equivalents

282,918

248,841

Accounts receivable (net of allowances of $10,357 and $11,185, respectively)

483,451

471,523

Inventories, net

197,837

192,792

Prepaid expenses and other current assets

53,596

59,369

Total current assets

1,017,802

972,525

Property, plant, and equipment, net

915,908

1,064,319

Intangible Assets, Net (Including Goodwill)

2,956,190

3,279,942

Other assets

34,555

29,630

Total assets

4,924,455

5,346,416

Current liabilities:

Accounts payable

133,479

139,572

Accrued Income Taxes, Current

14,640

13,683

Accrued payroll and other related liabilities

78,575

93,976

Accrued expenses and other

154,889

153,375

Total current liabilities

381,583

400,606

Long-term indebtedness

1,478,361

1,567,796

Deferred income taxes, net

171,805

254,824

Other Liabilities, Noncurrent

82,673

84,298

Total liabilities

2,114,422

2,307,524

Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding

Ordinary shares, with £0.10 par value; £17,006 aggregate par amount authorized; 84,948 and 85,920 ordinary shares issued and outstanding, respectively

2,085,134

2,151,719

Retained earnings

954,155

939,459

Accumulated other comprehensive income

(240,702)

(68,159)

Total shareholders' equity

2,798,602

3,023,034

Noncontrolling interest

11,431

15,858

Total equity

2,810,033

3,038,892

Total liabilities and equity

$ 4,924,455

$ 5,346,416

[1]	Net allowance for doubtful accounts and allowance for sales and returns.

CONSOLIDATED BALANCE SHEETS (Parenthetical)
£ in Thousands, $ in Thousands

Mar. 31, 2017

GBP (£)

£ / shares

Mar. 31, 2017

USD ($)

Mar. 31, 2016

GBP (£)

£ / shares

Mar. 31, 2016

USD ($)

Statement of Financial Position [Abstract]

Allowance for Doubtful Accounts Receivable, Current | $

$ 10,357

$ 11,185

^[1]

Serial preferred shares authorized

100,000

Serial preferred shares issued

100,000

Preferred Stock, Shares Outstanding

100,000

Preferred Stock, Par or Stated Value Per Share | £ / shares

£ 0.10

Aggregate Amount of Shares Authorized | £

£ 17,006

Common shares issued

84,948,000

85,920,000

Common shares outstanding

84,948,000

85,920,000

Common Stock, Par or Stated Value Per Share | £ / shares

£ 0.10

[1]	Net allowance for doubtful accounts and allowance for sales and returns.

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Product	$ 1,199,350	$ 1,130,046	$ 1,047,805
Service	1,413,406	1,108,718	802,458
Total revenues	2,612,756	2,238,764	1,850,263
Cost of revenues:
Product	624,542	618,161	584,210
Service	962,582	725,122	491,752
Total cost of revenues	1,587,124	1,343,283	1,075,962
Gross Profit	1,025,632	895,481	774,301
Operating expenses:
Selling, general, and administrative	680,069	626,710	493,342
Goodwill, Impairment Loss	58,356	0	0
Research and development	59,397	56,664	54,139
Restructuring Costs	215	(820)	(391)
Total operating expenses	798,037	682,554	547,090
Income (loss) from operations	227,595	212,927	227,211
Non-operating expenses, net:
Interest expense	44,520	42,708	19,187
Interest income and miscellaneous expense	(1,571)	(1,665)	(796)
Total non-operating expenses, net	42,949	41,043	18,391
Income (loss) before income tax expense (benefit)	184,646	171,884	208,820
Income tax expense (benefit)	74,015	60,299	73,756
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	110,631	111,585	135,064
Net Income (Loss) Attributable to Noncontrolling Interest	666	822	0
Net (loss) income	$ 109,965	$ 110,763	$ 135,064
Net income (loss) per common share
Basic	$ 1.29	$ 1.57	$ 2.27
Diluted	1.28	1.56	2.25
Cash dividends declared per common share outstanding	$ 1.09	$ 0.98	$ 0.90

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 110,631	$ 111,585	$ 135,064
Net Income (Loss) Attributable to Noncontrolling Interest	666	822	0
Net Income (Loss) Attributable to Parent	109,965	110,763	135,064
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Tax	963	(700)	4,007
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	851	(1,741)	507
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax	(7,463)	(3,032)	(6,461)
Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax	0	17,029	0
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(165,931)	(13,746)	(65,196)
Total other comprehensive loss attributable to shareholders	(172,543)	(1,490)	(71,150)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	(62,578)	109,273	63,914
Other Comprehensive Income (Loss), Available-for-sale Securities, Tax	402	(266)	85
Other Comprehensive Income (Loss), Defined Benefit Plan, Adjustment for Settlement or Curtailment Gain (Loss), Tax	0	10,563	0
Accumulated Other Comprehensive Income (Loss)
Net Income (Loss) Attributable to Parent		0	0
Total other comprehensive loss attributable to shareholders	$ (172,543)	$ (1,490)	$ (71,150)

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 110,631	$ 111,585	$ 135,064
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation, depletion, and amortization	188,142	143,740	91,541
Deferred income taxes	31,274	704	(4,916)
Share-based compensation	18,794	16,147	14,921
Pension Cost (Reversal of Cost)	0	26,470	0
Payment for Pension Benefits	0	(4,641)	0
Loss on the disposal of property, plant, equipment, and intangibles, net	760	1,813	(151)
Loss (Gain) on Disposition of Business	86,574	0	0
Excess Tax Benefit from Share-based Compensation, Operating Activities	0	(6,281)	(11,526)
Goodwill, Impairment Loss	58,356	0	0
Other items	(13,242)	(14,328)	(9,238)
Changes in operating assets and liabilities:
Accounts receivable, net	(48,140)	(31,560)	(2,774)
Inventories, net	(12,829)	1,810	(9,902)
Other current assets	2,324	(9,599)	2,089
Accounts payable	6,884	5,249	(3,146)
Accruals and other, net	(5,442)	13,566	44,078
Net cash provided by operating activities	424,086	254,675	246,040
Investing activities:
Purchases of property, plant, equipment, and intangibles, net	(172,901)	(126,407)	(85,255)
Proceeds from the sale of property, plant, equipment, and intangibles	4,846	844	829
Proceeds from Divestiture of Businesses	135,713	0	0
Payments to Acquire Investments	(6,356)	0	(4,681)
Investments in businesses, net of cash acquired	(65,557)	(604,021)	(194,662)
Net cash used in investing activities	(104,255)	(729,584)	(283,769)
Financing activities:
Proceeds from Issuance of Private Placement	293,730	350,000	0
Repayments of Long-term Debt	(172,500)	(92,567)	0
Proceeds Under Credit Facility, net	(196,613)	369,451	129,770
Amortization of Financing Costs	(1,073)	(5,169)	(14,370)
Payments of Merger Related Costs, Financing Activities	(9,918)	0	(1,250)
Repurchases of ordinary shares	(97,509)	(14,369)	(30,687)
Cash dividends paid to common shareholders	(93,193)	(65,203)	(53,513)
Proceeds from Issuance or Sale of Equity	5,022	625	0
Stock option and other equity transactions, net	4,955	11,240	28,274
Excess Tax Benefit from Share-based Compensation, Financing Activities	0	6,281	11,526
Net cash (used in) provided by financing activities	(267,099)	560,289	69,750
Effect of exchange rate changes on cash and cash equivalents	(18,655)	(4,228)	(17,134)
Increase (Decrease) in cash and cash equivalents	34,077	81,152	14,887
Cash and cash equivalents at beginning of period	248,841	167,689	152,802
Cash and cash equivalents at end of period	$ 282,918	$ 248,841	$ 167,689

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Ordinary Shares	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interest
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 1,041,246	$ 246,186	$ (324,202)	$ 1,112,240	$ 4,481	$ 2,541
Shares, Issued		58,968,000	11,072,000
Ordinary Shares, Dividends, Per Share, Cash Paid	$ 0.90
Net Income (Loss) Attributable to Parent	$ 135,064	$ 0	$ 0	135,064	0	0
Net Income (Loss) Attributable to Noncontrolling Interest	0
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	135,064
Total other comprehensive loss attributable to shareholders	(71,150)				(71,150)
Ordinary Shares, Acquired		(542,000)	(542,000)
Payments for Repurchase of Ordinary Shares	(30,687)	$ 0	$ (30,687)	0	0	0
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		1,249,000	(1,250,000)
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	41,687	$ 7,141	$ 34,546	0	0	0
Stock Issued During Period, Value, Stock Options Exercised		0	0
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	11,526	11,526	0	0	0	0
Dividends, Ordinary Shares, Cash	(53,513)	0	0	(53,513)	0	0
Noncontrolling Interest, Change in Redemption Value	(527)	0	0	0	0	(527)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 1,073,646	$ 264,853	$ (320,343)	1,193,791	(66,669)	2,014
Shares, Issued		59,675,000	10,364,000
Ordinary Shares, Dividends, Per Share, Cash Paid	$ 0.98
Net Income (Loss) Attributable to Parent	$ 110,763	$ 0	$ 0	110,763	0	822
Net Income (Loss) Attributable to Noncontrolling Interest	822
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	111,585
Total other comprehensive loss attributable to shareholders	(1,490)				(1,490)
Ordinary Shares, Acquired		(267,000)	(248,000)
Payments for Repurchase of Ordinary Shares	(14,369)	$ 1,020	$ (12,974)	(375)	0	13,574
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		664,000	(538,000)
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	27,291	$ 13,624	$ 13,667	0	0	0
Noncontrolling Interest, Increase from Subsidiary Equity Issuance	1,443					1,443
Stock Repurchased and Retired During Period, Value	(319,650)	$ 20,133		299,517
Noncontrolling Interest, Increase from Business Combination		25,839,000
Treasury Stock, Shares, Retired			(10,074,000)
Stock Issued During Period, Value, Acquisitions	1,901,068	$ 1,887,479
Purchase of subsidiary shares from non controlling interests		9,000
Purchase of subsidiary shares from non controlling interest		$ 635
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests	(818)					(1,453)
Stock Issued During Period, Value, Stock Options Exercised		0	$ 0
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	6,281	6,281
Excess tax benefit from share-based compensation			0	0	0	0
Dividends, Ordinary Shares, Cash	(65,203)	0	0	(65,203)	0	0
Noncontrolling Interest, Change in Redemption Value	(542)	0	0	0	0	(542)
Net Income (Loss) Attributable to Parent	57,740
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,038,892
Stockholders' Equity Attributable to Parent	3,023,034	$ 2,151,719	$ 0	939,459	(68,159)
Noncontrolling interest	$ 15,858					15,858
Shares, Issued		85,920,000	0
Preferred Stock, Shares Outstanding	100,000
Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding	$ 15
Ordinary Shares, Dividends, Per Share, Cash Paid	$ 1.09
Net Income (Loss) Attributable to Parent	$ 109,965			109,965
Net Income (Loss) Attributable to Noncontrolling Interest	666					666
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	110,631
Total other comprehensive loss attributable to shareholders	(172,543)				(172,543)
Ordinary Shares, Acquired		(1,455,000)	0
Payments for Repurchase of Ordinary Shares	(97,509)	$ 95,433	$ 0	2,076	0
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures		416,000	0
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	23,826	$ 23,826	$ 0	0	0	0
Noncontrolling Interest, Increase from Subsidiary Equity Issuance	530					530
Purchase of subsidiary shares from non controlling interests		67,000
Purchase of subsidiary shares from non controlling interest		$ 5,022
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests	(352)					(5,374)
Dividends, Ordinary Shares, Cash	(93,193)	0	0	(93,193)	0	0
Noncontrolling Interest, Change in Redemption Value	(249)					(249)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	2,810,033
Stockholders' Equity Attributable to Parent	2,798,602	$ 2,085,134	$ 0	$ 954,155	$ (240,702)
Noncontrolling interest	$ 11,431					$ 11,431
Shares, Issued		84,948,000	0
Preferred Stock, Shares Outstanding	100,000
Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding	$ 15

Nature of Operations and Summary of Significant Accounting Policies

12 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations. STERIS plc (“Parent”) was organized in 2014 under the laws of England and Wales under the name Solar New HoldCo Limited as a private limited company for the purpose of effecting the combination (“Combination”) of STERIS Corporation, an Ohio corporation (“Old STERIS”), and Synergy Health plc, a public limited company organized under the laws of England and Wales (“Synergy”). Effective November 2, 2015, the Parent was re-registered as a public company under the name of STERIS plc and the Combination closed. As a result of the Combination closing, STERIS plc became the ultimate parent company of Old STERIS and Synergy. Synergy has been re-registered under the name of Synergy Health Limited. The acquisition of Old STERIS was accounted for in the consolidated financial statements as a merger between entities under common control; accordingly the historical consolidated financial statements of Old STERIS for periods prior to November 2, 2015, are considered to be the historical financial statements of STERIS plc. Due to the timing of the Combination, the results of Synergy are only reflected in the results of operations of the Company from November 2, 2015, forward and will affect the comparability to the prior period historical operations of the Company throughout this Annual Report on Form 10-K.

STERIS develops, manufactures and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental Customers throughout the world.

As a result of the Combination, we reorganized our operations into four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. We describe our business segments in Note 11 to our consolidated financial statements titled, "Business Segment Information."

Our fiscal year ends on March 31. References in this Annual Report to a particular "year," "fiscal year," or "year-end" mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below.

Principles of Consolidation. We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. In prior periods, we presented income attributable to noncontrolling interests in the "Interest income and miscellaneous expense" line of our Consolidated Statements of Income and the amounts were not material.

Use of Estimates. We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available.

Cash Equivalents and Supplemental Cash Flow Information. Cash equivalents are all highly liquid investments with a maturity of three months or less when purchased. We invest our excess cash in short-term instruments including money market funds and time deposits with major banks and financial institutions. We select investments in accordance with the criteria established in our investment policy. Our investment policy specifies, among other things, maturity, credit quality and concentration restrictions with the objective of preserving capital and maintaining adequate liquidity.

Information supplementing our Consolidated Statements of Cash Flows is as follows:



Years Ended March 31,	2017		2016		2015
Cash paid during the year for:
Interest	$	42,797	$	37,165	$	19,124
Income taxes	78,009		60,885		52,707
Cash received during the year for income tax refunds	2,002		1,697		2,405

Revenue Recognition. We recognize revenue for products when ownership passes to the Customer, which is based on contract or shipping terms and for services when the service is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor. We have no further obligations related to bringing about resale and our standard return and restocking fee policies are applied. Revenues are reported net of sales and value-added taxes collected from Customers.

We also have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. Returns, rebates, and similar allowances are estimated based on historical experience and trend analysis.

In transactions that contain multiple elements, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each element based on its relative fair value, based on the price for the product or service when it is sold separately.

We offer preventive maintenance agreements to our Customers with contract terms of one to five years which require us to maintain and repair our products during this time. Amounts received under these Customer contracts are initially recorded as deferred service revenues and then recognized as service revenues ratably over the contract term.

Accounts Receivable. Accounts receivable are presented at their face amount, less allowances for sales returns and uncollectible accounts. Accounts receivable consist of amounts billed and currently due from Customers and amounts earned but unbilled. We generally obtain and perfect security interest in products sold in the United States when we have a concern with the Customer's risk profile.

We maintain an allowance for uncollectible accounts receivable for estimated losses in the collection of amounts owed by Customers. We estimate the allowance based on analyzing a number of factors, including amounts written off historically, Customer payment practices, and general economic conditions. We also analyze significant Customer accounts on a regular basis and record a specific allowance when we become aware of a specific Customer’s inability to pay. As a result, the related accounts receivable are reduced to an amount that we reasonably believe is collectible.

We maintain an allowance for sales returns based upon known returns and estimated returns for both capital equipment and consumables. We estimate returns of capital equipment and consumables based upon recent historical experience.

Inventories, net. Inventories are stated at the lower of their cost or market value. We determine cost based upon a combination of the last-in, first-out (“LIFO”) and first-in, first-out (“FIFO”) cost methods. For inventories valued using the LIFO method, we believe that the use of the LIFO method results in a matching of current costs and revenues. Inventories valued using the LIFO method represented approximately 29.0% and 31.0% of total inventories at March 31, 2017 and 2016, respectively. Inventory costs include material, labor, and overhead. If we had used only the FIFO method of inventory costing, inventories would have been $16,706 and $17,608 higher than those reported at March 31, 2017 and 2016, respectively.

We review inventory on an ongoing basis, considering factors such as deterioration, obsolescence, and other items. We record an allowance for estimated losses when the facts and circumstances indicate that particular inventories will not be usable. If future market conditions vary from those projected, and our estimates prove to be inaccurate, we may be required to write-down inventory values and record an adjustment to cost of revenues.

Property, Plant, and Equipment. Our property, plant, and equipment consists of land and land improvements, buildings and leasehold improvements, machinery and equipment, information systems, radioisotope (cobalt-60), linens and construction in progress. Property, plant, and equipment are presented at cost less accumulated depreciation and depletion. We capitalize additions and improvements. Repairs and maintenance are charged to expense as they are incurred.

Land is not depreciated and construction in progress is not depreciated until placed in service. Depreciation of most assets is computed on the cost less the estimated salvage value by using the straight-line method over the estimated remaining useful lives. Depletion of radioisotope is computed using the annual decay factor of the material, which is similar to the sum-of-the-years-digits method.

We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table:



Asset Type		Useful Life (years)
Land improvements		3-40
Buildings and leasehold improvements		2-50
Machinery and equipment		2-20
Information Systems		2-20
Radioisotope (cobalt-60)		20
Linens		1-5

When we sell, retire, or dispose of property, plant, and equipment, we remove the asset’s cost and accumulated depreciation from our Consolidated Balance Sheet. We recognize the net gain or loss on the sale or disposition in the Consolidated Statements of Income in the period when the transaction occurs.

Interest. We capitalize interest costs incurred during the construction of long-lived assets. We capitalized interest costs of $1,141 and $723 for the years ended March 31, 2017 and 2016, respectively. Total interest expense for the years ended March 31, 2017, 2016, and 2015 was $44,520, $42,708, and $19,187, respectively.

Identifiable Intangible Assets. Our identifiable intangible assets include product technology rights, trademarks, licenses, and Customer and vendor relationships. We record these assets at cost, or when acquired as part of a business acquisition, at estimated fair value. We generally amortize identifiable intangible assets over periods ranging from 5 to 20 years using the straight-line method. Our intangible assets also include indefinite lived assets including certain trademarks and tradenames that were acquired in connection with business combinations. These assets are tested at least annually for impairment.

Investments. Investments in marketable securities are stated at fair value and are included in "Other assets" on the Consolidated Balance Sheets. Unrealized gains and losses on marketable securities classified as available-for-sale are recorded in Accumulated Other Comprehensive Income (Loss).

Asset Impairment Losses. Property, plant, equipment, and identifiable intangible assets are reviewed for impairment when indicators of impairment exist and circumstances indicate that the carrying value of such assets may not be recoverable. Impaired assets are recorded at the lower of carrying value or estimated fair value. We monitor for such indicators on an ongoing basis and if an impairment exists, we record the loss in the Consolidated Statements of Income during that period.

Asset Retirement Obligations. We incur retirement obligations for certain assets. We recorded initial liabilities for the asset retirement obligations ("ARO") at fair value. Recognition of ARO includes: estimating the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and a periodic review of the ARO liability estimates and discount rates used in the analysis. We provide additional information about our asset retirement obligations in Note 5 to our consolidated financial statements titled, “Property, Plant and Equipment.”

Acquisitions of Business. Assets acquired and liabilities assumed in a business combination are accounted for at fair value on the date of acquisition. Costs related to the acquisition are expensed as incurred.

Goodwill. We perform our annual impairment test for goodwill in the third quarter of each year. We may consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. We may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. We review the book value compared to the fair value at the reporting unit level. We calculate the fair value of our reporting units based on the present value of estimated future cash flows. Considerable management judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows to measure fair value. Assumptions used in our impairment evaluations, such as forecasted growth rates and cost of capital, are consistent with internal projections, strategic plans, and operating plans. We believe such assumptions and estimates are also comparable to those that would be used by other marketplace participants.

Self-Insurance Liabilities. We record a liability for self-insured risks that we retain for general and product liabilities, workers’ compensation, and automobile liabilities based on actuarial calculations. We use our historical loss experience and actuarial methods to calculate the liability. This liability includes estimates for both losses and incurred but not reported claims. We review the assumptions used to calculate the estimated liability at least annually to evaluate the adequacy of the amount recorded. We maintain insurance policies to cover losses greater than our estimated liability, which are subject to the terms and conditions of those policies. We are also self-insured for certain employee medical claims. We estimate a liability for incurred but not reported claims based upon recent claims experience.

Benefit Plans. We sponsor defined benefit pension plans. We also sponsor a post-retirement benefits plan for certain former employees. We determine our costs and obligations related to these plans by evaluating input from third-party professional advisers. These costs and obligations are affected by assumptions including the discount rate, expected long-term rate of return on plan assets, the annual rate of change in compensation for eligible employees, estimated changes in costs of healthcare benefits, and other factors. We review the assumptions used on an annual basis.

We recognize an asset for the overfunded status or a liability for the underfunded status of defined benefit pension and post-retirement benefits plans in our consolidated balance sheets. This amount is measured as the difference between the fair value of plan assets and the benefit obligation (the projected benefit obligation for pension plans and the accumulated post-retirement benefit obligation for other post-retirement benefit plans). Changes in the funded status of the plans are recorded in other comprehensive income in the year they occur. We measure plan assets and obligations as of the balance sheet date. We provide additional information about our pension and other post-retirement benefits plans in Note 9 to our consolidated financial statements titled, “Benefit Plans.”

Fair Value of Financial Instruments. Except for long-term debt, our financial instruments are highly liquid or have short-term maturities. We provide additional information about the fair value of our financial instruments in Note 17 titled, “Fair Value Measurements.”

Foreign Currency Translation. Most of our operations use their local currency as their functional currency. Financial statements of subsidiaries are translated into U.S. dollars using the exchange rate at each balance sheet date for assets and liabilities and a weighted average exchange rate for each period for revenues, expenses, gains and losses. Translation adjustments for subsidiaries whose local currency is their functional currency are recorded as a component of accumulated other comprehensive income (loss) within equity. Transaction gains and losses resulting from fluctuations in currency exchange rates on transactions denominated in currencies other than the functional currency are recognized as incurred in the accompanying Consolidated Statement of Income, except for certain inter-company balances designated as long-term investments.

Forward and Swap Contracts. We enter into foreign currency forward contracts to hedge assets and liabilities denominated in foreign currencies, including inter-company transactions. We do not use derivative financial instruments for speculative purposes. These contracts are marked to market, with gains and losses recognized within “Selling, general, and administrative expenses” or "Cost of revenues" in the accompanying Consolidated Statements of Income.

Warranty. Warranties are provided on the sale of certain of our products and services and an accrual for estimated future claims is recorded at the time revenue is recognized. We estimate warranty expense based primarily on historical warranty claim experience.

Shipping and Handling. We record shipping and handling costs in costs of revenues. Shipping and handling costs charged to Customers are recorded as revenues in the period the product revenues are recognized.

Advertising Expenses. Costs incurred for communicating, advertising and promoting our products are generally expensed when incurred as a component of Selling, General and Administrative Expense. We incurred $12,622, $10,785, and $9,732 of advertising costs during the years ended March 31, 2017, 2016, and 2015, respectively.

Research and Development. We incur research and development costs associated with commercial products and expense these costs as incurred. If a Customer reimburses us for research and development costs, the costs are charged to the related contracts as costs of revenues.

Income Taxes. We defer income taxes for all temporary differences between pre-tax financial and taxable income and between the book and tax basis of assets and liabilities. We record valuation allowances to reduce net deferred tax assets to an amount that we expect will more-likely-than-not be realized. In making such a determination, we consider all available information, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and if applicable, any carryback claims that can be filed. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes and the effective tax rate.

We evaluate uncertain tax positions in accordance with a two-step process. The first step is recognition: The determination of whether or not it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, we presume that the position will be examined by the appropriate tax authority and that the tax authority will have full knowledge of all relevant information. The second step is measurement: A tax position that meets the more-likely-than-not threshold is measured to determine the amount of benefit to recognize in the financial statements. The measurement process requires the determination of the range of possible settlement amounts and the probability of achieving each of the possible settlements. The tax position is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. No tax benefits are recognized for positions that do not meet the more-likely-than-not threshold. Tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not recognition threshold are derecognized in the first subsequent financial reporting period in which the threshold is no longer met. We describe income taxes further in Note 8 to our consolidated financial statements titled, “Income Taxes.”

Medical Device Excise Tax. The Medical Device Excise Tax became effective January 1, 2013. The excise tax was mandated by the 2010 health care reform legislation and assesses a 2.3% tax on the sale or use of certain medical devices that are sold or manufactured in the United States. Many of our products are subject to the excise tax. Late in 2015, Congress enacted legislation that suspended the excise tax for 2016 and 2017. As a result, we did not incur Medical Device Excise taxes during fiscal 2017. We incurred Medical Device Excise taxes of $5,802, and $7,917 during fiscal years 2016 and 2015, respectively, which was included in cost of revenues in the period of sale.

Share-Based Compensation. We describe share-based compensation in Note 14 to our consolidated financial statements titled, “Share-Based Compensation.” We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. We record liability awards at fair value each reporting period and the change in fair value is reflected as share-based compensation expense in our Consolidated Statements of Income. The expense is classified as cost of goods sold, selling, general and administrative expenses or research and development expenses in a manner consistent with the employee’s compensation and benefits. These costs are recognized in the Consolidated Statement of Income over the period during which an employee is required to provide service in exchange for the award.

Restructuring. We recognize restructuring expenses as incurred. Asset impairment and accelerated depreciation expenses primarily relate to inventory write-downs for rationalized products and adjustments in the carrying value of the related facilities and machinery and equipment to their estimated fair value. In addition, the remaining useful lives of other property, plant, and equipment associated with the related operations are reevaluated based on the respective restructuring plan, which may result in the acceleration of depreciation and amortization of certain assets.

Recently Issued Accounting Standards Impacting the Company

Recently Issued Accounting Standards Impacting the Company are presented in the following table:



Standard	Date of Issuance	Description	Date of Adoption	Effect on the financial statements or other significant matters
Standards that have recently been adopted
ASU 2015-05, "Goodwill and other-Internal-Use Software" (Subtopic 350-40)	April 2015	The standard provides guidance on a customer's accounting for fees paid in cloud computing arrangements. Previously, there was no U.S. GAAP guidance on accounting for such fees from the customer's perspective. Under the standard, customers will apply the same criteria as vendors to determine whether the arrangement contains a software license or is solely a service contract. The determination could impact the classification of advance payments in the statements of financial position and cash flows as well as the classification of the expenses in the results of operations. The standard is effective for annual periods beginning after December 15, 2015 and interim periods within that period. Early adoption is permitted.	First Quarter Fiscal 2017	The prospective adoption of this standard did not have a material impact on our statements of consolidated financial position, results of operations and cash flows.
ASU 2015-07, "Fair Value Measurement: Disclosures for Investments in Certain Entities that Calculate Net Asset Value per Share (or its Equivalent)" (Topic 820)	May 2015	This standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the asset value per share practical expedient. The standard also removes the requirement to make certain disclosures for these investments that are eligible to be measured at fair value using the net asset value per share practical expedient.	Fourth Quarter Fiscal 2017	We retrospectively applied the requirements of this standard to investments that use net asset value per share as a practical expedient for all comparative periods presented in Note 9. Benefit Plans and Note 17. Fair Value Measurements.
ASU 2016-09, "Stock Compensation: Improvements to Employee Share-Based Payment Accounting" (Topic 718)	March 2016	The update simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, the classification of awards as either equity or liabilities, and the classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted.	First Quarter Fiscal 2017	As a result of the adoption of this standard, we recorded $5.1 million of excess tax benefits associated with share based compensation in the Consolidated Statements of Income for the year-ended March 31, 2017 and have included the associated cash flows as cash provided by operating activities. Prior periods have not been restated.



Standards that have not yet been adopted
ASU 2014-09, "Revenue from Contracts with Customers" and subsequently issued amendments	May 2014	The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is not permitted before the original public entity effective date of December 15, 2016.	N/A	We have not completed our assessment of the new revenue recognition standard, however, we currently anticipate adopting this standard using the modified-retrospective method. We are in the process of quantifying the potential impacts that the standard will have on our consolidated statements of financial position, results of operations and cash flows.
ASU 2015-11, "Inventory - Simplifying the Measurement of Inventory" (Topic 330)	July 2015	The standard requires an entity to measure inventory within the scope of this update at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years and should be applied prospectively. Early adoption is permitted.	N/A	We do not expect the adoption of this standard to have a material impact on our consolidated financial statements.
ASU 2016-01, "Financial Instruments - Overall - Recognition and Measurement of Financial Assets and Liabilities" (Subtopic 825-10)	January 2016	The standard changes how equity investments are measured and presents changes in the fair value of financial liabilities measured under the fair value option. Presentation and disclosure requirements for financial instruments are also affected. Entities will be required to measure equity investments that do not result in consolidation and are not recorded under the equity method at fair value with changes in fair value recognized in net income. The standard clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.	N/A	We are in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows.
ASU 2016-02, "Leases" (Topic 842)	February 2016	The update will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted.	N/A	We are in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows.



ASU 2016-07, "Investments - Equity Method and Joint Ventures, Simplifying the Transition to the Equity Method of Accounting" (Topic 323)	March 2016	The update replaces the previous requirement to retroactively adopt the equity method. The new standard requires that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor's previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted.	N/A	We do not expect the adoption of this standard to have a material impact on our statements of consolidated financial position, results of operations and cash flows.
ASU 2016-15, "Statement of Cash Flows" (Topic 230)	August 2016	This update provides guidance on the following specific cash flow issues: Debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, beneficial interests in securitization transactions, and separately identifiable cash flows and application of the predominance principle. The standard is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is permitted.	N/A	We are in the process of evaluating the impact that the standard will have on our statement of cash flows.
ASU 2016-16, "Income Taxes, Intra-Entity Transfers of Assets Other Than Inventory" (Topic 740)	October 2016	The update improves the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. The new standard requires the recognition of income tax consequences resulting from an intra-entity transfer of an asset other than inventory when the transfer occurs. The standard is effective for annual periods beginning after December 15, 2018. Early adoption is permitted.	N/A	We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.
ASU 2017-04, "Intangibles - Goodwill and Other, Simplifying the Test for Goodwill Impairment" (Topic 350)	January 2017	This update eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedures that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, under the amendments of this standard, an entity would perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. The loss should not exceed the total amount of goodwill allocated to that reporting unit. Tax effects should be considered. The standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted.	N/A	We are in process of evaluating the impact that the standard will have on our annual goodwill impairment test.




ASU 2017-07 "Compensation - Retirement Benefits - Improving the Presentation of Net Periodic Pension and Net Periodic Postretirement Benefit Cost" (Topic 715)	March 2017	This standard requires that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside the subtotal of income from operations, if one is presented.	N/A	We are in process of evaluating the impact that the standard will have on our annual goodwill impairment test.

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)

12 Months Ended

Mar. 31, 2017

Business Combinations and Divestitures [Abstract]

Business Combination Disclosure [Text Block]

Fiscal 2017 Acquisitions

Compass Medical, Inc.

On September 16, 2016, we purchased the assets of Compass Medical, Inc. ("Compass'') for approximately $16.0 million. The purchase price was financed with bank credit facility borrowings. Compass specializes in the sale and repair of flexible endoscopes. On an annual basis, Compass has generated revenues of approximately $6.0 million and is being integrated into our Healthcare Specialty Services segment.

Phoenix Surgical Holdings, Ltd. and Endo-Tek LLP

On August 31, 2016, we purchased 100% of the shares of Phoenix Surgical Holdings, Ltd. and the assets of Endo-Tek LLP ("Phoenix Surgical and Endo-Tek") for approximately $14.3 million combined, net of cash acquired. The purchase price was financed with cash on hand. On an annual basis, these operations, which specialize in the repair of endoscopes, generated approximately $8.0 million in combined revenue and is being integrated into our Healthcare Specialty Services segment.

Medisafe

On July 22, 2016, we purchased 100% of the shares of Medisafe Holdings, Ltd. ("Medisafe"), a U.K. manufacturer of washer/disinfector equipment and related consumables and services for approximately $34.5 million, net of cash acquired. The purchase price was financed with cash on hand. On an annual basis, the Medisafe product line has generated $18.0 million in revenue. The acquisition of Medisafe provides washer manufacturing and research and development capabilities in the U.K. Medisafe's products and services is being integrated into our Healthcare Products segment.

Fiscal 2016 Acquisitions

Synergy Health plc

On November 2, 2015, STERIS acquired all outstanding shares of Synergy in a cash and stock transaction valued at £24.80 ($38.17) per Synergy share, or a total of approximately $2.3 billion based on the low trading price of Old STERIS’s stock of $73.02 per share on November 2, 2015. The Combination brought together businesses that generate revenues from over 100 countries and that are geographically complementary. Total costs of approximately $63,789 before tax were incurred during fiscal year 2016 related to the Combination and are reported in Selling, general and administrative expense.

Total consideration for the transaction is presented in the table below. At the closing date of the Combination, vested share option awards remained outstanding under Synergy's Save As You Earn Plans ("SAYE"). In accordance with the provisions of SAYE, vested option awards were exercisable to the extent that the exercise price funds had been accumulated in accordance with the option holder's savings contract. The number of Synergy shares issued were fair valued based on the same cash and stock consideration available to other Synergy shareholders at the time of the Combination.



Cash consideration	$	402,494
STERIS plc shares (25,848,798 ordinary shares issued)	1,887,479
Fair value of consideration available to vested Synergy share option holders	4,819
Total purchase consideration	$	2,294,792

The acquisition of Synergy has been accounted for using the acquisition method of accounting which requires, among other things, the assets acquired, liabilities assumed and noncontrolling interests be recognized at their respective fair values as of the acquisition date. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates.

During the fiscal 2017 third quarter, adjustments were made to finalize the opening balance sheet fair value estimates. Adjustments related primarily to property, plant and equipment, intangible assets and goodwill. The cumulative impact of the final purchase price allocation resulted in a cumulative decrease in depreciation, amortization and depletion expense of approximately $20 million, of which approximately $17 million was recorded within Selling, general and administrative expense and approximately $3 million was recorded within Cost of revenues in the Consolidated Statements of Income. The cumulative foreign currency translation adjustment recorded as a result of the finalization of purchase accounting was approximately $170 million. The purchase price allocation below represents Synergy's opening balance sheet as of November 2, 2015:



	November 2, 2015 (as previously reported)			Adjustments			November 2, 2015 (revised)
Cash	$	53,057		$	—		$	53,057
Accounts receivable	107,341			(4,248		)	103,093
Inventory	30,074			—			30,074
Property, plant and equipment	534,879			(38,324		)	496,555
Other assets	19,708			(533		)	19,175
Intangible assets	806,526			(302,330		)	504,196
Goodwill	1,411,781			273,743			1,685,524
Total assets	2,963,366			(71,692		)	2,891,674

Current liabilities	(108,192		)	260			(107,932		)

Long-term indebtedness	(321,082		)	—			(321,082		)
Non-current liabilities	(230,544		)	71,432			(159,112		)
Total Liabilities	(659,818		)	71,692			(588,126		)

Net Assets	$	2,303,548		$	—		$	2,303,548

The fair value of machinery and equipment was primarily determined using the cost approach, considering replacement cost, reproduction costs and trend factors based on price indices, which are classified as level 2 inputs within the fair value hierarchy.

The fair values of intangible assets were determined using an income approach considering useful lives, future revenues and margins and a risk adjusted discount rate, which are classified as level 3 inputs within the fair value hierarchy. The estimated fair values and useful lives of these intangible assets are as follows:



	Total		Useful Life
Customer relationships	$	459,074	15 years
Trade names	19,404		15 years
Technology	25,718		6 years
Total intangible assets acquired	$	504,196

Goodwill was allocated to the Applied Sterilization Technologies and Healthcare Specialty Services segments. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce, which are further described above. Goodwill recognized as a result of the acquisition is not deductible for income tax reporting purposes.

Contingent liabilities assumed as part of the Combination totaled $3,031 at the date of the Combination, and were included within accrued expenses and other liabilities in the consolidated balance sheet. These contingent liabilities included $1,470 related to income taxes (including uncertain tax positions) and $1,561 related to contingent consideration associated with prior acquisitions completed by Synergy. Contingent liabilities were recorded at their estimated fair values, aside from those pertaining to uncertainty in income taxes which are an exception to the fair value basis of accounting. See Note 17, titled "Fair Value Measurements" to the consolidated financial statements for additional information on contingent liabilities.

Actual and Pro Forma Impact

Our fiscal 2016 consolidated financial statements include Synergy's results of operations from the date of acquisition on November 2, 2015 through March 31, 2016. Net sales and operating income attributable to Synergy during this period and included in our consolidated financial statements for the fiscal year ended March 31, 2016 total $254,911 and $3,695, respectively.

The following unaudited pro forma information gives effect to our acquisition of Synergy as if the acquisition had occurred on April 1, 2014 and Synergy had been included in our consolidated results of operations for fiscal years ended March 31, 2016 and March 31, 2015.



	Fiscal Year Ended March 31,
Amounts are unaudited	2016		2015
Net revenues	$	2,619,056	$	2,499,140
Net income from continuing operations	188,269		152,057

The historical consolidated financial information of STERIS and Synergy has been adjusted in the pro forma information to give effect to pro forma events that are (1) directly attributable to the transaction, (2) factually supportable and (3) expected to have a continuing impact on the combined results. In order to reflect the occurrence of the acquisition on April 1, 2014 as required, the unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up, the incremental depreciation from the fair value adjustments to property, plant and equipment, and the incremental intangible asset amortization to be incurred based on the valuations of the assets acquired. Adjustments to financing costs and income tax expense also were made to reflect the capital structure and anticipated effective tax rate of the combined entity. These pro forma amounts are not necessarily indicative of the results that would have been obtained if the acquisition had occurred as of the beginning of the period presented or that may occur in the future, and does not reflect future synergies, integration costs, or other such costs or savings.

Gepco

On July 31, 2015, we acquired all of the outstanding shares of General Econopak, Inc. (“Gepco”), since renamed STERIS Barrier Products Solutions, Inc., for a purchase price of $176,474 in cash, including a customary working capital adjustment. Gepco is a Pennsylvania-based manufacturer of product solutions in the areas of sterility maintenance, barrier protection, and sterile cleanroom products for pharmaceutical, biotechnology and veterinary Customers. Gepco has been integrated into our Life Sciences business segment. The purchase price was financed through a combination of credit facility borrowings and cash on hand. The purchase price has been allocated to the net assets acquired based on fair values at the acquisition date. The acquisition qualified for joint election tax benefit under Section 338 (h)(10) of the Internal Revenue Code, which allows goodwill and intangibles to be fully deductible for tax purposes.

Black Diamond

On June 12, 2015, we acquired the capital stock of Black Diamond Video, Inc. ("Black Diamond"), a California-based developer and provider of operating room integration systems. The purchase price was approximately $46,155, which included a working capital adjustment, deferred consideration of $5,870 and contingent consideration of $800. The transaction consideration paid at closing was funded with cash on hand. Black Diamond has been integrated into our Healthcare Products business segment. The purchase price has been allocated to the net assets acquired based on fair values at the acquisition date.

Other 2016 Acquisitions

We also completed several other minor purchases that continued to expand our service offerings in the Healthcare Products, Healthcare Specialty Services and Life Sciences segments. The aggregate purchase price associated with these transactions was approximately $41,079, including potential contingent consideration of $1,760.

Fiscal Year 2015

Dana Products, Inc.

On March 9, 2015, the Company purchased all the outstanding shares of capital stock of Dana Products, Inc. ("Dana"), an Illinois manufacturer of chemical indicators used in steam sterilizers. The purchase price was approximately $12,414, including a customary working capital adjustment. Dana has been integrated into the Healthcare Products business segment. The purchase price has been allocated to the net assets acquired based on fair values at the acquisition date. The acquisition of Dana qualified for a joint election tax benefit under Section 338(h)(10) of the Internal Revenue Code, which allows goodwill and intangibles to be fully deductible for tax purposes. Intangible assets acquired consist of product names and patents, which are being amortized on a straight line basis over their useful lives of up to ten years.

AGAPE Instruments Service, Inc.

On December 31, 2014, a newly formed subsidiary of the Company purchased the assets and assumed certain liabilities of AGAPE Instruments Service, Inc. ("AGAPE"), an Ohio based provider of certification services. The purchase price was approximately $3,415, including a customary working capital adjustment. The AGAPE business has been integrated into the Life Sciences business segment. The purchase price has been allocated to the net assets acquired based on fair values at the acquisition date. Intangible assets acquired consist of Customer relationships, which are being amortized on a straight line basis over seven years.

Integrated Medical Systems International, Inc.

On May 9, 2014, we completed the acquisition of all of the outstanding shares of capital stock of Integrated Medical Systems International, Inc. ("IMS") pursuant to a Stock Purchase Agreement dated March 31, 2014. The purchase price was approximately $162,905, including a customary working capital adjustment. In addition, we purchased certain real estate used in the IMS business for approximately $10,000. IMS has facilities located in Alabama, Florida and Maryland and provides a variety of services including: endoscope repair, surgical instrument management and sterile processing consulting. IMS has been integrated into our Healthcare Specialty Services segment.

The acquisition of IMS qualified for a joint election tax benefit under Section 338(h)(10) of the Internal Revenue Code, which allows goodwill and intangibles to be fully deductible for tax purposes. Intangible assets acquired consist of trade names and Customer relationships, which are being amortized on a straight line basis over their useful lives of up to nine years, with the exception of the IMS trade name which has an indefinite life.

Fair Value of Assets Acquired and Liabilities Assumed

The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2017, 2016 and 2015 acquisitions.



	Fiscal Year 2017									Fiscal Year 2016												Fiscal Year 2015
	Medisafe⁽¹⁾			Compass ⁽¹⁾			Phoenix Surgical and Endo-Tek ⁽¹⁾			Synergy Health plc			Gepco			Black Diamond			Other Acquisitions			Dana			AGAPE			IMS
Cash	$	3,751		$	—		$	769		$	53,057		$	1,108		$	—		$	—		$	135		$	—		$	—
Accounts receivable	3,614			629			1,123			103,093			4,161			2,966			3,859			617			342			16,594
Inventory	2,454			659			950			30,074			1,926			3,309			1,108			388			—			8,478
Property, plant and equipment	639			13			1,092			496,555			3,421			607			1,979			743			—			15,074
Other assets	—			31			46			19,175			946			54			—			—			—			842
Intangible assets	17,151			5,992			—			504,196			61,900			13,500			14,829			6,363			1,200			62,000
Goodwill	19,618			8,987			12,794			1,685,524			104,485			31,792			20,630			4,311			1,899			81,587
Total Assets	47,227			16,311			16,774			2,891,674			177,947			52,228			42,405			12,557			3,441			184,575
Current liabilities	(6,082		)	(309		)	(1,373		)	(107,932		)	(1,473		)	(4,525		)	(1,277		)	(143		)	(26		)	(11,670		)
Long-term indebtedness	—			—			—			(321,082		)	—			—			—			—			—			—
Non-current liabilities	(2,877		)	—			(295		)	(159,112		)	—			(1,548		)	(49		)	—			—			—
Total Liabilities	(8,959		)	(309		)	(1,668		)	(588,126		)	(1,473		)	(6,073		)	(1,326		)	(143		)	(26		)	(11,670		)
Net Assets	$	38,268		$	16,002		$	15,106		$	2,303,548		$	176,474		$	46,155		$	41,079		$	12,414		$	3,415		$	172,905

⁽¹⁾Purchase price allocation is still preliminary as of March 31, 2017, as valuations have not been finalized.

Acquisition related transaction and integration costs totaled $30,082, $82,891, and $32,762 for the fiscal years ended March 31, 2017, 2016, and 2015, respectively. These costs are included in Selling, general, and administrative expenses in the Consolidated Statements of Income.

Divestitures

Netherlands Linen Management Services

On February 9, 2017, we sold our Synergy Health Netherlands Linen Management Services business to EMEA B.V. Annual revenues for Synergy Health Netherlands Linen Management Services were approximately $75 million and were included in the Healthcare Specialty Services segment. We recorded a $42.9 million pre-tax loss on the sale in Selling, general, and administrative expense in the Consolidated Statements of Income as a result of the divestiture. In connection with the divestiture, we entered into a loan agreement to provide financing of up to €15 million for a term of up to 15 years. The loan carries an interest rate of 4 percent for the first four years and 12 percent thereafter. No borrowings were outstanding at March 31, 2017.

US Linen Management Services

On November 3, 2016, we sold our Synergy Health US Linen Management Services business to SRI Healthcare LLC. Annual revenues for US Linen Management Services were approximately $50 million and were included in the Healthcare Specialty Services segment. We recorded proceeds of $4.5 million and recognized a pre-tax loss on the sale, subject to final adjustments, of $31.2 million in Selling, general, and administrative expense in the Consolidated Statements of Income.

Synergy Health Labs

On September 2, 2016, we sold Synergy Health Laboratory Services to SYNLAB International. Annual revenues for the Synergy Health Labs were approximately $15 million and were included in the Applied Sterilization Technologies segment. We recorded proceeds of $25.0 million, net of cash divested, and recognized a pre-tax gain on the sale of $17.4 million in Selling, general, and administrative expense in the Consolidated Statements of Income.

Applied Infection Control

On August 31, 2016, we completed the sale of our Applied Infection Control ("AIC") product line to DEB USA, Inc., a wholly-owned subsidiary of S.C. Johnson & Son, Inc. Annual revenues for the AIC product line were typically less than $50 million and were included in the Healthcare Products segment. We recorded proceeds of $41.8 million and recognized a pre-tax gain on the sale of $36.5 million in Selling, general, and administrative expense in the Consolidated Statements of Income.

UK Linen Management Services

On July 1, 2016, we sold our Synergy Health UK Linen Management Services business to STAR Mayan Limited. Annual revenues for UK Linen Management Services were approximately $50 million and were included in the Healthcare Specialty Services segment. We recorded proceeds of $65.4 million, net of cash divested, and recognized a pre-tax loss on the sale of $66.3 million in Selling, general, and administrative expense in the Consolidated Statements of Income.

Fiscal 2017 Acquisitions

Compass Medical, Inc.

Phoenix Surgical Holdings, Ltd. and Endo-Tek LLP

Medisafe

Fiscal 2016 Acquisitions

Synergy Health plc



Cash consideration	$	402,494
STERIS plc shares (25,848,798 ordinary shares issued)	1,887,479
Fair value of consideration available to vested Synergy share option holders	4,819
Total purchase consideration	$	2,294,792



	November 2, 2015 (as previously reported)			Adjustments			November 2, 2015 (revised)
Cash	$	53,057		$	—		$	53,057
Accounts receivable	107,341			(4,248		)	103,093
Inventory	30,074			—			30,074
Property, plant and equipment	534,879			(38,324		)	496,555
Other assets	19,708			(533		)	19,175
Intangible assets	806,526			(302,330		)	504,196
Goodwill	1,411,781			273,743			1,685,524
Total assets	2,963,366			(71,692		)	2,891,674

Current liabilities	(108,192		)	260			(107,932		)

Long-term indebtedness	(321,082		)	—			(321,082		)
Non-current liabilities	(230,544		)	71,432			(159,112		)
Total Liabilities	(659,818		)	71,692			(588,126		)

Net Assets	$	2,303,548		$	—		$	2,303,548



	Total		Useful Life
Customer relationships	$	459,074	15 years
Trade names	19,404		15 years
Technology	25,718		6 years
Total intangible assets acquired	$	504,196

Actual and Pro Forma Impact



	Fiscal Year Ended March 31,
Amounts are unaudited	2016		2015
Net revenues	$	2,619,056	$	2,499,140
Net income from continuing operations	188,269		152,057

Gepco

Black Diamond

Other 2016 Acquisitions

Fiscal Year 2015

Dana Products, Inc.

AGAPE Instruments Service, Inc.

Integrated Medical Systems International, Inc.

Fair Value of Assets Acquired and Liabilities Assumed

The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2017, 2016 and 2015 acquisitions.



	Fiscal Year 2017									Fiscal Year 2016												Fiscal Year 2015
	Medisafe⁽¹⁾			Compass ⁽¹⁾			Phoenix Surgical and Endo-Tek ⁽¹⁾			Synergy Health plc			Gepco			Black Diamond			Other Acquisitions			Dana			AGAPE			IMS
Cash	$	3,751		$	—		$	769		$	53,057		$	1,108		$	—		$	—		$	135		$	—		$	—
Accounts receivable	3,614			629			1,123			103,093			4,161			2,966			3,859			617			342			16,594
Inventory	2,454			659			950			30,074			1,926			3,309			1,108			388			—			8,478
Property, plant and equipment	639			13			1,092			496,555			3,421			607			1,979			743			—			15,074
Other assets	—			31			46			19,175			946			54			—			—			—			842
Intangible assets	17,151			5,992			—			504,196			61,900			13,500			14,829			6,363			1,200			62,000
Goodwill	19,618			8,987			12,794			1,685,524			104,485			31,792			20,630			4,311			1,899			81,587
Total Assets	47,227			16,311			16,774			2,891,674			177,947			52,228			42,405			12,557			3,441			184,575
Current liabilities	(6,082		)	(309		)	(1,373		)	(107,932		)	(1,473		)	(4,525		)	(1,277		)	(143		)	(26		)	(11,670		)
Long-term indebtedness	—			—			—			(321,082		)	—			—			—			—			—			—
Non-current liabilities	(2,877		)	—			(295		)	(159,112		)	—			(1,548		)	(49		)	—			—			—
Total Liabilities	(8,959		)	(309		)	(1,668		)	(588,126		)	(1,473		)	(6,073		)	(1,326		)	(143		)	(26		)	(11,670		)
Net Assets	$	38,268		$	16,002		$	15,106		$	2,303,548		$	176,474		$	46,155		$	41,079		$	12,414		$	3,415		$	172,905

⁽¹⁾Purchase price allocation is still preliminary as of March 31, 2017, as valuations have not been finalized.

Divestitures

Netherlands Linen Management Services

US Linen Management Services

Synergy Health Labs

Applied Infection Control

UK Linen Management Services

Goodwill and Intangible Assets

12 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

Changes to the carrying amount of goodwill for the years ended March 31, 2017, 2016 and 2015 were as follows:



	Healthcare Products Segment			Healthcare Specialty Services Segment			Life Sciences Segment			Applied Sterilization Technologies Segment			Synergy Combination			Total
Balance at March 31, 2015	$	324,873		$	150,844		$	33,889		$	83,035		$	—		$	592,641
Goodwill acquired or allocated	40,043			3,428			113,284			—			1,408,192			1,564,947
Foreign currency translation adjustments	(1,146		)	—			161			—			—			(985		)
Balance at March 31, 2016	363,770			154,272			147,334			83,035			1,408,192			2,156,603
Goodwill acquired or allocated	19,618			21,781			—			—			—			41,399
Synergy allocation	—			376,807			—			1,308,717			(1,411,781		)	273,743
Divestitures	—			(85,806		)	—			—			—			(85,806		)
Impairment	—			(58,356		)	—			—			—			(58,356		)
Foreign currency translation adjustments	(5,623		)	(32,819		)	(820		)	(60,607		)	3,589			(96,280		)
Balance at March 31, 2017	$	377,765		$	375,879		$	146,514		$	1,331,145		$	—		$	2,231,303

The fiscal 2017 goodwill increase within the Healthcare Products segment primarily relates to the acquisition of Medisafe. The fiscal 2017 goodwill increase within the Healthcare Specialty Services and Applied Sterilization Technologies segments was primarily the result of the finalization of purchase accounting related to the Synergy acquisition. The Healthcare Specialty Services segment was also impacted by the fiscal 2017 acquisitions of Compass Medical, Inc., Phoenix Surgical Holdings, Ltd., and Endo-Tek LLP, the Synergy Health UK Linen Management Services divestiture and the Synergy Health Netherlands goodwill impairment discussed below.

The fiscal 2016 increase in the overall goodwill balance related to the Synergy acquisition, which had not been allocated to the business segments as of March 31, 2016. The fiscal 2016 increase of goodwill associated with the Healthcare Products segment resulted primarily from the acquisition of the capital stock of Black Diamond. The increase associated with the Life Sciences segment resulted primarily from the acquisition of the capital stock of Gepco. Other minor purchases also impacted goodwill associated with the Healthcare Products, Healthcare Specialty Services and Life Sciences segments.

We evaluate the recoverability of recorded goodwill amounts annually during the third fiscal quarter, or when evidence of potential impairment exists. As a result of our annual goodwill impairment review for fiscal year 2017, we concluded that the carrying value of one of our reporting units exceeded its fair value. The Synergy Health Netherlands linen management unit is reported within our Healthcare Specialty Services segment. Financial forecasts prepared for the annual assessment reflected pricing pressures, volume declines driven by overcapacity in the market, and a decline in the overall market size. These factors resulted in further degradation of the already low operating margin and cash flows of this unit. We incurred a goodwill impairment charge of $58,356 as a result, which is recorded within Goodwill impairment loss in the Consolidated Statements of Income. The fair market value of the reporting unit was determined under an income approach using discounted cash flows and estimated fair market values. Fair value calculated using a discounted cash flow analysis is classified within level 3 of the fair value hierarchy and requires several assumptions including risk adjusted discount rates and financial forecasts.

Our fiscal 2017, 2016, and 2015 acquisitions are described in Note 2 to our consolidated financial statements titled, "Business Acquisitions and Divestitures".

Information regarding our intangible assets is as follows:



	2017				2016
March 31,	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Customer relationships	$	597,386	$	96,648	$	879,525	$	64,268
Non-compete agreements	4,722		3,629		4,730		3,503
Patents and technology	211,812		86,665		213,317		70,801
Trademarks and tradenames	80,223		32,547		129,690		18,318
Supplier relationships	54,800		4,567		54,800		1,827
Other	10		10		10		16
Total	$	948,953	$	224,066	$	1,282,072	$	158,733

Certain trademarks and tradenames obtained as a result of business combinations are indefinite-lived assets. The approximate carrying value of these assets at March 31, 2017 and March 31, 2016 was $34,970 and $35,340, respectively. Total amortization expense for finite-lived intangible assets was $68,607, $49,782, and $24,500 for the years ended March 31, 2017, 2016, and 2015, respectively. Based upon the current amount of intangible assets subject to amortization, the amortization expense for each of the five succeeding fiscal years is estimated to be as follows:



	2018		2019		2020		2021		2022
Estimated amortization expense	$	64,863	$	64,540	$	63,486	$	62,847	$	60,018

The estimated annual amortization expense presented in the preceding table has been calculated based upon March 31, 2017 foreign currency exchange rates.

During the third quarter of fiscal 2017, we adopted a new branding strategy change as part of the integration of certain Synergy Health operations into the Healthcare Specialty Services Segment. Under this new branding strategy, hospital sterilization services and instrument repair services will utilize the STERIS Instrument Management Services brand name. The Synergy Health trade name was phased out during the fourth quarter of fiscal 2017. As a result, we have shortened the estimated useful life of the Synergy Health trade name and accelerated the corresponding amortization expense over the remainder of fiscal 2017, resulting in an additional expense of $14,444 within the Selling, general and administrative expense line on the Consolidated Statements of Income.

However, during the second quarter of fiscal 2015, a new branding strategy for surgical instrument and endoscope repair services was adopted as part of the integration of IMS into the Healthcare Specialty Services segment. This new strategy represented an indicator of impairment of the carrying value of the Spectrum trade-name as it now will be used solely for Healthcare Specialty Services product offerings. We estimated the fair value of the Spectrum trade-name using the relief from royalty method and concluded that the carrying value of the trade-name exceeded its fair value. As a result, an impairment charge of approximately $5,561 was recorded to reduce the carrying value of the intangible asset. The impairment charge is reported in the Selling, general, and administrative expense line of the Consolidated Statements of Income.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Property, Plant and Equipment

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Property, Plant and Equipment

Information related to the major categories of our depreciable assets is as follows:



March 31,	2017			2016
Land and land improvements ⁽¹⁾	$	46,848		$	39,051
Buildings and leasehold improvements	393,692			452,120
Machinery and equipment	508,247			599,631
Linens ⁽²⁾	—			42,874
Information systems	119,920			127,464
Radioisotope	436,787			447,892
Construction in progress ⁽¹⁾	77,421			79,291
Total property, plant, and equipment	1,582,915			1,788,323
Less: accumulated depreciation and depletion	(667,007		)	(724,004		)
Property, plant, and equipment, net	$	915,908		$	1,064,319

⁽¹⁾ Land is not depreciated. Construction in progress is not depreciated until placed in service.

⁽²⁾Linen assets were first acquired as part of our Combination with Synergy and were depreciated over useful lives ranging from one to five years. All linen businesses utilizing linens were divested during fiscal 2017.

Depreciation and depletion expense were $119,536, $93,958 and $61,481, for the years ended March 31, 2017, 2016, and 2015, respectively.

Rental expense for operating leases was $32,740, $23,238, and $18,602 for the years ended March 31, 2017, 2016, and 2015, respectively. Operating leases relate to manufacturing, warehouse and office space, service facilities, vehicles, equipment, and communication systems. Certain lease agreements grant us varying renewal and purchase options.

Future minimum annual rentals payable under noncancelable operating lease agreements at March 31, 2017 were as follows:



	Operating Leases
2018	$	23,718
2019	15,132
2020	11,088
2021	7,329
2022 and thereafter	40,140
Total minimum lease payments	$	97,407

In the preceding table, the future minimum annual rentals payable under noncancelable leases denominated in foreign currencies have been calculated using March 31, 2017 foreign currency exchange rates.

Asset Retirement Obligations

We provide contract sterilization services including Gamma irradiation which utilizes cobalt-60 in the form of cobalt pencils. We have incurred asset retirement obligations (ARO) associated with the future disposal of these assets once depleted. Recognition of ARO includes: the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and the periodic review of the ARO liability estimates and discount rates used in the analysis.

The following table summarizes the activity in the liability for asset retirement obligations.



	Asset Retirement Obligations
Balance at March 31, 2016	$	10,342
Liabilities incurred during the period	222
Accretion expense and change in estimate	(231		)
Foreign currency movement	(380		)
Balance at March 31, 2017	$	9,953

Debt

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Debt

Indebtedness as of March 31, 2017 and 2016 was as follows:



	2017			2016
Private Placement	$	960,684		$	666,000
Deferred financing fees	(3,927		)	(3,420		)
Credit Agreement and Swing Line Facility	521,604			905,216
Total long term debt	$	1,478,361		$	1,567,796

On February 27, 2017, we issued and sold an aggregate principal amount of $95,000, €99,000, and £75,000, or a total of approximately $293,730 based upon February 27, 2017 exchange rates, of senior notes in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. Maturities of these senior notes are as follows, and the dollar amounts shown are based upon foreign exchange rates as of March 31, 2017:



	2017
$50,000 Senior notes at 3.93% due 2027	$	50,000
€60,000 Senior notes at 1.86% due 2027	64,414
$45,000 Senior notes at 4.03% due 2029	45,000
€20,000 Senior notes at 2.04% due 2029	21,471
£45,000 Senior notes at 3.04% due 2029	56,040
€19,000 Senior notes at 2.30% due 2032	20,398
£30,000 Senior notes at 3.17% due 2032	37,360
Total 2017 Senior Notes	$	294,683

All or substantially all of the net proceeds of these borrowings were used to repay floating-rate bank debt under the bank credit facility, thereby, increasing the Company's proportion of fixed-rate debt. Total debt levels for the Company remained relatively unchanged after giving effects to these actions.

In order to fund the acquisition of Synergy, including the cash payments made in respect of Synergy shares, the repayment of Synergy debt and certain transaction expenses, on November 2, 2015, STERIS plc borrowed (i) $132,000, £49,000, and €127,750 under the revolving credit facility provided under the Credit Agreement and (ii) $400,000 under the term loan facility provided under the Credit Agreement (as hereinafter defined). Borrowings bear interest at the Company’s option based upon either the Base Rate or the Eurocurrency Rate, plus the Applicable Margin in effect from time to time under the Credit Agreement. The Applicable Margin is determined based on the ratio of Consolidated Total Debt to a Consolidated EBITDA (as such terms are defined in the Credit Agreement). Interest on Base Rate Advances is payable quarterly in arrears and interest on Eurocurrency Rate Advances is payable at the end of the relevant interest period therefor, but in no event less frequently than every three months.

On May 15, 2015, Old STERIS issued and sold $350,000 of senior notes, in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. Of the $350,000 in senior notes, $125,000 have a maturity of 10 years from the issue date at an annual interest rate of 3.45%, $125,000 have a maturity of 12 years from the issue date at an annual interest rate of 3.55% and $100,000 have a maturity of 15 years from the issue date at an annual interest rate of 3.70%. These borrowings were used for repayment of Credit Agreement debt and for other corporate purposes. The agreement governing these notes contains leverage and interest coverage covenants.

On March 31, 2015, Old STERIS and STERIS entered into a Credit Agreement (the "Credit Agreement") with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as Administrative Agent. The Credit Agreement replaced prior bank facilities of Old STERIS. As of March 31, 2017, the Credit Agreement provided $1,072,500 of credit, which includes an $850,000 revolver facility, which may be utilized for revolving credit borrowings, swing line borrowings and letters of credit, with sublimits for swing line borrowings and letters of credit, plus a term loan facility with a limit and outstanding principal amount of $222,500. As repayments are made under the term facility, the term facility limit declines. The revolver and term loan facilities may be increased in specified circumstances by up to $500,000. Term loans are repayable quarterly pursuant to a specified amortization schedule, with principal payments increasing from 1.25% to 2.50% over the term, and with a balloon payment for the remaining unpaid balance at maturity. The Credit Agreement also allows for voluntary principal reduction pre-payments on the term loan. The Credit Agreement will mature on March 31, 2020, and all unpaid borrowings, together with accrued and unpaid interest thereon, are repayable on that date. The Credit Agreement contains leverage and interest coverage covenants.

In February 2013, Old STERIS issued and sold $100,000 of senior notes, of which $98,000 remained outstanding as of March 31, 2017, in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. Of the $98,000 of outstanding notes, $45,500 have a maturity of nine years and 10 months from issuance and have a current annual interest rate of 3.70%, an additional $40,000 have a maturity of 11 years and 10 months from issuance and have a current annual interest rate of 3.85%, and the remaining $12,500 have a maturity of 14 years and 10 months from issuance and have a current annual interest rate of 4.05%. These borrowings were used primarily for the repayment of then existing bank credit facility debt. The agreements governing these notes, which also govern the below described senior notes issued in December 2012, and the notes were amended and restated in their entirety on March 31, 2015. The amended and restated agreements, which have been consolidated into a single agreement, contain leverage and interest coverage covenants.

In December 2012, Old STERIS issued and sold $100,000 of senior notes, of which $98,000 remained outstanding as of March 31, 2017, in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. Of the $98,000 of outstanding notes, $45,500 have a maturity of 10 years from issuance and have a current annual interest rate of 3.70%, an additional $40,000 have a maturity of 12 years from issuance and have a current annual interest rate of 3.85%, and the remaining $12,500 have a maturity of 15 years from issuance and have a current annual interest rate of 4.05%. These borrowings were used primarily for the repayment of then existing credit facility debt. The agreements governing these notes and the notes, which also govern the previously described senior notes issued in February 2013, were amended and restated in their entirety on March 31, 2015. The amended and restated agreements, which have been consolidated into a single agreement, contain leverage and interest coverage covenants.

On August 15, 2008, Old STERIS issued and sold $150,000 of senior notes, of which $120,000 remained outstanding as of March 31, 2017, in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. Of the outstanding notes $85,000 have a maturity of 10 years from issuance and have a current annual interest rate of 6.83%, and the remaining $35,000 have a maturity of 12 years from issuance and have a current annual interest rate of 6.93%. The agreements governing these notes and the notes were amended and restated in their entirety on March 31, 2015. The amended and restated agreements, which have been consolidated into a single agreement, contain leverage and interest coverage covenants.

As of March 31, 2017, a total $521,604 was outstanding under the Credit Agreement.

At March 31, 2017, we were in compliance with all financial covenants associated with our indebtedness.

The combined annual aggregate amount of maturities of our outstanding debt by fiscal year is as follows:



2018	$	30,000
2019	117,500
2020	459,104
2021	35,000
2022 and thereafter	840,684
Total	$	1,482,288

Additional Consolidated Balance Sheets Information

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Additional Consolidated Balance Sheets Information

Additional information related to our Consolidated Balance Sheet is as follows:



March 31,	2017		2016
Accrued payroll and other related liabilities:
Compensation and related items	$	29,777	$	30,175
Accrued vacation/paid time off	8,651		14,368
Accrued bonuses	20,715		31,502
Accrued employee commissions	16,201		13,809
Other post-retirement benefits obligations-current portion	2,187		2,463
Other employee benefit plans' obligations-current portion	1,044		1,659
Total accrued payroll and other related liabilities	$	78,575	$	93,976
Accrued expenses and other:
Deferred revenues	$	71,020	$	56,238
Self-insured risk reserves-current portion	6,633		8,266
Accrued dealer commissions	16,122		12,717
Accrued warranty	6,861		5,909
Other	54,253		70,245
Total accrued expenses and other	$	154,889	$	153,375
Other liabilities:
Self-insured risk reserves-long-term portion	$	15,584	$	13,257
Other post-retirement benefits obligations-long-term portion	13,821		15,932
Defined benefit pension plans obligations-long-term portion	27,234		25,301
Other employee benefit plans obligations-long-term portion	3,661		4,366
Accrued long-term income taxes	2,089		—
Asset retirement obligation-long-term portion	9,953		10,342
Other	10,331		15,100
Total other liabilities	$	82,673	$	84,298

Income Tax Expense

12 Months Ended

Mar. 31, 2017

Income Tax Expense [Abstract]

Income Tax Expense (Benefit)

Income from continuing operations before income taxes was as follows:



Years Ended March 31,	2017			2016			2015
United States operations	$	189,429		$	105,758		$	161,165
United Kingdom operations	(36,420		)	(20,553		)	15,824
Other Foreign Locations operations	31,637			86,679			31,831
	$	184,646		$	171,884		$	208,820

The components of the provision for income taxes related to income from continuing operations consisted of the following:



Years Ended March 31,	2017			2016			2015
Current:
United States federal	$	43,900		$	41,653		$	52,234
United States state and local	8,171			7,943			8,551
United Kingdom	362			2,194			3,633
Other foreign locations	21,094			13,924			8,842
	73,527			65,714			73,260
Deferred:
United States federal	10,293			1,427			1,436
United States state and local	2,131			299			214
United Kingdom	(2,292		)	(6,973		)	(676		)
Other foreign locations	(9,644		)	(168		)	(478		)
	488			(5,415		)	496
Total Provision for Income Taxes	$	74,015		$	60,299		$	73,756

The total provision for income taxes can be reconciled to the tax computed at the United Kingdom federal statutory tax rate for 2017 and the United States federal statutory tax rate for 2016 and 2015 as follows:



Years Ended March 31,	2017		2016		2015
Federal statutory tax rate	20.0	%	35.0	%	35.0	%
Increase (decrease) in accruals for uncertain tax positions	0.3	%	0.2	%	—	%
State and local taxes, net of federal income tax benefit	3.8	%	3.3	%	2.8	%
Increase in valuation allowances	0.1	%	1.0	%	2.1	%
Research and development credit	(1.1	)%	—	%	—	%
Foreign income tax credit	—	%	(0.6	)%	(1.0	)%
Difference in non-United States tax rates	—	%	(8.5	)%	(3.6	)%
Difference in non-United Kingdom tax rates	6.0	%	—	%	—	%
Excise tax gross-up	—	%	3.4	%	—	%
U.S. manufacturing deduction	(2.5	)%	(2.5	)%	(1.6	)%
Excess tax benefit for equity compensation	(2.8	)%	—	%	—	%
Rate changes on deferred tax assets and liabilities	(2.3	)%	—	%	—	%
Acquisitions and divestitures	9.0	%	—	%	—	%
Goodwill impairment on divestitures	7.9	%	—	%	—	%
Capitalized acquisition costs	0.2	%	5.3	%	2.2	%
All other, net	1.5	%	(1.5	)%	(0.6	)%
Total Provision for Income Taxes	40.1	%	35.1	%	35.3	%

Unrecognized Tax Benefits. We classify uncertain tax positions and related interest and penalties as long-term liabilities within “Other liabilities” in our accompanying Consolidated Balance Sheets, unless they are expected to be paid within 12 months, in which case, the uncertain tax positions would be classified as current liabilities within “Accrued income taxes.” We recognize interest and penalties related to unrecognized tax benefits within “Income tax expense” in our accompanying Consolidated Statements of Income.

A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows:



	2017			2016
Unrecognized Tax Benefits Balance at April 1	$	3,527		$	—
Increases for tax provisions of current year	510			316
Balances related to acquired/disposed businesses	(1,502		)	3,422
Other decreases, including currency translation	(651		)	(211		)
Unrecognized Tax Benefits Balance at March 31	$	1,884		$	3,527

We recognized interest and penalties related to uncertain tax positions in the provision for income taxes. As of March 31, 2017, we had $184 accrued for interest and penalties. The decrease during fiscal 2017 is primarily associated with the release of prior year uncertain tax positions. If all unrecognized tax benefits were recognized, the net impact on the provision for income tax expense would be $2,068. It is reasonably possible that during the next twelve months, there will be no material reductions in unrecognized tax benefits as a result of the expiration of various statutes of limitations or matters related to transfer pricing.

We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2014 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2012. We remain subject to tax authority audits in various jurisdictions wherever we do business. We do not expect the results of these examinations to have a material adverse effect on our consolidated financial statements.

We estimate that the tax benefit from our Costa Rican Tax Holiday is $933 (or $0.01 per fully diluted share), annually. The Tax Holiday runs fully exempt, from income tax, through 2025 and partially exempt through 2029.

Deferred Taxes. The significant components of the deferred tax assets and liabilities recorded in our accompanying balance sheets at March 31, 2017 and 2016 were as follows:



March 31,	2017			2016
Deferred Tax Assets:
Post-retirement benefit accrual	$	6,116		$	7,016
Compensation	17,196			25,436
Net operating loss carryforwards	35,129			26,151
Accrued expenses	7,807			7,521
Insurance	4,957			4,226
Deferred income	8,962			7,910
Bad debt	1,740			2,059
Pension	4,647			5,155
Other	781			2,208
Deferred Tax Assets	87,335			87,682
Less: Valuation allowance	16,366			16,435
Total Deferred Tax Assets	70,969			71,247
Deferred Tax Liabilities:
Depreciation and depletion	74,092			85,807
Intangibles	156,291			226,809
Other	3,631			3,744
Total Deferred Tax Liabilities	234,014			316,360
Net Deferred Tax Assets (Liabilities)	$	(163,045	)	$	(245,113	)

At March 31, 2017, we had U.S. federal operating loss carryforwards of $44,112, which if unused, these U.S. federal operating loss carryforwards will expire between fiscal years 2031 and 2037. Additionally, we had non-U.S. operating loss carry forwards of $57,574. Although the majority of the non-U.S. carryforwards have indefinite expiration periods, those carryforwards that have definite expiration periods will expire if unused between fiscal years 2018 and 2026. In addition, we have recorded tax benefits of $2,177 related to state operating loss carryforwards. If unused, these state operating loss carryforwards will expire between fiscal years 2018 and 2037. At March 31, 2017, we had $1,810 of tax credit carryforwards. These credit carryforwards can be used through fiscal 2026.

We review the need for a valuation allowance against our deferred tax assets. A valuation allowance of $16,366 has been applied to a portion of the net deferred tax assets because we do not believe it is more-likely-than-not that we will receive future benefit. The valuation allowance decreased during fiscal 2017 by $69.

No provision has been made for income taxes on undistributed earnings of foreign subsidiaries of approximately $954.1 million at March 31, 2017, since it is our intention to indefinitely reinvest undistributed earnings of our foreign subsidiaries. It is not practicable to estimate the additional income taxes and applicable withholding taxes that would be payable on the remittance of such undistributed earnings.

In October 2015, the Organization for Economic Cooperation and Development (OECD), in conjunction with the G20, finalized broad-based international tax policy guidelines that involve transfer pricing and other international tax subjects. While some member jurisdictions automatically adopt the new OECD guidelines, most member countries can adopt the guidelines only by new law or regulations. We are currently adopting processes to comply with the reporting requirements specified by the guidelines and are evaluating the other parts of the guidelines.

Benefit Plans

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Benefit Plans

In the United States, we sponsor an unfunded post-retirement benefits plan for two groups of United States retirees. Benefits under this plan include retiree life insurance and retiree medical insurance, including prescription drug coverage.

During the second quarter of fiscal 2009, we amended our United States post-retirement welfare benefits plan, reducing the benefits to be provided to retirees under the plan and increasing their share of the costs. The amendments resulted in a decrease of $46,001 in the accumulated post-retirement benefit obligation. The impact of this change was recognized in our Consolidated Balance Sheets in fiscal 2009 and is being amortized as a component of the annual net periodic benefit cost over a period of approximately thirteen years.

In July 2014, the Board of Directors of American Sterilizer Company (“AMSCO”) approved the termination of the American Sterilizer Company Retirement Income Plan (“Plan”) effective October 1, 2014. An Application for Determination was filed with the Internal Revenue Service (IRS) on August 22, 2014, with respect to the Plan termination. A Form 500 Standard Termination Notice was filed with the Pension Benefit Guaranty Corporation ("PBGC") on November 17, 2014. The 60-day PBGC waiting period lapsed without objection by the PBGC. AMSCO received a favorable determination from the IRS regarding the termination. On August 19, 2015, an annuity contract was purchased from Massachusetts Mutual Life Insurance Company to provide Plan benefits. Plan assets were converted to cash to fund the purchase. The purchase price of the annuity contract was $51,805. An additional employer contribution of $4,641 was made to the Plan to fund the annuity purchase obligation on August 26, 2015. As a result of the purchase of the annuity, we recognized a pension settlement of $26,470. In addition, plan benefits and benefit administration became the responsibility of the annuity provider. The assumptions used to measure the benefit obligation as of March 31, 2015 reflected this effort.

As a result of the combination with Synergy, we now participate in five defined benefit pension schemes outside the United States: one in the UK, one in the Netherlands, two in Germany, and one in Switzerland. Unfunded obligations of $23,507 were recorded as of the November 2, 2015 closing date.

In the United Kingdom, we sponsor a scheme that is a defined benefit (final salary) funded pension scheme. Previously, this scheme was three separate schemes: Synergy Health plc Retirement Benefits Scheme, Shiloh Group Pension Scheme, and Vernon-Carus Limited Pension and Assurance Scheme. During fiscal 2017, the Shiloh Group Pension Scheme and Vernon-Carus Limited Pension and Assurance Scheme were merged into the Synergy Health plc Retirement Benefit Scheme.

In previous years, Synergy sponsored a funded defined benefit arrangement in the Netherlands. This was a separate fund holding the pension scheme assets to meet long term pension liabilities for past and present employees. Accrual of benefits ceased under the scheme effective January 1, 2013.

Synergy Radeberg and Synergy Allershausen Schemes: These schemes are defined benefit funded pension schemes, closed to new entrants.

Synergy Daniken Scheme: The scheme is a defined benefit funded pension scheme.

We recognize the funded status of our defined benefit pension and post-retirement benefit plans in our Consolidated Balance Sheets, with a corresponding adjustment to accumulated other comprehensive income, net of tax. The funded status is measured as of March 31 each year and is calculated as the difference between the fair value of plan assets and the benefit obligation (which is the projected benefit obligation for pension plans and the accumulated post-retirement benefit obligation for post-retirement benefit plans). Accumulated comprehensive income (loss) represents the net unrecognized actuarial losses and unrecognized prior service cost. These amounts will be recognized in net periodic benefit cost as they are amortized. We will recognize future changes to the funded status of these plans in the year the change occurs, through other comprehensive income.

Obligations and Funded Status. The following table reconciles the funded status of the defined benefit pension plans and the other post-retirement benefits plan to the amounts recorded on our Consolidated Balance Sheets at March 31, 2017 and 2016, respectively. Benefit obligation balances presented in the following table reflect the projected benefit obligations for our defined benefit pension plans and the accumulated other post-retirement benefit obligation for our post-retirement benefits plan. The measurement date of our defined benefit pension plans and other post-retirement benefits plan is March 31, for both periods presented.



	AMSCO Plan					Other Defined Benefit Pension Plans						Other Post-Retirement Benefits Plan
	2017		2016			2017			2016			2017			2016
Change in Benefit Obligations:
Benefit Obligations at Beginning of Year	$	—	$	56,612		$	128,942		$	—		$	18,380		$	21,278
Obligation assumed in Combination	—		—			—			121,468			—			—
Service cost	—		27			1,650			961			—			—
Interest cost	—		560			3,434			1,659			554			593
Actuarial loss (gain)	—		(2,365		)	16,633			5,399			(531		)	(673		)
Benefits and expenses	—		(3,029		)	(7,190		)	(2,346		)	(2,395		)	(2,818		)
Employee contributions	—		—			629			517			—			—
Curtailments/settlements	—		(51,805		)	—			(326		)	—			—
Impact of foreign currency exchange rate changes	—		—			(15,201		)	1,610			—			—
Benefit Obligations at End of Year	—		—			128,897			128,942			16,008			18,380
Change in Plan Assets:
Fair Value of Plan Assets at Beginning of Year	—		50,426			104,353			—			—			—
Assets assumed in Combination	—		—			—			99,511			—			—
Actual return on plan assets	—		(279		)	11,910			2,989			—			—
Employer contributions	—		4,687			4,838			2,280			2,395			2,818
Employee contributions	—		—			629			517			—			—
Benefits and expenses paid	—		(3,029		)	(7,190		)	(2,204		)	(2,395		)	(2,818		)
Curtailments/settlements	—		(51,805		)	—			—			—			—
Impact of foreign currency exchange rate changes	—		—			(12,877		)	1,260			—			—
Fair Value of Plan Assets at End of Year	—		—			101,663			104,353			—			—
Funded Status of the Plans	$	—	$	—		$	(27,234	)	$	(24,589	)	$	(16,008	)	$	(18,380	)

Amounts recognized in the consolidated balance sheets consist of the following:



	Other Defined Benefit Pension Plans						Other Post-Retirement Benefits Plan
	2017			2016			2017			2016
Current liabilities	$	—		$	—		$	(2,187	)	$	(2,463	)
Noncurrent liabilities	(27,234		)	(24,589		)	(13,821		)	(15,917		)
	$	(27,234	)	$	(24,589	)	$	(16,008	)	$	(18,380	)

The pre-tax amount of unrecognized actuarial net loss and unamortized prior service cost included in accumulated other comprehensive (loss) income at March 31, 2017 was $7 million and $16 million, respectively. During fiscal 2018, we will amortize the following pre-tax amounts from accumulated other comprehensive income:



	Other Post-Retirement Benefits Plan
	Other Post-Retirement Benefits Plan
Actuarial loss	$	739
Prior Service Cost	(3,263		)

Defined benefit plans with an accumulated benefit obligation and projected benefit obligation exceeding the fair value of plan assets had the following plan assets and obligations at March 31, 2017 and 2016:



	Other Defined Benefit Pension Plans
	2017		2016
Aggregate fair value of plan assets	$	101,663	$	104,353
Aggregate accumulated benefit obligations	128,897		128,942
Aggregate projected benefit obligations	128,897		128,942

Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Income. Components of the annual net periodic benefit cost of our defined benefit pension plans and our other post-retirement benefits plan were as follows:



	AMSCO Plan								Other Defined Benefit Pension Plans								Other Post-Retirement Benefits Plan
	2017		2016			2015			2017			2016			2015		2017			2016			2015
Service cost	$	—	$	27		$	140		$	1,650		$	961		$	—	$	—		$	—		$	—
Interest cost	—		560			1,887			3,434			1,659			—		554			593			691
Expected return on plan assets	—		(1,008		)	(3,139		)	(2,853		)	(1,324		)	—		—			—			—
Prior service cost recognition	—		—			—			—			(142		)	—		(3,263		)	(3,263		)	(3,263		)
Net amortization and deferral	—		602			1,106			—			—			—		739			828			721
Curtailments/settlements	—		26,470			—			—			(326		)	—		—			—			—
Net periodic benefit cost	$	—	$	26,651		$	(6	)	$	2,231		$	828		$	—	$	(1,970	)	$	(1,842	)	$	(1,851	)
Recognized in other comprehensive loss (income) before tax:
Net loss (gain) occurring during year	$	—	$	—		$	6,706		$	(7,553	)	$	(3,733	)	$	—	$	531		$	673		$	2,327
Amortization of prior service credit	—		—			—			—			—			—		3,263			3,263			3,263
Amortization of net loss	—		(602		)	(1,106		)	—			—			—		(739		)	(721		)	(721		)
Total recognized in other comprehensive loss (income)	—		(602		)	5,600			(7,553		)	(3,733		)	—		3,055			3,215			4,869
Total recognized in total benefits cost and other comprehensive loss (income)	$	—	$	26,049		$	5,594		$	(5,322	)	$	(2,905	)	$	—	$	1,085		$	1,373		$	3,018

Assumptions Used in Calculating Benefit Obligations and Net Periodic Benefit Cost. The following table presents significant assumptions used to determine the projected benefit obligations at March 31:



	2017		2016
Discount Rate:
Synergy Health PLC Retirement Benefits Scheme	2.60	%	3.50	%
Isotron BV Pension Plan	1.60	%	1.60	%
Synergy Health Daniken AG	0.65	%	0.40	%
Synergy Health Radeberg	1.50	%	1.60	%
Synergy Health Allershausen	1.50	%	1.60	%
Other post-retirement plan	3.50	%	3.25	%

The following table presents significant assumptions used to determine the net periodic benefit costs for the years ended March 31:



	2017		2016		2015
Discount Rate:
AMSCO Plan	n/a		n/a		4.00	%
Other defined benefit pension plans
Synergy Health PLC Retirement Benefits Scheme	3.50	%	3.20	%	n/a
Isotron BV Pension Plan	1.60	%	2.10	%	n/a
Synergy Health Daniken AG	0.65	%	0.40	%	n/a
Synergy Health Radeberg	1.50	%	1.60	%	n/a
Synergy Health Allershausen	1.50	%	1.60	%	n/a
Other post-retirement plan	3.50	%	3.25	%	3.00	%
Expected Return on Plan Assets:
AMSCO Plan	n/a		n/a		6.75	%
Other defined benefit pension plans
Synergy Health PLC Retirement Benefits Scheme	4.87	%	5.19	%	n/a
Isotron BV Pension Plan	1.60	%	2.10	%	n/a
Synergy Health Daniken AG	1.40	%	1.40	%	n/a

The net periodic benefit cost and the actuarial present value of projected benefit obligations are based upon assumptions that we review on an annual basis. These assumptions may be revised annually based upon an evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing benefits.

We develop our expected long-term rate of return on plan assets assumptions by evaluating input from third-party professional advisers, taking into consideration the asset allocation of the portfolios and the long-term asset class return expectations.

We develop our discount rate assumptions by evaluating input from third-party professional advisers, taking into consideration the current yield on country specific investment grade long-term bonds which provide for similar cash flow streams as our projected obligations.

We have made assumptions regarding healthcare costs in computing our other post-retirement benefit obligation. The assumed rates of increase generally decline ratably over a five-year period from the assumed current year healthcare cost trend rate to the assumed long-term healthcare cost trend rate noted below.



	2017		2016		2015
Healthcare cost trend rate – medical	7.0	%	7.0	%	7.0	%
Healthcare cost trend rate – prescription drug	7.0	%	7.0	%	7.0	%
Long-term healthcare cost trend rate	4.5	%	4.5	%	4.5	%

To determine the healthcare cost trend rates, we evaluate a combination of information, including ongoing claims cost monitoring, annual statistical analyses of claims data, reconciliation of forecasted claims against actual claims, review of trend assumptions of other plan sponsors and national health trends, and adjustments for plan design changes, workforce changes, and changes in plan participant behavior.

A one-percentage-point change in assumed healthcare cost trend rates (including medical, prescription drug, and long-term rates) would have had the following effect at March 31, 2017:



	One-Percentage Point
	Increase		Decrease
Effect on total service and interest cost components	$	1	$	(1	)
Effect on other post-retirement benefit obligation	32		(32		)

Plan Assets. The investment policies for our plans are generally established by the local pension plan trustees and seek to maintain the plans' ability to meet liabilities and to comply with local minimum funding requirements. Plan assets are invested in diversified portfolios that provide adequate levels of return at an acceptable level of risk. The investment policies are reviewed at least annually and revised, as deemed appropriate to ensure that the objectives are being met. At March 31, 2017, the targeted allocation for the plans were approximately 75% equity investments and 25% fixed income investments.

Financial instruments included in pension plan assets are categorized into three tiers. These tiers include a fair value hierarchy of three levels, based on the degree of subjectivity inherent in the valuation methodology as follows:

Level 1 - Quoted prices for identical assets in active markets.

Level 2 - Quoted prices for similar assets in active markets with inputs that are observable, either directly or indirectly.

Level 3 - Unobservable prices or inputs in which little or no market data exists.

The fair value of our pension benefits plan assets at March 31, 2017 and 2016 by asset category is as follows:



	Fair Value Measurements at March 31, 2017
(In thousands)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Cash	$	182	$	182	$	—	$	—
Insured annuities	10,813		—		10,813		—
Insurance contracts	3,959		—		—		3,959
Common and collective trusts valued at net asset value:
Equity security trusts	64,922
Debt security trusts	21,787
Total Plan Assets	$	101,663	$	182	$	10,813	$	3,959



	Fair Value Measurements at March 31, 2016
(In thousands)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Cash and short term securities	$	7,221	$	7,221	$	—	$	—
Insured annuities	11,279		—		11,279		—
Insurance contracts	4,192		—		—		4,192
Common and collective trusts valued at net asset value:
Equity security trusts	50,125
Debt security trusts	26,152
Real estate security trusts	5,384
Total Plan Assets	$	104,353	$	7,221	$	11,279	$	4,192

Collective investment trusts are measured at fair value using the net asset value per share practical expedient. These trusts have not been categorized in the fair value hierarchy and are being presented in the tables above to permit a reconciliation of the fair value hierarchy to the total plan assets.

The fair value measurement of plan assets using significant unobservable inputs (Level 3) changed during fiscal year 2017 due to the following:



	Insurance contracts
Balance at March 31, 2016	$	4,192
Gains (losses) related to assets still held at year-end	116
Purchases, sales, settlements - net	(208		)
Foreign currency	(141		)
Balance at March 31, 2017	$	3,959

Cash Flows. We contribute amounts to our defined benefit pension plans at least equal to the minimum amounts required by applicable employee benefit laws and local tax laws. In addition, we have agreed with the trustees of the UK defined benefit plans to aim to eliminate the deficit over the next approximately 5 years. As a result, we expect to make contributions of approximately $4,640 per year.

Based upon the actuarial assumptions utilized to develop our benefit obligations at March 31, 2017, the following benefit payments are expected to be made to plan participants:



	Other Defined Benefit Pension Plans		Other Post-Retirement Benefits Plan
2018	$	3,498	$	2,187
2019	3,472		1,910
2020	3,915		1,707
2021	3,706		1,565
2022	4,121		1,456
2023-2028	24,117		5,390

The Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the “Act”) provides a prescription drug benefit for Medicare beneficiaries, a benefit we provide to Medicare eligible retirees covered by our post-retirement benefits plan. We have concluded that the prescription drug benefit provided in our post-retirement benefit plan is considered to be actuarially equivalent to the benefit provided under the Act and thus qualifies for the subsidy under the Act. Benefits are subject to a per capita per month cost cap and any costs above the cap become the responsibility of the retiree. The subsidy is applied to reduce the retiree responsibility. As a result, the expected future subsidy no longer reduces our accumulated post-retirement benefit obligation and net periodic benefit cost. We collected subsidies totaling approximately $326 and $284, during fiscal 2017 and fiscal 2016, respectively, which reduced the retiree responsibility for costs in excess of the caps established in the post-retirement benefit plan.

Defined Contribution Plans. We maintain a 401(k) defined contribution plan for eligible United States employees, a 401(k) defined contribution plan for eligible Puerto Rico employees and a similar savings plan for Canadian employees. We provide a match on a specified portion of an employee’s contribution. The United States plan assets are held in trust and invested as directed by the plan participants. The Canadian plan assets are held by insurance companies. The aggregate fair value of plan assets was $556,007 at March 31, 2017. At March 31, 2017, the U.S. plan held 705,876 STERIS ordinary shares with a fair value of $49,030. We paid dividends of $734, $669, and $606 to the plan and participants on STERIS shares held by the plan for the years ended March 31, 2017, 2016, and 2015, respectively. We contributed $15,069, $13,354, and $10,895, to the defined contribution plans for the years ended March 31, 2017, 2016, and 2015, respectively.

We also maintain a domestic non-qualified deferred compensation plan covering certain employees, which formerly allowed for the deferral of compensation for an employee-specified term or until retirement or termination. There have been no employee contributions made to this plan since fiscal 2012. The Plan was amended in fiscal 2012 to disallow deferrals of salary payable in 2012 and subsequent calendar years and of commissions and other incentive compensation payable in respect of the 2013 and subsequent fiscal years. We hold investments in mutual funds to satisfy future obligations of the plan. We account for these assets as available-for-sale securities and they are included in “Other assets” on our accompanying Consolidated Balance Sheets, with a corresponding liability for the plan’s obligation recorded in “Accrued expenses and other.” The aggregate value of the assets was $1,604 and $1,696 at March 31, 2017 and March 31, 2016, respectively. Realized gains and losses on these investments are recorded in “Interest and miscellaneous income” within “Non-operating expenses” on our accompanying Consolidated Statements of Income. Changes in the fair value of the assets are recorded in other comprehensive income on our accompanying balance sheets.

Contingencies	12 Months Ended
Contingencies	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Loss Contingencies by Contingency [Text Block]	We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. On May 31, 2012, our Albert Browne Limited subsidiary received a warning letter from the FDA regarding chemical indicators manufactured in the United Kingdom. These devices are intended for the monitoring of certain sterilization and other processes. The FDA warning letter states that the agency has concerns regarding operational business processes. We do not believe that the FDA's concerns are related to product performance, or that they result from Customer complaints. We have reviewed our processes with the agency and finalized our remediation measures, and are awaiting FDA reinspection. We do not currently believe that the impact of this event will have a material adverse effect on our financial results. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the risks and uncertainties described under the title "product related regulations and claims" in Item 1A. of this Annual Report on Form 10-K. From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 8 to our consolidated financial statements titled, “Income Taxes” in this Annual Report on Form 10-K. Additional information regarding our contingencies is included in Item 7 of Part II titled, “Management’s Discussion and Analysis of Financial Conditions and Results of Operations under "Contingencies". As of March 31, 2017 and 2016, our commercial commitments totaled $57,709 and $56,649, respectively. Commercial commitments include standby letters of credit, letters of credit required as security under our self-insured risk retention policies, and other potential cash outflows resulting from an event that requires payment by us. Approximately $7,694 and $7,050 of the March 31, 2017 and 2016 totals relate to letters of credit required as security under our self-insured risk retention policies. As of March 31, 2017, we had minimum purchase commitments with suppliers for raw material purchases totaling $85,154. As of March 31, 2017, we also had commitments of $1,703 for long term construction contracts.

Business Segment Information

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Business Segment Information

Our Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment and related maintenance and installation services, as well as consumables.

Our Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repairs, and linen management. Linen management services were divested in fiscal 2017.

Our Life Sciences segment offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities.

Our Applied Sterilization Technologies segment offers a contract sterilization and laboratory services for medical device and pharmaceutical Customers and others.

The accounting policies for reportable segments are the same as those for the consolidated Company. Management evaluates performance and allocates resources based on a segment operating income measure. Operating income (loss) for each segment is calculated as the segment’s gross profit less direct expenses and indirect cost allocations, which result in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare Products segment is responsible for the management of all but two manufacturing facilities and uses standard cost to sell products to the other segments. Corporate and other includes the gross profit and direct expenses of the Defense and Industrial business unit, as well as certain unallocated corporate costs related to being a publicly traded company and legacy pension and post-retirement benefits. Segment operating income excludes certain adjustments which include acquisition related costs, amortization of acquired intangibles, restructuring costs and other charges that management believes may or may not recur with similar materiality or impact on operating income in future periods. Management believes that by excluding these items they gain better insight and greater transparency of the operating performance of the segments, thus aiding them in more meaningful financial trend analysis and operational decision making.

The accounting policies for reportable segments are the same as those for the consolidated Company. For the year ended March 31, 2017, revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues.



Years Ended March 31,	2017			2016			2015
Revenues:
Healthcare Products	$	1,260,878		$	1,202,820		$	1,143,336
Healthcare Specialty Services	560,175			427,198			248,538
Life Sciences	327,276			295,970			250,845
Applied Sterilization Technologies	458,231			310,120			205,675
Total reportable segments	2,606,560			2,236,108			1,848,394
Corporate and other	6,196			2,656			1,869
Total revenues	$	2,612,756		$	2,238,764		$	1,850,263
Segment operating income (loss):
Healthcare Products	224,522			180,263			166,515
Healthcare Specialty Services	13,450			25,197			16,629
Life Sciences	96,983			85,466			56,072
Applied Sterilization Technologies	156,010			99,224			59,458
Total reportable segments	490,965			390,150			298,674
Corporate and other	(14,433		)	(11,488		)	(7,542		)
Total segment operating income	$	476,532		$	378,662		$	291,132
Less: Adjustments
Goodwill impairment loss ⁽¹⁾	58,356			—			—
Amortization of inventory and property "step up" to fair value ⁽²⁾	4,743			9,907			1,330
Amortization of purchased intangible assets ⁽²⁾	66,398			47,704			28,317
Acquisition and integration related transaction charges ⁽³⁾	30,082			82,891			32,762
Loss (gain) on fair value adjustment of acquisition related contingent consideration	2,569			(736		)	2,271
Net loss on divestiture of businesses ⁽²⁾	86,574			—			—
Settlement of pension obligation ⁽⁴⁾	—			26,470			—
Restructuring charges	215			(501		)	(759		)
Total operating income	$	227,595		$	212,927		$	227,211

⁽¹⁾For more information regarding our goodwill impairment loss see Note 3 titled, "Goodwill and Intangible Assets".

⁽²⁾For more information regarding our recent acquisitions and divestitures see Note 2 titled, "Business Acquisitions and Divestitures".

⁽³⁾Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.

⁽⁴⁾ See Note 9 titled, "Benefit Plans" for more information related to the settlement of the pension obligation.

Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare Products and Life Sciences segments. Corporate and other includes assets directly attributable to the Defense and Industrial business unit, as well as certain unallocated amounts related to being a publicly traded company.

Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare Products and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare Products and Life Sciences segments. Therefore, their respective amounts are reported together.



March 31,	2017		2016
Assets:
Healthcare Products and Life Sciences	$	1,706,222	$	1,682,457
Healthcare Specialty Services	446,714		759,012
Applied Sterilization Technologies	2,770,366		1,494,638
Total reportable segments	4,923,302		3,936,107
Corporate and other	1,153		2,117
Synergy related goodwill not yet allocated ⁽¹⁾	—		1,408,192
Total assets	$	4,924,455	$	5,346,416

⁽¹⁾Amount is still preliminary as of March 31, 2016, as valuations have not been finalized. Goodwill will be allocated to the Healthcare Products, Healthcare Specialty Services and Applied Sterilization Technologies business segments.



Years Ended March 31,	2017		2016		2015
Capital Expenditures:
Healthcare Products and Life Sciences	$	38,613	$	34,567	$	34,174
Healthcare Specialty Services	42,247		31,309		2,777
Applied Sterilization Technologies	90,941		60,517		48,286
Total Reportable Segments	171,801		126,393		85,237
Corporate and other	1,100		14		18
Total Capital Expenditures	$	172,901	$	126,407	$	85,255
Depreciation, Depletion, and Amortization:
Healthcare Products and Life Sciences	$	46,627	$	49,063	$	41,201
Healthcare Specialty Services	56,890		36,130		19,934
Applied Sterilization Technologies	84,492		58,468		30,369
Total Reportable Segments	188,009		143,661		91,504
Corporate and other	133		79		37
Total Depreciation, Depletion, and Amortization	$	188,142	$	143,740	$	91,541

Financial information for each of our United States and international geographic areas is presented in the following table. Revenues are based on the location of these operations and their Customers. Property, plant and equipment, net are those assets that are identified within the operations in each geographic area.



Years Ended March 31,	2017		2016		2015
Revenues:
United Kingdom	$	229,603	$	144,577	$	51,889
United States	1,803,457		1,662,050		1,449,223
Other foreign locations	579,696		432,137		349,151
Total Revenues	$	2,612,756	$	2,238,764	$	1,850,263



March 31,	2017		2016
Property, Plant, and Equipment, Net
United Kingdom	$	38,535	$	121,853
United States	499,760		505,169
Other foreign locations	377,613		437,297
Property, Plant, and Equipment, Net	$	915,908	$	1,064,319

The decrease in Property, plant and equipment, net within the United Kingdom is primarily related to the divestiture of the Synergy Health UK Linen Management Services business during fiscal 2017.

Common Shares

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Earnings Per Share [Text Block]

Common and Ordinary Shares

In connection with the Combination, each Old STERIS common shareholder received one ordinary share, par value 10 pence, of the Company for each Old STERIS common share held, and each Synergy ordinary shareholder received 0.4308 ordinary shares, par value 10 pence, of the Company and 439 pence in cash, for each Synergy ordinary share held.

We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share:



Years ended March 31,	2017	2016	2015
Denominator (shares in thousands):
Weighted average shares outstanding—basic	85,473	70,698	59,413
Dilutive effect of share equivalents	621	486	632
Weighted average shares outstanding and share equivalents—diluted	86,094	71,184	60,045

Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:



Years ended March 31,	2017	2016	2015
Number of common share options (shares in thousands)	576	263	342

Preferred Shares

Pursuant to an engagement letter dated October 23, 2015, we issued 100,000 preferred shares, par value of £0.10 each, for an aggregate consideration of approximately $15, in satisfaction of debt owed to a service provider. The holders of the preferred shares are entitled to a fixed cumulative preferential annual dividend of 5 percent on the amount paid periodically on the preferred shares respectively held by them. On a return of capital of the Company whether on liquidation or otherwise, the holders of the preferred shares shall be entitled to receive out of the assets of the Company available for distribution to its shareholders the sum of £0.10 per preferred share plus any accrued but unpaid dividend, but will not be entitled to any further participation in the assets of the Company. The holders of the preferred shares will have no right to attend, speak or vote, whether in person or by proxy, at any general meeting of the Company or any meeting of a class of members of the Company in respect of the preferred shares and will not be entitled to receive any notice of meetings.

Repurchases of Common Shares	12 Months Ended
Repurchases of Common Shares	Mar. 31, 2017
Repurchases of Common Shares [Abstract]
Schedule of Treasury Stock by Class [Text Block]	On August 9, 2016, the Company announced that its Board of Directors had authorized the purchase of up to $300 million of our ordinary shares. We may enter into share repurchase contracts until August 2, 2021 to effect these purchases. Shares may be repurchased from time to time through open market transactions, including 10b5-1 plans. The repurchase program may be suspended or discontinued at any time. We obtained 1,286,183 of our ordinary shares during fiscal 2017 for the aggregate amount of $90,475. Prior to the Combination, the Company’s Board of Directors provided authorization to repurchase up to $300 million of STERIS common shares. Under this authorization, we were able to purchase shares from time to time through open market purchases, including transactions pursuant to Rule 10b5-1 plans, or privately negotiated transactions. The authorization was no longer applicable after the Combination with Synergy. We did not make any purchases during fiscal years 2016 or 2015 under the prior stock repurchase authorization. We obtained 168,906 of our shares during fiscal 2017 in the aggregate amount of $7,034 in connection with stock based compensation award programs. We obtained 267,696 of our shares during fiscal 2016 in the aggregate amount of $14,369 in connection with these programs. We obtained 541,700 of our shares during fiscal 2015 in the aggregate amount of $30,687 in connection with these programs.

Share-Based Compensation

12 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

We maintain a long-term incentive plan which we assumed from Old STERIS, that makes available shares for grants, at the discretion of the Compensation Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. Prior to the Combination, awards were made in respect of common shares of Old STERIS. In conjunction with the Combination all outstanding common share denominated awards were converted into an equivalent number of Company ordinary share denominated awards, with the same terms and conditions as applied to the replaced awards. We satisfy share award incentives through the issuance of new ordinary shares.

Stock options provide the right to purchase our ordinary shares at the market price on the date of grant, subject to the terms of the option plans and agreements. Generally, one-fourth of the stock options granted become exercisable for each year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or earlier if the option holder is no longer employed by us (subject to an extended exercise period in some cases for optionees who are age 55 and have at least five years of service). Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of March 31, 2017, 5,628,258 shares remained available for grant under the long-term incentive plan.

The fair value of share-based stock option compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits.

The following weighted-average assumptions were used for options granted during fiscal 2017, fiscal 2016 and fiscal 2015:



	Fiscal 2017		Fiscal 2016		Fiscal 2015
Risk-free interest rate	1.29	%	1.51	%	1.89	%
Expected life of options	5.7 years		5.7 years		5.8 years
Expected dividend yield of stock	1.54	%	1.40	%	1.87	%
Expected volatility of stock	22.92	%	25.06	%	29.86	%

The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 1.85%, 1.55% and 1.46% was applied in fiscal 2017, 2016 and 2015, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually.

A summary of share option activity is as follows:



	Number of Options		Weighted Average Exercise Price		Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at March 31, 2016	1,729,517		$	—
Granted	402,141		69.85
Exercised	(163,563	)	30.36
Forfeited	(22,351	)	62.81
Canceled	(470	)	25.98
Outstanding at March 31, 2017	1,945,274		$	50.28	6.3 years	$	37,462
Exercisable at March 31, 2017	1,126,875		$	40.34	4.9 years	$	32,880

We estimate that 807,550 of the non-vested stock options outstanding at March 31, 2017 will ultimately vest.

The aggregate intrinsic value in the table above represents the total pre-tax difference between the $69.46 closing price of our ordinary shares on March 31, 2017 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of our ordinary shares.

The total intrinsic value of stock options exercised during the years ended March 31, 2017, 2016 and 2015 was $6,454, $13,000 and $31,555, respectively. Net cash proceeds from the exercise of stock options were $4,955, $11,240 and $28,274 for the years ended March 31, 2017, 2016 and 2015, respectively. The tax benefit from stock option exercises was $5,058, $6,281 and $11,526 for the years ended March 31, 2017, 2016 and 2015, respectively.

The weighted average grant date fair value of stock option grants was $13.42, $14.66 and $13.41 for the years ended March 31, 2017, 2016 and 2015, respectively.

Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of March 31, 2017 and 2016 was $1,622 and $2,165, respectively. The fair value of outstanding SARS is revalued at each reporting date and the related liability and expense are adjusted appropriately.

A summary of the non-vested restricted share activity is presented below:



	Number of Restricted Shares		Number of Restricted Share Units		Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2016	872,972		41,641		$	51.98
Granted	241,065		20,309		69.96
Vested	(270,062	)	(21,022	)	40.41
Forfeited	(63,449	)	(6,915	)	63.80
Non-vested at March 31, 2017	780,526		34,013		$	60.87

Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during fiscal 2017 was $11,763.

As of March 31, 2017, there was a total of $33,082 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 2.04 years.

Financial and Other Guarantees

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Product Warranty Disclosure [Text Block]

We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.

Changes in our warranty liability during the periods presented are as follows:



Years Ended March 31,	2017			2016			2015
Balance, Beginning of Year	$	5,909		$	5,579		$	7,765
Warranties issued during the period	11,823			11,194			7,604
Settlements made during the period	(10,871		)	(10,864		)	(9,790		)
Balance, End of Year	$	6,861		$	5,909		$	5,579

We also sell product maintenance contracts to our Customers. These contracts range in terms from one to five years and require us to maintain and repair the product over the maintenance contract term. We initially record amounts due from Customers under these contracts as a liability for deferred service contract revenue on the accompanying Consolidated Balance Sheets within “Accrued expenses and other.” The liability recorded for such deferred service revenue was $32,136, $33,416 and $30,720 as of March 31, 2017, 2016 and 2015, respectively. Such deferred revenue is then amortized on a straight-line basis over the contract term and recognized as service revenue on our accompanying Consolidated Statements of Income. The activity related to the liability for deferred service contract revenues is excluded from the table presented above.

Forward and Swap Contracts

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At March 31, 2017, we held foreign currency forward contracts to buy 110 million Mexican pesos and 10 million Canadian dollars. At March 31, 2017, we held commodity swap contracts to buy 581.5 thousand pounds of nickel.



	Asset Derivatives				Liability Derivatives
	Fair Value at		Fair Value at		Fair Value at		Fair Value at
Balance Sheet Location	March 31, 2017		March 31, 2016		March 31, 2017		March 31, 2016
Prepaid & Other	$	160	$	145	$	—	$	—
Accrued expenses and other	$	—	$	—	$	35	$	122

The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:



	Location of (loss) gain recognized in income	Amount of (loss) gain recognized in income
		Years Ended March 31,
		2017			2016			2015
Foreign currency forward contracts	Selling, general and administrative	$	(1,886	)	$	(683	)	$	(1,457	)
Commodity swap contracts	Cost of revenues	$	376		$	(461	)	$	(373	)

Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of non-functional currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $59,510 at March 31, 2017. These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Fair Value Measurements

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Fair Value Disclosures [Text Block]

Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at March 31, 2017 and March 31, 2016:



									Fair Value Measurements
At March 31,	Carrying Value				Financial assets and liabilities measured at net asset value				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs
									Level 1				Level 2				Level 3
	2017		2016		2017		2016		2017		2016		2017		2016		2017		2016
Assets:
Cash and cash equivalents ⁽¹⁾	$	282,918	$	248,841	$	—	$	23,751	$	282,918	$	225,090	$	—	$	—	$	—	$	—
Forward and swap contracts ⁽²⁾	160		145		—		—		—		—		160		145		—		—
Investments ⁽³⁾	12,552		6,192		—		—		12,552		6,192		—		—		—		—
Liabilities:
Forward and swap contracts ⁽²⁾	$	35	$	122	$	—	$	—	$	—	$	—	$	35	$	122	$	—	$	—
Deferred compensation plans ⁽³⁾	1,587		1,765		—		—		1,587		1,765		—		—		—		—
Long term debt ⁽⁴⁾	1,478,361		1,567,796		—		—		—		—		1,496,966		1,588,764		—		—
Contingent consideration obligations ⁽⁵⁾	4,451		5,886		—		—		—		—		—		—		4,451		5,886

⁽¹⁾ Money market fund holdings are valued at fair value using the net asset value per share practical expedient and are not included within the fair value hierarchy. These money market funds are being presented in the table above to permit a reconciliation of the fair value hierarchy to total cash and cash equivalents.

⁽²⁾ The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.

⁽³⁾We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the value of the investment are recognized each period based on the fair value of the investment.

⁽⁴⁾We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.

⁽⁵⁾ Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at March 31, 2017 are summarized as follows:



	Contingent Consideration
Balance at March 31, 2015	$	2,500
Liabilities assumed as a result of the Combination	1,561
Additions	2,730
Payments	(858		)
Foreign currency translation adjustments	(47		)
Balance at March 31, 2016	$	5,886
Additions	3,592
Payments	(5,416		)
Foreign currency translation adjustments	389
Balance at March 31, 2017	$	4,451

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Reclassifications out of AOCI (Notes)

12 Months Ended

Mar. 31, 2017

Reclassifications out of AOCI Equity [Abstract]

Reclassifications of out AOCI [Text Block]

Accumulated other comprehensive income (loss) shown in our Consolidated Statements of Shareholders' Equity consists of the following:



Years Ended March 31,	2017			2016			2015
Cumulative foreign currency translation adjustment	$	(238,525	)	$	(72,594	)	$	(58,848	)
Amortization of pension and postretirement benefit plans costs, net of taxes	(2,355		)	5,108			(8,889		)
Unrealized gain (loss) on available for sale securities	178			(673		)	1,068
Total	$	(240,702	)	$	(68,159	)	$	(66,669	)

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]

Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the years ended March 31, 2017 and March 31, 2016 were as follows:



	Gain (Loss) on Available for Sale Securities ⁽¹⁾						Defined Benefit Plans ⁽²⁾						Foreign Currency Translation ⁽³⁾						Total Accumulated Other Comprehensive Income (Loss)
	2017			2016			2017			2016			2017			2016			2017			2016
Beginning Balance	$	(673	)	$	1,068		$	5,108		$	(8,889	)	$	(72,594	)	$	(58,848	)	$	(68,159	)	$	(66,669	)
Other Comprehensive Income (Loss) before reclassifications	745			(2,278		)	(5,491		)	(1,371		)	(165,931		)	(13,746		)	(170,677		)	(17,395		)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	106			537			(1,972		)	15,368			—			—			(1,866		)	15,905
Net current-period Other Comprehensive Income (Loss)	851			(1,741		)	(7,463		)	13,997			(165,931		)	(13,746		)	(172,543		)	(1,490		)
Ending Balance	$	178		$	(673	)	$	(2,355	)	$	5,108		$	(238,525	)	$	(72,594	)	$	(240,702	)	$	(68,159	)

⁽¹⁾ Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the Consolidated

Statements of Income.

⁽²⁾ Amortization (gain) of defined benefit pension items is reported in the Selling, general, and administrative expense line of the Consolidated

Statements of Income.

⁽³⁾ The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated other comprehensive income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Related Party Transactions (Notes)	12 Months Ended
Related Party Transactions (Notes)	Mar. 31, 2017
Related Party Transaction [Line Items]
Related Party Transactions Disclosure [Text Block]	20. RELATED PARTY TRANSACTIONS On October 26, 2015, in connection with the consummation of the Combination, Dr. Richard Steeves, Group Executive Officer and Director of Synergy, elected to exercise employee stock options and hold the resulting Synergy shares. This exercise created an obligation on the part of Dr. Steeves totaling £3.1 million for income taxes and United Kingdom National Insurance contributions to be remitted by Synergy on his behalf, as well as the option exercise price. Synergy’s past practice, when requested by the employee who elected to exercise stock options and hold the resulting shares, was to pay income taxes and U.K. National Insurance contributions when due and obtain reimbursement from the employee for such taxes and the option exercise price within 90 days from the date of remittance. Upon completion of the Combination on November 2, 2015, Dr. Steeves ceased to be the Group Executive Officer and a Director of Synergy and became a non-executive Director of STERIS plc. Pursuant to the terms of the Combination, Dr. Steeves received STERIS plc shares and cash proceeds on November 6, 2015 in exchange for his Synergy equity holdings. The amount of the cash proceeds was £1.25 million, which was retained by Synergy and applied to his obligation, thereby reducing it to £1.86 million. Synergy remitted the £3.1 million of income taxes and U.K. National Insurance contributions to the appropriate United Kingdom agencies on November 20, 2015. Dr. Steeves remitted the balance of £1.86 million to Synergy on January 27, 2016 in satisfaction of his obligation to reimburse Synergy for the sums remitted by Synergy on his behalf. The arrangement between Dr. Steeves and Synergy effectively created a receivable that, under U.S. GAAP, was considered a loan. Loans by a public company to its executive officers and directors are prohibited under the Sarbanes-Oxley Act of 2002 and are also prohibited by the Company’s corporate governance policies and procedures. STERIS Corporation was not aware at the time of the closing of the Combination that Synergy had agreed to defer to a later date Dr. Steeves's obligation to reimburse the income taxes and U.K. National Insurance contributions and the option exercise price. Senior management learned of the arrangement when it was identified in the Company’s third quarter internal controls processes. As a result of these transactions, Prepaid expenses and other current assets in the Company’s consolidated balance sheet as of the November 2, 2015 acquisition date, included the amount outstanding from Dr. Steeves, as well as a further amount due from another Synergy employee who also elected to exercise and hold Synergy shares immediately prior to the completion of the Combination. The other employee was neither an executive officer nor director of the Company. This additional amount was $368, which resulted in total receivables for both option exercises of $5,152 at the November 2, 2015 acquisition date. The balances were remitted to Synergy in January 2016 and as a result of the repayments, no such amounts remain outstanding.

Quarterly Results (Unaudited)

12 Months Ended

Mar. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information [Text Block]



Quarters Ended	March 31,			December 31,			September 30,			June 30,
Fiscal 2017
Revenues:
Product	$	333,124		$	302,260		$	292,216		$	271,750
Service	348,065			344,514			354,199			366,628
Total Revenues	681,189			646,774			646,415			638,378
Cost of Revenues:
Product	173,855			152,879			155,110			142,698
Service	227,209			236,286			243,397			255,690
Total Cost of Revenues	401,064			389,165			398,507			398,388
Gross Profit	280,125			257,609			247,908			239,990
Percentage of Revenues	41.1		%	39.8		%	38.4		%	37.6		%
Restructuring Expenses	(5		)	18			48			154
Net Income Attributable to Shareholders	$	26,143		$	(4,996	)	$	40,416		$	48,401
Basic Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.31		$	(0.06	)	$	0.47		$	0.56
Diluted Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.31		$	(0.06	)	$	0.47		$	0.56

Fiscal 2016
Revenues:
Product	$	318,438		$	305,156		$	274,145		$	232,307
Service	371,839			313,532			215,752			207,595
Total Revenues	690,277			618,688			489,897			439,902
Cost of Revenues:
Product	174,642			165,575			148,088			129,856
Service	251,746			214,932			132,488			125,956
Total Cost of Revenues	426,388			380,507			280,576			255,812
Gross Profit	263,889			238,181			209,321			184,090
Percentage of Revenues	38.2		%	38.5		%	42.7		%	41.8		%
Restructuring Expenses	156			(194		)	(56		)	(726		)
Net Income Attributable to Shareholders	$	57,740		$	20,045		$	8,687		$	24,291
Basic Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.67		$	0.26		$	0.15		$	0.41
Diluted Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.67		$	0.26		$	0.14		$	0.40

Nature of Operations and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Consolidation, Policy

Use of Estimates, Policy

Cash and Cash Equivalents, Policy

Information supplementing our Consolidated Statements of Cash Flows is as follows:



Years Ended March 31,	2017		2016		2015
Cash paid during the year for:
Interest	$	42,797	$	37,165	$	19,124
Income taxes	78,009		60,885		52,707
Cash received during the year for income tax refunds	2,002		1,697		2,405

Revenue Recognition, Policy

Trade and Other Accounts Receivable, Policy

Inventory, Policy

Property, Plant and Equipment, Policy

We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table:



Asset Type		Useful Life (years)
Land improvements		3-40
Buildings and leasehold improvements		2-50
Machinery and equipment		2-20
Information Systems		2-20
Radioisotope (cobalt-60)		20
Linens		1-5

Goodwill and Intangible Assets, Policy

Investment, Policy

Impairment or Disposal of Long-Lived Assets, Policy

Asset Retirement Obligation [Policy Text Block]

Business Combinations Policy

Liability Reserve Estimate, Policy

Pension and Other Postretirement Plans, Policy

Fair Value of Financial Instruments, Policy

Foreign Currency Transactions and Translations Policy

Derivatives, Policy

Standard Product Warranty, Policy

Shipping and Handling Cost, Policy

Advertising Costs, Policy

Research and Development Expense, Policy

Income Tax, Policy

Medical Device Excise Tax

Share-based Compensation, Option and Incentive Plans Policy

Costs Associated with Exit or Disposal Activities or Restructurings, Policy

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Standards Impacting the Company are presented in the following table:



Standard	Date of Issuance	Description	Date of Adoption	Effect on the financial statements or other significant matters
Standards that have recently been adopted
ASU 2015-05, "Goodwill and other-Internal-Use Software" (Subtopic 350-40)	April 2015	The standard provides guidance on a customer's accounting for fees paid in cloud computing arrangements. Previously, there was no U.S. GAAP guidance on accounting for such fees from the customer's perspective. Under the standard, customers will apply the same criteria as vendors to determine whether the arrangement contains a software license or is solely a service contract. The determination could impact the classification of advance payments in the statements of financial position and cash flows as well as the classification of the expenses in the results of operations. The standard is effective for annual periods beginning after December 15, 2015 and interim periods within that period. Early adoption is permitted.	First Quarter Fiscal 2017	The prospective adoption of this standard did not have a material impact on our statements of consolidated financial position, results of operations and cash flows.
ASU 2015-07, "Fair Value Measurement: Disclosures for Investments in Certain Entities that Calculate Net Asset Value per Share (or its Equivalent)" (Topic 820)	May 2015	This standard removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the asset value per share practical expedient. The standard also removes the requirement to make certain disclosures for these investments that are eligible to be measured at fair value using the net asset value per share practical expedient.	Fourth Quarter Fiscal 2017	We retrospectively applied the requirements of this standard to investments that use net asset value per share as a practical expedient for all comparative periods presented in Note 9. Benefit Plans and Note 17. Fair Value Measurements.
ASU 2016-09, "Stock Compensation: Improvements to Employee Share-Based Payment Accounting" (Topic 718)	March 2016	The update simplifies several aspects of the accounting for share-based payment award transactions, including income tax consequences, the classification of awards as either equity or liabilities, and the classification on the statement of cash flows. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted.	First Quarter Fiscal 2017	As a result of the adoption of this standard, we recorded $5.1 million of excess tax benefits associated with share based compensation in the Consolidated Statements of Income for the year-ended March 31, 2017 and have included the associated cash flows as cash provided by operating activities. Prior periods have not been restated.



Standards that have not yet been adopted
ASU 2014-09, "Revenue from Contracts with Customers" and subsequently issued amendments	May 2014	The standard will replace existing revenue recognition standards and significantly expand the disclosure requirements for revenue arrangements. It may be adopted either retrospectively or on a modified retrospective basis to new contracts and existing contracts with remaining performance obligations as of the effective date. The standard update is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is not permitted before the original public entity effective date of December 15, 2016.	N/A	We have not completed our assessment of the new revenue recognition standard, however, we currently anticipate adopting this standard using the modified-retrospective method. We are in the process of quantifying the potential impacts that the standard will have on our consolidated statements of financial position, results of operations and cash flows.
ASU 2015-11, "Inventory - Simplifying the Measurement of Inventory" (Topic 330)	July 2015	The standard requires an entity to measure inventory within the scope of this update at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The standard is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years and should be applied prospectively. Early adoption is permitted.	N/A	We do not expect the adoption of this standard to have a material impact on our consolidated financial statements.
ASU 2016-01, "Financial Instruments - Overall - Recognition and Measurement of Financial Assets and Liabilities" (Subtopic 825-10)	January 2016	The standard changes how equity investments are measured and presents changes in the fair value of financial liabilities measured under the fair value option. Presentation and disclosure requirements for financial instruments are also affected. Entities will be required to measure equity investments that do not result in consolidation and are not recorded under the equity method at fair value with changes in fair value recognized in net income. The standard clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years.	N/A	We are in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows.
ASU 2016-02, "Leases" (Topic 842)	February 2016	The update will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted.	N/A	We are in the process of evaluating the impact that the standard will have on our statements of consolidated financial position, results of operations and cash flows.



ASU 2016-07, "Investments - Equity Method and Joint Ventures, Simplifying the Transition to the Equity Method of Accounting" (Topic 323)	March 2016	The update replaces the previous requirement to retroactively adopt the equity method. The new standard requires that the equity method investor add the cost of acquiring the additional interest in the investee to the current basis of the investor's previously held interest and adopt the equity method of accounting as of the date the investment becomes qualified for equity method accounting. The standard is effective for annual periods beginning after December 15, 2016 and interim periods within that period. Early adoption is permitted.	N/A	We do not expect the adoption of this standard to have a material impact on our statements of consolidated financial position, results of operations and cash flows.
ASU 2016-15, "Statement of Cash Flows" (Topic 230)	August 2016	This update provides guidance on the following specific cash flow issues: Debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees, beneficial interests in securitization transactions, and separately identifiable cash flows and application of the predominance principle. The standard is effective for annual periods beginning after December 15, 2017 and interim periods within that period. Early adoption is permitted.	N/A	We are in the process of evaluating the impact that the standard will have on our statement of cash flows.
ASU 2016-16, "Income Taxes, Intra-Entity Transfers of Assets Other Than Inventory" (Topic 740)	October 2016	The update improves the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. The new standard requires the recognition of income tax consequences resulting from an intra-entity transfer of an asset other than inventory when the transfer occurs. The standard is effective for annual periods beginning after December 15, 2018. Early adoption is permitted.	N/A	We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.
ASU 2017-04, "Intangibles - Goodwill and Other, Simplifying the Test for Goodwill Impairment" (Topic 350)	January 2017	This update eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities (including unrecognized assets and liabilities) following the procedures that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, under the amendments of this standard, an entity would perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. The loss should not exceed the total amount of goodwill allocated to that reporting unit. Tax effects should be considered. The standard is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted.	N/A	We are in process of evaluating the impact that the standard will have on our annual goodwill impairment test.




ASU 2017-07 "Compensation - Retirement Benefits - Improving the Presentation of Net Periodic Pension and Net Periodic Postretirement Benefit Cost" (Topic 715)	March 2017	This standard requires that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside the subtotal of income from operations, if one is presented.	N/A	We are in process of evaluating the impact that the standard will have on our annual goodwill impairment test.

Nature of Operations and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Cash Flow, Supplemental Disclosures

Information supplementing our Consolidated Statements of Cash Flows is as follows:



Years Ended March 31,	2017		2016		2015
Cash paid during the year for:
Interest	$	42,797	$	37,165	$	19,124
Income taxes	78,009		60,885		52,707
Cash received during the year for income tax refunds	2,002		1,697		2,405

Property, Plant and Equipment

We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table:



Asset Type		Useful Life (years)
Land improvements		3-40
Buildings and leasehold improvements		2-50
Machinery and equipment		2-20
Information Systems		2-20
Radioisotope (cobalt-60)		20
Linens		1-5

Information related to the major categories of our depreciable assets is as follows:



March 31,	2017			2016
Land and land improvements ⁽¹⁾	$	46,848		$	39,051
Buildings and leasehold improvements	393,692			452,120
Machinery and equipment	508,247			599,631
Linens ⁽²⁾	—			42,874
Information systems	119,920			127,464
Radioisotope	436,787			447,892
Construction in progress ⁽¹⁾	77,421			79,291
Total property, plant, and equipment	1,582,915			1,788,323
Less: accumulated depreciation and depletion	(667,007		)	(724,004		)
Property, plant, and equipment, net	$	915,908		$	1,064,319

⁽¹⁾ Land is not depreciated. Construction in progress is not depreciated until placed in service.

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables)

12 Months Ended

Mar. 31, 2017

Business Acquisition [Line Items]

Business Combination With Synergy Total Consideration [Table Text Block]



Cash consideration	$	402,494
STERIS plc shares (25,848,798 ordinary shares issued)	1,887,479
Fair value of consideration available to vested Synergy share option holders	4,819
Total purchase consideration	$	2,294,792

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

The estimated fair values and useful lives of these intangible assets are as follows:



	Total		Useful Life
Customer relationships	$	459,074	15 years
Trade names	19,404		15 years
Technology	25,718		6 years
Total intangible assets acquired	$	504,196

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

he table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2017, 2016 and 2015 acquisitions.



	Fiscal Year 2017									Fiscal Year 2016												Fiscal Year 2015
	Medisafe⁽¹⁾			Compass ⁽¹⁾			Phoenix Surgical and Endo-Tek ⁽¹⁾			Synergy Health plc			Gepco			Black Diamond			Other Acquisitions			Dana			AGAPE			IMS
Cash	$	3,751		$	—		$	769		$	53,057		$	1,108		$	—		$	—		$	135		$	—		$	—
Accounts receivable	3,614			629			1,123			103,093			4,161			2,966			3,859			617			342			16,594
Inventory	2,454			659			950			30,074			1,926			3,309			1,108			388			—			8,478
Property, plant and equipment	639			13			1,092			496,555			3,421			607			1,979			743			—			15,074
Other assets	—			31			46			19,175			946			54			—			—			—			842
Intangible assets	17,151			5,992			—			504,196			61,900			13,500			14,829			6,363			1,200			62,000
Goodwill	19,618			8,987			12,794			1,685,524			104,485			31,792			20,630			4,311			1,899			81,587
Total Assets	47,227			16,311			16,774			2,891,674			177,947			52,228			42,405			12,557			3,441			184,575
Current liabilities	(6,082		)	(309		)	(1,373		)	(107,932		)	(1,473		)	(4,525		)	(1,277		)	(143		)	(26		)	(11,670		)
Long-term indebtedness	—			—			—			(321,082		)	—			—			—			—			—			—
Non-current liabilities	(2,877		)	—			(295		)	(159,112		)	—			(1,548		)	(49		)	—			—			—
Total Liabilities	(8,959		)	(309		)	(1,668		)	(588,126		)	(1,473		)	(6,073		)	(1,326		)	(143		)	(26		)	(11,670		)
Net Assets	$	38,268		$	16,002		$	15,106		$	2,303,548		$	176,474		$	46,155		$	41,079		$	12,414		$	3,415		$	172,905

⁽¹⁾Purchase price allocation is still preliminary as of March 31, 2017, as valuations have not been finalized.

Divestitures

Netherlands Linen Management Services

US Linen Management Services

Synergy Health Labs

Applied Infection Control

UK Linen Management Services

The purchase price allocation below represents Synergy's opening balance sheet as of November 2, 2015:



	November 2, 2015 (as previously reported)			Adjustments			November 2, 2015 (revised)
Cash	$	53,057		$	—		$	53,057
Accounts receivable	107,341			(4,248		)	103,093
Inventory	30,074			—			30,074
Property, plant and equipment	534,879			(38,324		)	496,555
Other assets	19,708			(533		)	19,175
Intangible assets	806,526			(302,330		)	504,196
Goodwill	1,411,781			273,743			1,685,524
Total assets	2,963,366			(71,692		)	2,891,674

Current liabilities	(108,192		)	260			(107,932		)

Long-term indebtedness	(321,082		)	—			(321,082		)
Non-current liabilities	(230,544		)	71,432			(159,112		)
Total Liabilities	(659,818		)	71,692			(588,126		)

Net Assets	$	2,303,548		$	—		$	2,303,548

The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2017, 2016 and 2015 acquisitions.



	Fiscal Year 2017									Fiscal Year 2016												Fiscal Year 2015
	Medisafe⁽¹⁾			Compass ⁽¹⁾			Phoenix Surgical and Endo-Tek ⁽¹⁾			Synergy Health plc			Gepco			Black Diamond			Other Acquisitions			Dana			AGAPE			IMS
Cash	$	3,751		$	—		$	769		$	53,057		$	1,108		$	—		$	—		$	135		$	—		$	—
Accounts receivable	3,614			629			1,123			103,093			4,161			2,966			3,859			617			342			16,594
Inventory	2,454			659			950			30,074			1,926			3,309			1,108			388			—			8,478
Property, plant and equipment	639			13			1,092			496,555			3,421			607			1,979			743			—			15,074
Other assets	—			31			46			19,175			946			54			—			—			—			842
Intangible assets	17,151			5,992			—			504,196			61,900			13,500			14,829			6,363			1,200			62,000
Goodwill	19,618			8,987			12,794			1,685,524			104,485			31,792			20,630			4,311			1,899			81,587
Total Assets	47,227			16,311			16,774			2,891,674			177,947			52,228			42,405			12,557			3,441			184,575
Current liabilities	(6,082		)	(309		)	(1,373		)	(107,932		)	(1,473		)	(4,525		)	(1,277		)	(143		)	(26		)	(11,670		)
Long-term indebtedness	—			—			—			(321,082		)	—			—			—			—			—			—
Non-current liabilities	(2,877		)	—			(295		)	(159,112		)	—			(1,548		)	(49		)	—			—			—
Total Liabilities	(8,959		)	(309		)	(1,668		)	(588,126		)	(1,473		)	(6,073		)	(1,326		)	(143		)	(26		)	(11,670		)
Net Assets	$	38,268		$	16,002		$	15,106		$	2,303,548		$	176,474		$	46,155		$	41,079		$	12,414		$	3,415		$	172,905

Business Acquisition, Pro Forma Information [Table Text Block]



	Fiscal Year Ended March 31,
Amounts are unaudited	2016		2015
Net revenues	$	2,619,056	$	2,499,140
Net income from continuing operations	188,269		152,057

Goodwill and Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Table Text Block]

Information regarding our intangible assets is as follows:



	2017				2016
March 31,	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Customer relationships	$	597,386	$	96,648	$	879,525	$	64,268
Non-compete agreements	4,722		3,629		4,730		3,503
Patents and technology	211,812		86,665		213,317		70,801
Trademarks and tradenames	80,223		32,547		129,690		18,318
Supplier relationships	54,800		4,567		54,800		1,827
Other	10		10		10		16
Total	$	948,953	$	224,066	$	1,282,072	$	158,733

Schedule of Goodwill [Table Text Block]

Changes to the carrying amount of goodwill for the years ended March 31, 2017, 2016 and 2015 were as follows:



	Healthcare Products Segment			Healthcare Specialty Services Segment			Life Sciences Segment			Applied Sterilization Technologies Segment			Synergy Combination			Total
Balance at March 31, 2015	$	324,873		$	150,844		$	33,889		$	83,035		$	—		$	592,641
Goodwill acquired or allocated	40,043			3,428			113,284			—			1,408,192			1,564,947
Foreign currency translation adjustments	(1,146		)	—			161			—			—			(985		)
Balance at March 31, 2016	363,770			154,272			147,334			83,035			1,408,192			2,156,603
Goodwill acquired or allocated	19,618			21,781			—			—			—			41,399
Synergy allocation	—			376,807			—			1,308,717			(1,411,781		)	273,743
Divestitures	—			(85,806		)	—			—			—			(85,806		)
Impairment	—			(58,356		)	—			—			—			(58,356		)
Foreign currency translation adjustments	(5,623		)	(32,819		)	(820		)	(60,607		)	3,589			(96,280		)
Balance at March 31, 2017	$	377,765		$	375,879		$	146,514		$	1,331,145		$	—		$	2,231,303

Schedule of Expected Amortization Expense

Based upon the current amount of intangible assets subject to amortization, the amortization expense for each of the five succeeding fiscal years is estimated to be as follows:



	2018		2019		2020		2021		2022
Estimated amortization expense	$	64,863	$	64,540	$	63,486	$	62,847	$	60,018

Inventories, Net (Tables)

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Schedule of Inventory, Current

Inventories, net consisted of the following:



March 31,	2017			2016
Raw materials	$	65,300		$	62,673
Work in process	26,538			19,614
Finished goods	140,559			146,820
LIFO reserve	(16,706		)	(17,608		)
Reserve for excess and obsolete inventory	(17,854		)	(18,707		)
Inventories, net	$	197,837		$	192,792

Property, Plant and Equipment (Tables)

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Schedule of Change in Asset Retirement Obligation [Table Text Block]

The following table summarizes the activity in the liability for asset retirement obligations.



	Asset Retirement Obligations
Balance at March 31, 2016	$	10,342
Liabilities incurred during the period	222
Accretion expense and change in estimate	(231		)
Foreign currency movement	(380		)
Balance at March 31, 2017	$	9,953

Schedule of Future Minimum Lease Payments for Capital Leases

Future minimum annual rentals payable under noncancelable operating lease agreements at March 31, 2017 were as follows:



	Operating Leases
2018	$	23,718
2019	15,132
2020	11,088
2021	7,329
2022 and thereafter	40,140
Total minimum lease payments	$	97,407

Property, Plant and Equipment

We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table:



Asset Type		Useful Life (years)
Land improvements		3-40
Buildings and leasehold improvements		2-50
Machinery and equipment		2-20
Information Systems		2-20
Radioisotope (cobalt-60)		20
Linens		1-5

Information related to the major categories of our depreciable assets is as follows:



March 31,	2017			2016
Land and land improvements ⁽¹⁾	$	46,848		$	39,051
Buildings and leasehold improvements	393,692			452,120
Machinery and equipment	508,247			599,631
Linens ⁽²⁾	—			42,874
Information systems	119,920			127,464
Radioisotope	436,787			447,892
Construction in progress ⁽¹⁾	77,421			79,291
Total property, plant, and equipment	1,582,915			1,788,323
Less: accumulated depreciation and depletion	(667,007		)	(724,004		)
Property, plant, and equipment, net	$	915,908		$	1,064,319

⁽¹⁾ Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Tables)

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

2017 Senior Notes [Table Text Block]

as of March 31, 2017:



	2017
$50,000 Senior notes at 3.93% due 2027	$	50,000
€60,000 Senior notes at 1.86% due 2027	64,414
$45,000 Senior notes at 4.03% due 2029	45,000
€20,000 Senior notes at 2.04% due 2029	21,471
£45,000 Senior notes at 3.04% due 2029	56,040
€19,000 Senior notes at 2.30% due 2032	20,398
£30,000 Senior notes at 3.17% due 2032	37,360
Total 2017 Senior Notes	$	294,683

Schedule of Maturities of Long-term Debt [Table Text Block]

The combined annual aggregate amount of maturities of our outstanding debt by fiscal year is as follows:



2018	$	30,000
2019	117,500
2020	459,104
2021	35,000
2022 and thereafter	840,684
Total	$	1,482,288

Schedule of Debt

Indebtedness as of March 31, 2017 and 2016 was as follows:



	2017			2016
Private Placement	$	960,684		$	666,000
Deferred financing fees	(3,927		)	(3,420		)
Credit Agreement and Swing Line Facility	521,604			905,216
Total long term debt	$	1,478,361		$	1,567,796

Additional Consolidated Balance Sheets Information (Tables)

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Schedule of Accrued Liabilities

Additional information related to our Consolidated Balance Sheet is as follows:



March 31,	2017		2016
Accrued payroll and other related liabilities:
Compensation and related items	$	29,777	$	30,175
Accrued vacation/paid time off	8,651		14,368
Accrued bonuses	20,715		31,502
Accrued employee commissions	16,201		13,809
Other post-retirement benefits obligations-current portion	2,187		2,463
Other employee benefit plans' obligations-current portion	1,044		1,659
Total accrued payroll and other related liabilities	$	78,575	$	93,976
Accrued expenses and other:
Deferred revenues	$	71,020	$	56,238
Self-insured risk reserves-current portion	6,633		8,266
Accrued dealer commissions	16,122		12,717
Accrued warranty	6,861		5,909
Other	54,253		70,245
Total accrued expenses and other	$	154,889	$	153,375
Other liabilities:
Self-insured risk reserves-long-term portion	$	15,584	$	13,257
Other post-retirement benefits obligations-long-term portion	13,821		15,932
Defined benefit pension plans obligations-long-term portion	27,234		25,301
Other employee benefit plans obligations-long-term portion	3,661		4,366
Accrued long-term income taxes	2,089		—
Asset retirement obligation-long-term portion	9,953		10,342
Other	10,331		15,100
Total other liabilities	$	82,673	$	84,298

Income Tax Expense (Tables)

12 Months Ended

Mar. 31, 2017

Income Tax Expense [Abstract]

Schedule of Deferred Tax Assets and Liabilities

The significant components of the deferred tax assets and liabilities recorded in our accompanying balance sheets at March 31, 2017 and 2016 were as follows:



March 31,	2017			2016
Deferred Tax Assets:
Post-retirement benefit accrual	$	6,116		$	7,016
Compensation	17,196			25,436
Net operating loss carryforwards	35,129			26,151
Accrued expenses	7,807			7,521
Insurance	4,957			4,226
Deferred income	8,962			7,910
Bad debt	1,740			2,059
Pension	4,647			5,155
Other	781			2,208
Deferred Tax Assets	87,335			87,682
Less: Valuation allowance	16,366			16,435
Total Deferred Tax Assets	70,969			71,247
Deferred Tax Liabilities:
Depreciation and depletion	74,092			85,807
Intangibles	156,291			226,809
Other	3,631			3,744
Total Deferred Tax Liabilities	234,014			316,360
Net Deferred Tax Assets (Liabilities)	$	(163,045	)	$	(245,113	)

Schedule of Income before Income Tax, Domestic and Foreign

Income from continuing operations before income taxes was as follows:



Years Ended March 31,	2017			2016			2015
United States operations	$	189,429		$	105,758		$	161,165
United Kingdom operations	(36,420		)	(20,553		)	15,824
Other Foreign Locations operations	31,637			86,679			31,831
	$	184,646		$	171,884		$	208,820

Schedule of Components of Income Tax Expense (Benefit)

The components of the provision for income taxes related to income from continuing operations consisted of the following:



Years Ended March 31,	2017			2016			2015
Current:
United States federal	$	43,900		$	41,653		$	52,234
United States state and local	8,171			7,943			8,551
United Kingdom	362			2,194			3,633
Other foreign locations	21,094			13,924			8,842
	73,527			65,714			73,260
Deferred:
United States federal	10,293			1,427			1,436
United States state and local	2,131			299			214
United Kingdom	(2,292		)	(6,973		)	(676		)
Other foreign locations	(9,644		)	(168		)	(478		)
	488			(5,415		)	496
Total Provision for Income Taxes	$	74,015		$	60,299		$	73,756

provision for taxes rate reconciliation



Years Ended March 31,	2017		2016		2015
Federal statutory tax rate	20.0	%	35.0	%	35.0	%
Increase (decrease) in accruals for uncertain tax positions	0.3	%	0.2	%	—	%
State and local taxes, net of federal income tax benefit	3.8	%	3.3	%	2.8	%
Increase in valuation allowances	0.1	%	1.0	%	2.1	%
Research and development credit	(1.1	)%	—	%	—	%
Foreign income tax credit	—	%	(0.6	)%	(1.0	)%
Difference in non-United States tax rates	—	%	(8.5	)%	(3.6	)%
Difference in non-United Kingdom tax rates	6.0	%	—	%	—	%
Excise tax gross-up	—	%	3.4	%	—	%
U.S. manufacturing deduction	(2.5	)%	(2.5	)%	(1.6	)%
Excess tax benefit for equity compensation	(2.8	)%	—	%	—	%
Rate changes on deferred tax assets and liabilities	(2.3	)%	—	%	—	%
Acquisitions and divestitures	9.0	%	—	%	—	%
Goodwill impairment on divestitures	7.9	%	—	%	—	%
Capitalized acquisition costs	0.2	%	5.3	%	2.2	%
All other, net	1.5	%	(1.5	)%	(0.6	)%
Total Provision for Income Taxes	40.1	%	35.1	%	35.3	%

Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible

A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows:



	2017			2016
Unrecognized Tax Benefits Balance at April 1	$	3,527		$	—
Increases for tax provisions of current year	510			316
Balances related to acquired/disposed businesses	(1,502		)	3,422
Other decreases, including currency translation	(651		)	(211		)
Unrecognized Tax Benefits Balance at March 31	$	1,884		$	3,527

Benefit Plans (Tables)

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Schedule of Expected Benefit Payments

Based upon the actuarial assumptions utilized to develop our benefit obligations at March 31, 2017, the following benefit payments are expected to be made to plan participants:



	Other Defined Benefit Pension Plans		Other Post-Retirement Benefits Plan
2018	$	3,498	$	2,187
2019	3,472		1,910
2020	3,915		1,707
2021	3,706		1,565
2022	4,121		1,456
2023-2028	24,117		5,390

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)

During fiscal 2018, we will amortize the following pre-tax amounts from accumulated other comprehensive income:



	Other Post-Retirement Benefits Plan
	Other Post-Retirement Benefits Plan
Actuarial loss	$	739
Prior Service Cost	(3,263		)

Schedule of Accrued Liabilities

Amounts recognized in the consolidated balance sheets consist of the following:



	Other Defined Benefit Pension Plans						Other Post-Retirement Benefits Plan
	2017			2016			2017			2016
Current liabilities	$	—		$	—		$	(2,187	)	$	(2,463	)
Noncurrent liabilities	(27,234		)	(24,589		)	(13,821		)	(15,917		)
	$	(27,234	)	$	(24,589	)	$	(16,008	)	$	(18,380	)

Schedule of Accumulated and Projected Benefit Obligations



	Other Defined Benefit Pension Plans
	2017		2016
Aggregate fair value of plan assets	$	101,663	$	104,353
Aggregate accumulated benefit obligations	128,897		128,942
Aggregate projected benefit obligations	128,897		128,942

Components of Net Periodic Benefits Cost and Other Amounts Recognized in Other Comprehensive Income [Table Text Block]

Components of the annual net periodic benefit cost of our defined benefit pension plans and our other post-retirement benefits plan were as follows:



	AMSCO Plan								Other Defined Benefit Pension Plans								Other Post-Retirement Benefits Plan
	2017		2016			2015			2017			2016			2015		2017			2016			2015
Service cost	$	—	$	27		$	140		$	1,650		$	961		$	—	$	—		$	—		$	—
Interest cost	—		560			1,887			3,434			1,659			—		554			593			691
Expected return on plan assets	—		(1,008		)	(3,139		)	(2,853		)	(1,324		)	—		—			—			—
Prior service cost recognition	—		—			—			—			(142		)	—		(3,263		)	(3,263		)	(3,263		)
Net amortization and deferral	—		602			1,106			—			—			—		739			828			721
Curtailments/settlements	—		26,470			—			—			(326		)	—		—			—			—
Net periodic benefit cost	$	—	$	26,651		$	(6	)	$	2,231		$	828		$	—	$	(1,970	)	$	(1,842	)	$	(1,851	)
Recognized in other comprehensive loss (income) before tax:
Net loss (gain) occurring during year	$	—	$	—		$	6,706		$	(7,553	)	$	(3,733	)	$	—	$	531		$	673		$	2,327
Amortization of prior service credit	—		—			—			—			—			—		3,263			3,263			3,263
Amortization of net loss	—		(602		)	(1,106		)	—			—			—		(739		)	(721		)	(721		)
Total recognized in other comprehensive loss (income)	—		(602		)	5,600			(7,553		)	(3,733		)	—		3,055			3,215			4,869
Total recognized in total benefits cost and other comprehensive loss (income)	$	—	$	26,049		$	5,594		$	(5,322	)	$	(2,905	)	$	—	$	1,085		$	1,373		$	3,018

Schedule of Net Benefit Costs

The following table presents significant assumptions used to determine the net periodic benefit costs for the years ended March 31:



	2017		2016		2015
Discount Rate:
AMSCO Plan	n/a		n/a		4.00	%
Other defined benefit pension plans
Synergy Health PLC Retirement Benefits Scheme	3.50	%	3.20	%	n/a
Isotron BV Pension Plan	1.60	%	2.10	%	n/a
Synergy Health Daniken AG	0.65	%	0.40	%	n/a
Synergy Health Radeberg	1.50	%	1.60	%	n/a
Synergy Health Allershausen	1.50	%	1.60	%	n/a
Other post-retirement plan	3.50	%	3.25	%	3.00	%
Expected Return on Plan Assets:
AMSCO Plan	n/a		n/a		6.75	%
Other defined benefit pension plans
Synergy Health PLC Retirement Benefits Scheme	4.87	%	5.19	%	n/a
Isotron BV Pension Plan	1.60	%	2.10	%	n/a
Synergy Health Daniken AG	1.40	%	1.40	%	n/a

Schedule of Assumptions Used

The following table presents significant assumptions used to determine the projected benefit obligations at March 31:



	2017		2016
Discount Rate:
Synergy Health PLC Retirement Benefits Scheme	2.60	%	3.50	%
Isotron BV Pension Plan	1.60	%	1.60	%
Synergy Health Daniken AG	0.65	%	0.40	%
Synergy Health Radeberg	1.50	%	1.60	%
Synergy Health Allershausen	1.50	%	1.60	%
Other post-retirement plan	3.50	%	3.25	%

Schedule of Health Care Cost Trend Rates

The assumed rates of increase generally decline ratably over a five-year period from the assumed current year healthcare cost trend rate to the assumed long-term healthcare cost trend rate noted below.



	2017		2016		2015
Healthcare cost trend rate – medical	7.0	%	7.0	%	7.0	%
Healthcare cost trend rate – prescription drug	7.0	%	7.0	%	7.0	%
Long-term healthcare cost trend rate	4.5	%	4.5	%	4.5	%

A one-percentage-point change in assumed healthcare cost trend rates (including medical, prescription drug, and long-term rates) would have had the following effect at March 31, 2017:



	One-Percentage Point
	Increase		Decrease
Effect on total service and interest cost components	$	1	$	(1	)
Effect on other post-retirement benefit obligation	32		(32		)

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The fair value of our pension benefits plan assets at March 31, 2017 and 2016 by asset category is as follows:



	Fair Value Measurements at March 31, 2017
(In thousands)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Cash	$	182	$	182	$	—	$	—
Insured annuities	10,813		—		10,813		—
Insurance contracts	3,959		—		—		3,959
Common and collective trusts valued at net asset value:
Equity security trusts	64,922
Debt security trusts	21,787
Total Plan Assets	$	101,663	$	182	$	10,813	$	3,959



	Fair Value Measurements at March 31, 2016
(In thousands)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Cash and short term securities	$	7,221	$	7,221	$	—	$	—
Insured annuities	11,279		—		11,279		—
Insurance contracts	4,192		—		—		4,192
Common and collective trusts valued at net asset value:
Equity security trusts	50,125
Debt security trusts	26,152
Real estate security trusts	5,384
Total Plan Assets	$	104,353	$	7,221	$	11,279	$	4,192

Schedule of Defined Benefit Plans Disclosures



	AMSCO Plan					Other Defined Benefit Pension Plans						Other Post-Retirement Benefits Plan
	2017		2016			2017			2016			2017			2016
Change in Benefit Obligations:
Benefit Obligations at Beginning of Year	$	—	$	56,612		$	128,942		$	—		$	18,380		$	21,278
Obligation assumed in Combination	—		—			—			121,468			—			—
Service cost	—		27			1,650			961			—			—
Interest cost	—		560			3,434			1,659			554			593
Actuarial loss (gain)	—		(2,365		)	16,633			5,399			(531		)	(673		)
Benefits and expenses	—		(3,029		)	(7,190		)	(2,346		)	(2,395		)	(2,818		)
Employee contributions	—		—			629			517			—			—
Curtailments/settlements	—		(51,805		)	—			(326		)	—			—
Impact of foreign currency exchange rate changes	—		—			(15,201		)	1,610			—			—
Benefit Obligations at End of Year	—		—			128,897			128,942			16,008			18,380
Change in Plan Assets:
Fair Value of Plan Assets at Beginning of Year	—		50,426			104,353			—			—			—
Assets assumed in Combination	—		—			—			99,511			—			—
Actual return on plan assets	—		(279		)	11,910			2,989			—			—
Employer contributions	—		4,687			4,838			2,280			2,395			2,818
Employee contributions	—		—			629			517			—			—
Benefits and expenses paid	—		(3,029		)	(7,190		)	(2,204		)	(2,395		)	(2,818		)
Curtailments/settlements	—		(51,805		)	—			—			—			—
Impact of foreign currency exchange rate changes	—		—			(12,877		)	1,260			—			—
Fair Value of Plan Assets at End of Year	—		—			101,663			104,353			—			—
Funded Status of the Plans	$	—	$	—		$	(27,234	)	$	(24,589	)	$	(16,008	)	$	(18,380	)

Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]

The fair value measurement of plan assets using significant unobservable inputs (Level 3) changed during fiscal year 2017 due to the following:



	Insurance contracts
Balance at March 31, 2016	$	4,192
Gains (losses) related to assets still held at year-end	116
Purchases, sales, settlements - net	(208		)
Foreign currency	(141		)
Balance at March 31, 2017	$	3,959

Business Segment Information (Tables)

12 Months Ended

Mar. 31, 2017

Segment Reporting Information [Line Items]

Reconciliation of Assets from Segment to Consolidated



March 31,	2017		2016
Property, Plant, and Equipment, Net
United Kingdom	$	38,535	$	121,853
United States	499,760		505,169
Other foreign locations	377,613		437,297
Property, Plant, and Equipment, Net	$	915,908	$	1,064,319

Schedule of Segment Reporting Information, by Segment



Years Ended March 31,	2017			2016			2015
Revenues:
Healthcare Products	$	1,260,878		$	1,202,820		$	1,143,336
Healthcare Specialty Services	560,175			427,198			248,538
Life Sciences	327,276			295,970			250,845
Applied Sterilization Technologies	458,231			310,120			205,675
Total reportable segments	2,606,560			2,236,108			1,848,394
Corporate and other	6,196			2,656			1,869
Total revenues	$	2,612,756		$	2,238,764		$	1,850,263
Segment operating income (loss):
Healthcare Products	224,522			180,263			166,515
Healthcare Specialty Services	13,450			25,197			16,629
Life Sciences	96,983			85,466			56,072
Applied Sterilization Technologies	156,010			99,224			59,458
Total reportable segments	490,965			390,150			298,674
Corporate and other	(14,433		)	(11,488		)	(7,542		)
Total segment operating income	$	476,532		$	378,662		$	291,132
Less: Adjustments
Goodwill impairment loss ⁽¹⁾	58,356			—			—
Amortization of inventory and property "step up" to fair value ⁽²⁾	4,743			9,907			1,330
Amortization of purchased intangible assets ⁽²⁾	66,398			47,704			28,317
Acquisition and integration related transaction charges ⁽³⁾	30,082			82,891			32,762
Loss (gain) on fair value adjustment of acquisition related contingent consideration	2,569			(736		)	2,271
Net loss on divestiture of businesses ⁽²⁾	86,574			—			—
Settlement of pension obligation ⁽⁴⁾	—			26,470			—
Restructuring charges	215			(501		)	(759		)
Total operating income	$	227,595		$	212,927		$	227,211

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area



Years Ended March 31,	2017		2016		2015
Revenues:
United Kingdom	$	229,603	$	144,577	$	51,889
United States	1,803,457		1,662,050		1,449,223
Other foreign locations	579,696		432,137		349,151
Total Revenues	$	2,612,756	$	2,238,764	$	1,850,263

Other Expense

Segment Reporting Information [Line Items]

Schedule of Segment Reporting Information, by Segment



Years Ended March 31,	2017		2016		2015
Capital Expenditures:
Healthcare Products and Life Sciences	$	38,613	$	34,567	$	34,174
Healthcare Specialty Services	42,247		31,309		2,777
Applied Sterilization Technologies	90,941		60,517		48,286
Total Reportable Segments	171,801		126,393		85,237
Corporate and other	1,100		14		18
Total Capital Expenditures	$	172,901	$	126,407	$	85,255
Depreciation, Depletion, and Amortization:
Healthcare Products and Life Sciences	$	46,627	$	49,063	$	41,201
Healthcare Specialty Services	56,890		36,130		19,934
Applied Sterilization Technologies	84,492		58,468		30,369
Total Reportable Segments	188,009		143,661		91,504
Corporate and other	133		79		37
Total Depreciation, Depletion, and Amortization	$	188,142	$	143,740	$	91,541

Assets

Segment Reporting Information [Line Items]

Schedule of Segment Reporting Information, by Segment



March 31,	2017		2016
Assets:
Healthcare Products and Life Sciences	$	1,706,222	$	1,682,457
Healthcare Specialty Services	446,714		759,012
Applied Sterilization Technologies	2,770,366		1,494,638
Total reportable segments	4,923,302		3,936,107
Corporate and other	1,153		2,117
Synergy related goodwill not yet allocated ⁽¹⁾	—		1,408,192
Total assets	$	4,924,455	$	5,346,416

Common Shares (Tables)

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Schedule of Weighted Average Number of Shares [Table Text Block]



Years ended March 31,	2017	2016	2015
Denominator (shares in thousands):
Weighted average shares outstanding—basic	85,473	70,698	59,413
Dilutive effect of share equivalents	621	486	632
Weighted average shares outstanding and share equivalents—diluted	86,094	71,184	60,045

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]



Years ended March 31,	2017	2016	2015
Number of common share options (shares in thousands)	576	263	342

Share-Based Compensation (Tables)

12 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Assumptions Used

The following weighted-average assumptions were used for options granted during fiscal 2017, fiscal 2016 and fiscal 2015:



	Fiscal 2017		Fiscal 2016		Fiscal 2015
Risk-free interest rate	1.29	%	1.51	%	1.89	%
Expected life of options	5.7 years		5.7 years		5.8 years
Expected dividend yield of stock	1.54	%	1.40	%	1.87	%
Expected volatility of stock	22.92	%	25.06	%	29.86	%

Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding

A summary of share option activity is as follows:



	Number of Options		Weighted Average Exercise Price		Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at March 31, 2016	1,729,517		$	—
Granted	402,141		69.85
Exercised	(163,563	)	30.36
Forfeited	(22,351	)	62.81
Canceled	(470	)	25.98
Outstanding at March 31, 2017	1,945,274		$	50.28	6.3 years	$	37,462
Exercisable at March 31, 2017	1,126,875		$	40.34	4.9 years	$	32,880

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of the non-vested restricted share activity is presented below:



	Number of Restricted Shares		Number of Restricted Share Units		Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2016	872,972		41,641		$	51.98
Granted	241,065		20,309		69.96
Vested	(270,062	)	(21,022	)	40.41
Forfeited	(63,449	)	(6,915	)	63.80
Non-vested at March 31, 2017	780,526		34,013		$	60.87

Financial and Other Guarantees (Tables)

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Schedule of Guarantor Obligations

Changes in our warranty liability during the periods presented are as follows:



Years Ended March 31,	2017			2016			2015
Balance, Beginning of Year	$	5,909		$	5,579		$	7,765
Warranties issued during the period	11,823			11,194			7,604
Settlements made during the period	(10,871		)	(10,864		)	(9,790		)
Balance, End of Year	$	6,861		$	5,909		$	5,579

Forward and Swap Contracts (Tables)

12 Months Ended

Mar. 31, 2017

Notes To Financial Statements [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value



	Asset Derivatives				Liability Derivatives
	Fair Value at		Fair Value at		Fair Value at		Fair Value at
Balance Sheet Location	March 31, 2017		March 31, 2016		March 31, 2017		March 31, 2016
Prepaid & Other	$	160	$	145	$	—	$	—
Accrued expenses and other	$	—	$	—	$	35	$	122

Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance

The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:



	Location of (loss) gain recognized in income	Amount of (loss) gain recognized in income
		Years Ended March 31,
		2017			2016			2015
Foreign currency forward contracts	Selling, general and administrative	$	(1,886	)	$	(683	)	$	(1,457	)
Commodity swap contracts	Cost of revenues	$	376		$	(461	)	$	(373	)

Fair Value Measurements (Tables)

12 Months Ended

Mar. 31, 2017

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value, Measurement Inputs, Disclosure [Table Text Block]

The following table shows the fair value of our financial assets and liabilities at March 31, 2017 and March 31, 2016:



									Fair Value Measurements
At March 31,	Carrying Value				Financial assets and liabilities measured at net asset value				Quoted Prices in Active Markets for Identical Assets				Significant Other Observable Inputs				Significant Unobservable Inputs
									Level 1				Level 2				Level 3
	2017		2016		2017		2016		2017		2016		2017		2016		2017		2016
Assets:
Cash and cash equivalents ⁽¹⁾	$	282,918	$	248,841	$	—	$	23,751	$	282,918	$	225,090	$	—	$	—	$	—	$	—
Forward and swap contracts ⁽²⁾	160		145		—		—		—		—		160		145		—		—
Investments ⁽³⁾	12,552		6,192		—		—		12,552		6,192		—		—		—		—
Liabilities:
Forward and swap contracts ⁽²⁾	$	35	$	122	$	—	$	—	$	—	$	—	$	35	$	122	$	—	$	—
Deferred compensation plans ⁽³⁾	1,587		1,765		—		—		1,587		1,765		—		—		—		—
Long term debt ⁽⁴⁾	1,478,361		1,567,796		—		—		—		—		1,496,966		1,588,764		—		—
Contingent consideration obligations ⁽⁵⁾	4,451		5,886		—		—		—		—		—		—		4,451		5,886

⁽⁴⁾We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.

Fair Value, by Balance Sheet Grouping [Table Text Block]

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at March 31, 2017 are summarized as follows:



	Contingent Consideration
Balance at March 31, 2015	$	2,500
Liabilities assumed as a result of the Combination	1,561
Additions	2,730
Payments	(858		)
Foreign currency translation adjustments	(47		)
Balance at March 31, 2016	$	5,886
Additions	3,592
Payments	(5,416		)
Foreign currency translation adjustments	389
Balance at March 31, 2017	$	4,451

Unrealized Gain (Loss) on Investments [Table Text Block]

Information regarding our investments is as follows:



					Investments
At March 31,	Cost				Unrealized Gains ⁽¹⁾				Unrealized Losses ⁽¹⁾						Fair Value
At March 31,	2017		2016		2017		2016		2017			2016			2017		2016
Available-for-sale securities:
Marketable equity securities ⁽¹⁾⁽²⁾	$	11,037	$	4,681	$	—	$	—	$	(72	)	$	(185	)	$	10,965	$	4,496
Mutual funds	1,091		1,289		496		407		—			—			1,587		1,696
Total available-for-sale securities	$	12,128	$	5,970	$	496	$	407	$	(72	)	$	(185	)	$	12,552	$	6,192

⁽¹⁾

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Accumulated Other Comprehensive Income (Tables)

12 Months Ended

Mar. 31, 2017

Equity [Abstract]

Schedule of Reclassification out of AOCI [Table Text Block]

ounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the years ended March 31, 2017 and March 31, 2016 were as follows:



	Gain (Loss) on Available for Sale Securities ⁽¹⁾						Defined Benefit Plans ⁽²⁾						Foreign Currency Translation ⁽³⁾						Total Accumulated Other Comprehensive Income (Loss)
	2017			2016			2017			2016			2017			2016			2017			2016
Beginning Balance	$	(673	)	$	1,068		$	5,108		$	(8,889	)	$	(72,594	)	$	(58,848	)	$	(68,159	)	$	(66,669	)
Other Comprehensive Income (Loss) before reclassifications	745			(2,278		)	(5,491		)	(1,371		)	(165,931		)	(13,746		)	(170,677		)	(17,395		)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	106			537			(1,972		)	15,368			—			—			(1,866		)	15,905
Net current-period Other Comprehensive Income (Loss)	851			(1,741		)	(7,463		)	13,997			(165,931		)	(13,746		)	(172,543		)	(1,490		)
Ending Balance	$	178		$	(673	)	$	(2,355	)	$	5,108		$	(238,525	)	$	(72,594	)	$	(240,702	)	$	(68,159	)

⁽¹⁾ Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the Consolidated

Statements of Income.

⁽²⁾ Amortization (gain) of defined benefit pension items is reported in the Selling, general, and administrative expense line of the Consolidated

Statements of Income.

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

Accumulated other comprehensive income (loss) shown in our Consolidated Statements of Shareholders' Equity consists of the following:



Years Ended March 31,	2017			2016			2015
Cumulative foreign currency translation adjustment	$	(238,525	)	$	(72,594	)	$	(58,848	)
Amortization of pension and postretirement benefit plans costs, net of taxes	(2,355		)	5,108			(8,889		)
Unrealized gain (loss) on available for sale securities	178			(673		)	1,068
Total	$	(240,702	)	$	(68,159	)	$	(66,669	)

Reclassifications out of AOCI (Tables)

12 Months Ended

Mar. 31, 2017

Reclassifications out of AOCI Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]



	Gain (Loss) on Available for Sale Securities ⁽¹⁾						Defined Benefit Plans ⁽²⁾						Foreign Currency Translation ⁽³⁾						Total Accumulated Other Comprehensive Income (Loss)
	2017			2016			2017			2016			2017			2016			2017			2016
Beginning Balance	$	(673	)	$	1,068		$	5,108		$	(8,889	)	$	(72,594	)	$	(58,848	)	$	(68,159	)	$	(66,669	)
Other Comprehensive Income (Loss) before reclassifications	745			(2,278		)	(5,491		)	(1,371		)	(165,931		)	(13,746		)	(170,677		)	(17,395		)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	106			537			(1,972		)	15,368			—			—			(1,866		)	15,905
Net current-period Other Comprehensive Income (Loss)	851			(1,741		)	(7,463		)	13,997			(165,931		)	(13,746		)	(172,543		)	(1,490		)
Ending Balance	$	178		$	(673	)	$	(2,355	)	$	5,108		$	(238,525	)	$	(72,594	)	$	(240,702	)	$	(68,159	)

⁽¹⁾ Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the Consolidated

Statements of Income.

⁽²⁾ Amortization (gain) of defined benefit pension items is reported in the Selling, general, and administrative expense line of the Consolidated

Statements of Income.

Quarterly Results (Unaudited) (Tables)

12 Months Ended

Mar. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Effect of Fourth Quarter Events [Table Text Block]



Quarters Ended	March 31,			December 31,			September 30,			June 30,
Fiscal 2017
Revenues:
Product	$	333,124		$	302,260		$	292,216		$	271,750
Service	348,065			344,514			354,199			366,628
Total Revenues	681,189			646,774			646,415			638,378
Cost of Revenues:
Product	173,855			152,879			155,110			142,698
Service	227,209			236,286			243,397			255,690
Total Cost of Revenues	401,064			389,165			398,507			398,388
Gross Profit	280,125			257,609			247,908			239,990
Percentage of Revenues	41.1		%	39.8		%	38.4		%	37.6		%
Restructuring Expenses	(5		)	18			48			154
Net Income Attributable to Shareholders	$	26,143		$	(4,996	)	$	40,416		$	48,401
Basic Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.31		$	(0.06	)	$	0.47		$	0.56
Diluted Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.31		$	(0.06	)	$	0.47		$	0.56

Fiscal 2016
Revenues:
Product	$	318,438		$	305,156		$	274,145		$	232,307
Service	371,839			313,532			215,752			207,595
Total Revenues	690,277			618,688			489,897			439,902
Cost of Revenues:
Product	174,642			165,575			148,088			129,856
Service	251,746			214,932			132,488			125,956
Total Cost of Revenues	426,388			380,507			280,576			255,812
Gross Profit	263,889			238,181			209,321			184,090
Percentage of Revenues	38.2		%	38.5		%	42.7		%	41.8		%
Restructuring Expenses	156			(194		)	(56		)	(726		)
Net Income Attributable to Shareholders	$	57,740		$	20,045		$	8,687		$	24,291
Basic Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.67		$	0.26		$	0.15		$	0.41
Diluted Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.67		$	0.26		$	0.14		$	0.40

Nature of Operations and Summary of Siginificant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Loss Contingencies [Line Items]
Medical Device Excise Tax Rate	2.30%
Excise and Sales Taxes		$ 5,802	$ 7,917
Percentage of LIFO Inventory	29.00%	31.00%
FIFO Inventory Amount	$ 16,706	$ 17,608
Interest Costs, Capitalized During Period	1,141	723
Interest Costs Incurred	44,520	42,708	19,187
Interest Paid	42,797	37,165	19,124
Income Taxes Paid, Net	78,009	60,885	52,707
Advertising Expense	12,622	10,785	9,732
Proceeds from Income Tax Refunds	2,002	$ 1,697	$ 2,405
Excess tax benefits from share-based compensation	$ 5,100
Land Improvements [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3-40
Building [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	2-50
Machinery and Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	2-20
Computer Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	2-20
Property, Plant and Equipment, Other Types [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	20
Linens [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	1-5
Minimum [Member]
Loss Contingencies [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	5 years
Maximum [Member]
Loss Contingencies [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum	20 years

Business Acquisitions and Divestitures Business Acquisitions and Divestitures Narrative (Details) $ / shares in Units, $ in Thousands	3 Months Ended								9 Months Ended	12 Months Ended
	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Dec. 31, 2016 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Feb. 09, 2017 USD ($)	Sep. 16, 2016 USD ($)	Aug. 31, 2016 USD ($)	Jul. 22, 2016 USD ($)	Nov. 02, 2015 £ / shares	Nov. 02, 2015 USD ($) $ / shares	Jul. 31, 2015 USD ($)	Jun. 12, 2015 USD ($)	Mar. 09, 2015 USD ($)	Dec. 31, 2014 USD ($)	May 09, 2014 USD ($)
Business Acquisition [Line Items]
acquisition and integration related charges										$ 30,082	$ 82,891	$ 32,762
Business Combination, Contingent Consideration, Liability	$ 4,451				$ 5,886					4,451	5,886	2,500
Amortization of Intangible Assets										68,607	49,782	24,500
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability																		$ 3,031
Translation adjustment on net assets									$ 170,000
Depreciation, amortization and depletion adjustment from purchase price allocation									20,000
Synergy Combination Cash Consideration																		402,494
Synergy Combination Total Stock Consideration																		$ 1,887,479
Revenues	681,189	$ 646,774	$ 646,415	$ 638,378	$ 690,277	$ 618,688	$ 489,897	$ 439,902		2,612,756	2,238,764	1,850,263
STERIS Closing Stock Price at 11/02/2015 \| $ / shares																		$ 73.02
FV of consideration available to vested Synergy share option holders																		$ 4,819
Operating Income (Loss)										227,595	212,927	227,211
Proceeds from Divestiture of Businesses										135,713	0	0
Gain (Loss) on Disposition of Business										$ (86,574)	0	$ 0
Other Loan Receivable													$ 15,000
Loan term										P15Y
Principal outstanding on loan receivable	0									$ 0
Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Depreciation, amortization and depletion adjustment from purchase price allocation									17,000
Cost of revenue [Member]
Business Acquisition [Line Items]
Depreciation, amortization and depletion adjustment from purchase price allocation									$ 3,000
Netherlands Linen Management [Domain]
Business Acquisition [Line Items]
Revenues											75,000
Gain (Loss) on Disposition of Business		42,900
US Linen Management Services [Member]
Business Acquisition [Line Items]
Revenues											50,000
Proceeds from Divestiture of Businesses		4,500
Gain (Loss) on Disposition of Business		$ 31,200
Black Diamond [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability																				$ 800
Compass Medical [Member]
Business Acquisition [Line Items]
Purchase price of acquired entity														$ 16,000
Revenues										6,000
Phoenix and Endo-Tek [Member]
Business Acquisition [Line Items]
Purchase price of acquired entity															$ 14,300
Revenues										8,000
Business Acquisition, Percentage of Voting Interests Acquired															100.00%
Medisafe [Member]
Business Acquisition [Line Items]
Purchase price of acquired entity																$ 34,500
Revenues										18,000
Business Acquisition, Percentage of Voting Interests Acquired																100.00%
Synergy Health plc [Member]
Business Acquisition [Line Items]
Revenues											254,911
Approximate purchase price of entity																		2,300,000
Business Combination, Acquisition Related Costs										63,789
Synergy Combination Total Consideration																		$ 2,294,792
Operating Income (Loss)											3,695
Other Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability	1,760									1,760
Synergy Health Labs [Member]
Business Acquisition [Line Items]
Revenues											15,000
Proceeds from Divestiture of Businesses			25,000
Gain (Loss) on Disposition of Business			17,400
Applied Infection Control [Member]
Business Acquisition [Line Items]
Revenues											50,000
Proceeds from Divestiture of Businesses			41,800
Gain (Loss) on Disposition of Business			36,500
UK Linen Management Services [Member]
Business Acquisition [Line Items]
Revenues											$ 50,000
Proceeds from Divestiture of Businesses			65,400
Gain (Loss) on Disposition of Business			$ 66,300
United Kingdom, Pounds
Business Acquisition [Line Items]
Value of transaction per Synergy Share \| £ / shares																	£ 24.80
United States of America, Dollars
Business Acquisition [Line Items]
Value of transaction per Synergy Share \| $ / shares																		$ 38.17
Income tax liabilities (including uncertain tax positions) acquired [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability																		$ 1,470
Contingent consideration acquired [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability																		$ 1,561
Dana Products [Member] [Member]
Business Acquisition [Line Items]
Purchase price of acquired entity																					$ 12,414
AGAPE [Member]
Business Acquisition [Line Items]
Purchase price of acquired entity																						$ 3,415
Econopak [Member] [Member]
Business Acquisition [Line Items]
Approximate purchase price of entity																			$ 176,474
IMS [Member]
Business Acquisition [Line Items]
Purchase price of acquired entity																							$ 162,905
Other Real Estate																							$ 10,000
Other Acquisitions [Member]
Business Acquisition [Line Items]
Approximate purchase price of entity	$ 41,079									$ 41,079
Black Diamond [Member]
Business Acquisition [Line Items]
Approximate purchase price of entity																				46,155
Deferred Purchase Price of Acquired Entity																				$ 5,870
Years 1-4, 4% Int Rate [Member]
Business Acquisition [Line Items]
Loan Receivable Interest Rate	4.00%									4.00%
Years 5-15, 12% Int Rate [Member]
Business Acquisition [Line Items]
Loan Receivable Interest Rate	12.00%									12.00%

Business Acquisitions and Divestitures Synergy Consideration (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Nov. 02, 2015
Business Acquisition [Line Items]
Synergy Combination Cash Consideration		$ 402,494
Synergy Combination Total Stock Consideration		1,887,479
FV of consideration available to vested Synergy share option holders		$ 4,819
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	25,848,798

Business Acquisitions and Divestitures Synergy Acquisition (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016	Nov. 02, 2015	Mar. 31, 2015
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			$ 53,057
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables			103,093
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			30,074
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			496,555
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other			19,175
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			504,196
Goodwill	$ 2,231,303	$ 2,156,603	1,685,524	$ 592,641
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			2,891,674
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities			(107,932)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			(321,082)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			(159,112)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			(588,126)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			2,303,548
Scenario, Adjustment [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables			(4,248)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			(38,324)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other			(533)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			(302,330)
Goodwill			273,743
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			(71,692)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities			(260)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			(71,432)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			(71,692)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			0
Synergy Health plc [Member] \| Scenario, Previously Reported [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			53,057
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables			107,341
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			30,074
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			534,879
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other			19,708
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			806,526
Goodwill			1,411,781
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			2,963,366
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities			(108,192)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			(321,082)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			(230,544)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			(659,818)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			$ 2,303,548

Business Acquisitions and Divestitures Synergy Finite-Lived Intangibles (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Nov. 02, 2015
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 504,196
Synergy Health plc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 504,196	504,196
Technology-Based Intangible Assets [Member] \| Synergy Health plc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		25,718
Finite-Lived Intangible Asset, Useful Life	6 years
Trade Names [Member] \| Synergy Health plc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		19,404
Finite-Lived Intangible Asset, Useful Life	15 years
Customer Relationships [Member] \| Synergy Health plc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 459,074
Finite-Lived Intangible Asset, Useful Life	15 years

Business Acquisitions and Divestitures Synergy Pro Forma (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Business Combinations [Abstract]
Business Acquisition, Pro Forma Revenue	$ 2,619,056	$ 2,499,140
Business Acquisition, Pro Forma Net Income (Loss)	$ 188,269	$ 152,057

Goodwill and Intangible Assets Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Nov. 02, 2015
Goodwill [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 34,970	$ 35,340
Asset Impairment Charges			$ 5,561
Goodwill	2,231,303	2,156,603	592,641	$ 1,685,524
Goodwill allocation related to Synergy	(273,743)
Goodwill, Written off Related to Sale of Business Unit	(85,806)
Goodwill, Impairment Loss	(58,356)	0	0
Finite-Lived Intangible Assets, Amortization Expense	68,607	49,782	24,500
Finite-Lived Intangible Assets, Gross	948,953	1,282,072
Finite-Lived Intangible Assets, Accumulated Amortization	224,066	158,733
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy	(1,308,717)
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Impairment Loss	0
Life Science Member [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy	0
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Impairment Loss	0
Healthcare Specialty Services [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy	(376,807)
Goodwill, Written off Related to Sale of Business Unit	(85,806)
Goodwill, Impairment Loss	(58,356)
goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	41,399	1,564,947
Healthcare Products [Member] [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy	0
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Impairment Loss	0
Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	(96,280)	(985)
Healthcare Specialty Services [Member]
Goodwill [Line Items]
Goodwill	375,879	154,272	150,844
Healthcare Specialty Services [Member] \| goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	21,781	3,428
Healthcare Specialty Services [Member] \| Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	(32,819)	0
Life Science Member [Member]
Goodwill [Line Items]
Goodwill	146,514	147,334	33,889
Life Science Member [Member] \| goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	0	113,284
Life Science Member [Member] \| Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	(820)	161
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill	1,331,145	83,035	83,035
Applied Sterilization Technologies [Member] \| goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	0	0
Applied Sterilization Technologies [Member] \| Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	(60,607)	0
Healthcare Products [Member] [Member]
Goodwill [Line Items]
Goodwill	377,765	363,770	324,873
Healthcare Products [Member] [Member] \| goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	19,618	40,043
Healthcare Products [Member] [Member] \| Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	(5,623)	(1,146)
synergy [Member]
Goodwill [Line Items]
Goodwill	0	1,408,192	$ 0
Goodwill allocation related to Synergy	(1,411,781)
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Impairment Loss	0
synergy [Member] \| goodwill acquired or allocated member
Goodwill [Line Items]
Goodwill, Acquired During Period	0	1,408,192
synergy [Member] \| Foreign Currency Gain (Loss)
Goodwill [Line Items]
Goodwill	3,589	0
Trademarks and Trade Names [Member]
Goodwill [Line Items]
Finite-Lived Intangible Assets, Amortization Expense	14,444
Finite-Lived Intangible Assets, Gross	80,223	129,690
Finite-Lived Intangible Assets, Accumulated Amortization	$ 32,547	$ 18,318

Goodwill and Intangible Assets Goodwill Rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Nov. 02, 2015
Goodwill [Line Items]
Goodwill	$ 2,231,303	$ 2,156,603	$ 592,641	$ 1,685,524
Goodwill allocation related to Synergy	273,743
Goodwill, Written off Related to Sale of Business Unit	85,806
Goodwill, Impairment Loss	58,356	0	0
Healthcare Products [Member] [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy	0
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Impairment Loss	0
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy	1,308,717
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Impairment Loss	0
Life Science Member [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy	0
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Impairment Loss	0
Healthcare Specialty Services [Member]
Goodwill [Line Items]
Goodwill allocation related to Synergy	376,807
Goodwill, Written off Related to Sale of Business Unit	85,806
Goodwill, Impairment Loss	58,356
goodwill acquired or allocated member [Member]
Goodwill [Line Items]
Goodwill, Acquired During Period	41,399	1,564,947
Foreign Currency Gain (Loss) [Member]
Goodwill [Line Items]
Goodwill	(96,280)	(985)
synergy [Member]
Goodwill [Line Items]
Goodwill	0	1,408,192	$ 0
Goodwill allocation related to Synergy	1,411,781
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Impairment Loss	0
synergy [Member] \| goodwill acquired or allocated member [Member]
Goodwill [Line Items]
Goodwill, Acquired During Period	0	1,408,192
synergy [Member] \| Foreign Currency Gain (Loss) [Member]
Goodwill [Line Items]
Goodwill	$ 3,589	$ 0

Goodwill and Intangible Assets Other Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 948,953	$ 1,282,072
Finite-Lived Intangible Assets, Accumulated Amortization	224,066	158,733
Customer Relationships [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	597,386	879,525
Finite-Lived Intangible Assets, Accumulated Amortization	96,648	64,268
Noncompete Agreements [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,722	4,730
Finite-Lived Intangible Assets, Accumulated Amortization	3,629	3,503
Patented Technology [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	211,812	213,317
Finite-Lived Intangible Assets, Accumulated Amortization	86,665	70,801
Trademarks and Trade Names [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	80,223	129,690
Finite-Lived Intangible Assets, Accumulated Amortization	32,547	18,318
supplier relationships [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	54,800	54,800
Finite-Lived Intangible Assets, Accumulated Amortization	4,567	1,827
Other Intangible Assets [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	10	10
Finite-Lived Intangible Assets, Accumulated Amortization	$ 10	$ 16

Goodwill and Intangible Assets Future Amortization of Intangible Assets (Details) $ in Thousands	Mar. 31, 2017 USD ($)
Other Intangible Assets [Abstract]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 64,863
Finite-Lived Intangible Assets, Amortization Expense, Year Two	64,540
Finite-Lived Intangible Assets, Amortization Expense, Year Three	63,486
Finite-Lived Intangible Assets, Amortization Expense, Year Four	62,847
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 60,018

Inventories, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Notes To Financial Statements [Abstract]
Inventory, Raw Materials	$ 65,300	$ 62,673
Inventory, Work in Process	26,538	19,614
Inventory, Finished Goods	140,559	146,820
Inventory, LIFO Reserve	(16,706)	(17,608)
Inventory Valuation Reserves	(17,854)	(18,707)	$ (17,597)	$ (15,986)
Inventories, net	$ 197,837	$ 192,792

Property, Plant and Equipment (Details) - USD ($)
$ in Thousands

12 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2015

Property, Plant and Equipment [Line Items]

Asset Retirement Obligation

$ 9,953

$ 10,342

Asset Retirement Obligation, Liabilities Incurred

222

Asset Retirement Obligation, Accretion Expense

(231)

Asset Retirement Obligation, Foreign Currency Translation Gain (Loss)

(380)

Land

^[1]

46,848

39,051

Buildings and Improvements, Gross

393,692

452,120

Machinery and Equipment, Gross

508,247

599,631

Linen

42,874

Capitalized Computer Software, Gross

119,920

127,464

Materials, Supplies, and Other

436,787

447,892

Construction in Progress, Gross

^[1]

77,421

79,291

Property, Plant and Equipment, Gross

1,582,915

1,788,323

Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment

(667,007)

(724,004)

Property, Plant and Equipment, Net

915,908

1,064,319

Depreciation

119,536

93,958

$ 61,481

Operating Leases, Rent Expense

32,740

$ 23,238

$ 18,602

Operating Leases, Future Minimum Payments Due, Current

23,718

Operating Leases, Future Minimum Payments, Due in Two Years

15,132

Operating Leases, Future Minimum Payments, Due in Three Years

11,088

Operating Leases, Future Minimum Payments, Due in Four Years

7,329

Operating Leases, Future Minimum Payments, Due Thereafter

40,140

Operating Leases, Future Minimum Payments Due

$ 97,407

[1]	Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Details)
€ in Thousands, £ in Thousands, $ in Thousands

3 Months Ended

12 Months Ended

Jun. 30, 2015

USD ($)

Mar. 31, 2014

USD ($)

Dec. 31, 2013

USD ($)

Sep. 30, 2008

USD ($)

Mar. 31, 2017

USD ($)

Mar. 31, 2016

USD ($)

Mar. 31, 2015

USD ($)

Feb. 27, 2017

GBP (£)

Feb. 27, 2017

USD ($)

Feb. 27, 2017

EUR (€)

Nov. 02, 2015

GBP (£)

Nov. 02, 2015

USD ($)

Nov. 02, 2015

EUR (€)

Dec. 31, 2012

Debt Instrument [Line Items]

Senior Notes

$ 293,730

Long-term Debt, Current Maturities

$ 30,000

Line of Credit Facility, Maximum Borrowing Capacity

1,072,500

Potential Increase to Line of Credit

500,000

Debt Instrument, Face Amount

^[1]

960,684

$ 666,000

Deferred Finance Costs, Own-share Lending Arrangement, Issuance Costs, Net

(3,927)

(3,420)

Line of Credit Facility, Amount Outstanding

521,604

905,216

Long-term Debt

1,482,288

Proceeds from Issuance of Private Placement

$ 350,000

$ 100,000

$ 150,000

293,730

350,000

$ 0

Long-term Debt

1,478,361

$ 1,567,796

Long-term Debt, Maturities, Repayments of Principal in Year Two

117,500

Long-term Debt, Maturities, Repayments of Principal in Year Three

459,104

Long-term Debt, Maturities, Repayments of Principal in Year Four

35,000

Long-term Debt, Maturities, Repayments of Principal after Year Five

840,684

9 year 10 month Feb 13

Debt Instrument [Line Items]

Proceeds from Issuance of Private Placement

45,500

Long-term Debt

98,000

15yearplacement

Debt Instrument [Line Items]

Proceeds from Issuance of Private Placement

12,500

12yearplacement

Debt Instrument [Line Items]

Proceeds from Issuance of Private Placement

40,000

10yearplacement

Debt Instrument [Line Items]

Proceeds from Issuance of Private Placement

$ 45,500

Long-term Debt

98,000

15yearplacementfeb13

Debt Instrument [Line Items]

Proceeds from Issuance of Private Placement

$ 12,500

14 year 10 months Feb 13

Debt Instrument [Line Items]

Debt Instrument, Maturity Date, Description

P14Y

12yearplacementfeb13

Debt Instrument [Line Items]

Proceeds from Issuance of Private Placement

$ 40,000

Debt Instrument, Maturity Date, Description

P11Y

9 year 10 months Feb 13

Debt Instrument [Line Items]

Debt Instrument, Maturity Date, Description

P9Y

9 year 10 month Feb 13

Debt Instrument [Line Items]

Debt Instrument, Maturity Date, Description

P10M

9 year Feb 13

Debt Instrument [Line Items]

Debt Instrument, Maturity Date, Description

P10M

9 year 10 month

Debt Instrument [Line Items]

Debt Instrument, Maturity Date, Description

P10M

Debt Instrument, Interest Rate, Stated Percentage

3.70%

10 year maturity

Debt Instrument [Line Items]

Proceeds from Issuance of Private Placement

$ 125,000

$ 85,000

Debt Instrument, Maturity Date, Description

P10Y

Debt Instrument, Interest Rate, Stated Percentage

3.45%

6.83%

3.70%

12 year maturity

Debt Instrument [Line Items]

Proceeds from Issuance of Private Placement

$ 125,000

$ 35,000

Debt Instrument, Maturity Date, Description

P12Y

Debt Instrument, Interest Rate, Stated Percentage

3.55%

6.93%

3.85%

15 year maturity

Debt Instrument [Line Items]

Proceeds from Issuance of Private Placement

$ 100,000

Debt Instrument, Maturity Date, Description

P15Y

Debt Instrument, Interest Rate, Stated Percentage

3.70%

4.05%

August 2008 Notes [Member] [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount

$ 120,000

14 year 10 months maturity

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.05%

10 year 11 months

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.85%

Credit Agreement- term loans principal payment minimum [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.25%

Credit Agreement- term loan principal payment maximum [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

2.50%

Revolving Credit Facility [Member]

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$ 850,000

United States of America, Dollars

Debt Instrument [Line Items]

Senior Notes

$ 95,000

Long-term Line of Credit, Noncurrent

$ 132,000

United Kingdom, Pounds

Debt Instrument [Line Items]

Senior Notes | £

£ 75,000

Long-term Line of Credit, Noncurrent | £

£ 49,000

Euro Member Countries, Euro

Debt Instrument [Line Items]

Senior Notes | €

€ 99,000

Long-term Line of Credit, Noncurrent | €

€ 127,750

Term Loan Agreement [Member]

Debt Instrument [Line Items]

Long-term Line of Credit, Noncurrent

$ 400,000

Term Loan Facility [Domain]

Debt Instrument [Line Items]

Line of Credit Facility, Fair Value of Amount Outstanding

$ 222,500

[1]	2017 2016Private Placement $960,684 $666,000Deferred financing fees (3,927) (3,420)Credit Agreement and Swing Line Facility 521,604 905,216Total long term debt $1,478,361 $1,567,796

Debt 2017 Senior Notes (Details)
€ in Thousands, £ in Thousands

Mar. 31, 2017

GBP (£)

Mar. 31, 2017

USD ($)

Mar. 31, 2017

EUR (€)

Mar. 31, 2016

USD ($)

Debt Instrument [Line Items]

Debt Instrument, Face Amount

^[1]

$ 960,684,000

$ 666,000,000

Long-term Debt

$ 1,478,361,000

$ 1,567,796,000

STE 3.93% due 2027 Senior Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.93%

Debt Instrument, Face Amount

$ 50,000,000

STE 1.86% due 2027 Senior Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.86%

Debt Instrument, Face Amount

$ 64,414,000

€ 60,000

STE 4.03% due 2029 Senior Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.03%

Debt Instrument, Face Amount

$ 45,000,000

STE 2.04% due 2029 Senior Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

2.04%

Debt Instrument, Face Amount

$ 21,471,000

€ 20,000

STE 3.04% due 2029 Senior Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.04%

Debt Instrument, Face Amount

£ 45,000

$ 56,040,000

STE 2.30% due 2032 Senior Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

2.03%

Debt Instrument, Face Amount

$ 20,398,000

€ 19,000

STE 3.17% due 2032 Senior Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.17%

Debt Instrument, Face Amount

£ 30,000

$ 37,360,000

Senior Notes [Member]

Debt Instrument [Line Items]

Long-term Debt

$ 294,683,000

[1]	2017 2016Private Placement $960,684 $666,000Deferred financing fees (3,927) (3,420)Credit Agreement and Swing Line Facility 521,604 905,216Total long term debt $1,478,361 $1,567,796

Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Notes To Financial Statements [Abstract]
Employee-related Liabilities	$ 29,777	$ 30,175
Accrued Vacation	8,651	14,368
Accrued Bonuses	20,715	31,502
Accrued Liabilities for Commissions, Expense and Taxes	16,201	13,809
Liability, Other Retirement Benefits	2,187	2,463
Liability, Retirement and Postemployment Benefits	1,044	1,659
Employee-related Liabilities, Current	78,575	93,976
Deferred Revenue	71,020	56,238
Self Insurance Reserve, Current	6,633	8,266
Accrued Sales Commission	16,122	12,717
Standard and Extended Product Warranty Accrual	6,861	5,909	$ 5,579	$ 7,765
Other Accrued Liabilities	54,253	70,245
Accrued Liabilities	154,889	153,375
Self Insurance Reserve, Noncurrent	15,584	13,257
Liability, Other Retirement Benefits, Noncurrent	13,821	15,932
Liability, Defined Benefit Pension Plan, Noncurrent	27,234	25,301
Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent	3,661	4,366
Accrued Income Taxes, Noncurrent	2,089	0
Asset Retirement Obligations, Noncurrent	9,953	10,342
Other Liabilities	10,331	15,100
Other Liabilities, Noncurrent	$ 82,673	$ 84,298

Income Tax Expense (Details) - USD ($) $ / shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Accrued	$ 184
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	2,068
Deferred Tax Assets, Tax Credit Carryforwards	1,810
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits	$ 6,116	$ 7,016
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	20.00%	35.00%	35.00%
Current Federal Tax Expense (Benefit)	$ 362	$ 2,194	$ 3,633
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ (36,420)	$ (20,553)	$ 15,824
Effective Income Tax Rate, Continuing Operations	40.10%	35.10%	35.30%
Unrecognized Tax Benefits	$ 1,884	$ 3,527	$ 0
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	184,646	171,884	208,820
Current State and Local Tax Expense (Benefit)	8,171	7,943	8,551
Current Income Tax Expense (Benefit)	73,527	65,714	73,260
Deferred Federal Income Tax Expense (Benefit)	(2,292)	(6,973)	(676)
Deferred State and Local Income Tax Expense (Benefit)	2,131	299	214
Increase (Decrease) in Deferred Income Taxes	488	(5,415)	496
Income Tax Expense (Benefit)	$ 74,015	$ 60,299	$ 73,756
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate	0.30%	0.20%	0.00%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes	3.80%	3.30%	2.80%
Increase (decrease) in Valuation Allowances	0.10%	1.00%	2.10%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent	(1.10%)	(0.00%)	(0.00%)
Effective Income Tax Rate Reconciliation, Tax Credits, Foreign	(0.00%)	(0.60%)	(1.00%)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential	0.00%	(8.50%)	(3.60%)
Effective Tax Rate Reconciliation, UK Tax Rate Differential	6.00%	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent	0.00%	3.40%	0.00%
Effective Income Tax Rate Reconciliation, Deductions, Qualified Production Activities	(2.50%)	(2.50%)	(1.60%)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent	(2.80%)	(0.00%)	(0.00%)
Effective Tax Reconciliation, deferred tax assets and liabilities	(2.30%)	(0.00%)	(0.00%)
Effective Tax Rate Reconciliation, acquisitions and divestitures	9.00%	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent	7.90%	0.00%	0.00%
Capitalized Interest Costs- Effective tax rate	0.20%	5.30%	2.20%
Effective Income Tax Rate Reconciliation, Other Adjustments	1.50%	(1.50%)	(0.60%)
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions	$ 510	$ 316
Unrecognized Tax Benefits, Increase Resulting from Acquisition	(1,502)	(3,422)
Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation	(651)	(211)
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	17,196	25,436
Deferred Tax Assets, Operating Loss Carryforwards	44,112
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	7,807	7,521
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance	4,957	4,226
Deferred Tax Assets, Deferred Income	8,962	7,910
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts	1,740	2,059
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Pensions	4,647	5,155
Deferred Tax Assets, Other	781	2,208
Deferred Tax Assets, Gross, Current	87,335	87,682
Deferred Tax Assets, Valuation Allowance	16,366	16,435	$ 14,380	$ 12,541
Deferred Tax Assets, Net	70,969	71,247
Deferred Tax Liabilities, Property, Plant and Equipment	74,092	85,807
Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets	156,291	226,809
Deferred Tax and Other Liabilities, Noncurrent	3,631	3,744
Deferred Tax Liabilities	234,014	316,360
Deferred Tax Assets (Liabilities), Net	(163,045)	(245,113)
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	57,574
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	2,177
Valuation Allowance, Deferred Tax Asset, Change in Amount	69
Deferred Tax Assets, Operating Loss Carryforwards	35,129	26,151
Undistributed Earnings of Foreign Subsidiaries	954,100
Costa Rica Exempt thorugh 2025 and partially exempt through 2029 [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Holiday, Aggregate Dollar Amount	$ 933
Income Tax Holiday, Income Tax Benefits Per Share	$ 0
UNITED STATES
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Foreign	$ 189,429	105,758	161,165
Current Foreign Tax Expense (Benefit)	43,900	41,653	52,234
Deferred Foreign Income Tax Expense (Benefit)	10,293	1,427	1,436
Other Foreign Entities [Member] [Member]
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Foreign	31,637	86,679	31,831
Current Foreign Tax Expense (Benefit)	21,094	13,924	8,842
Deferred Foreign Income Tax Expense (Benefit)	$ (9,644)	$ (168)	$ (478)

Benefit Plans (Change in benefit obligations funded status) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	$ (141)
Defined benefit plan repayment of obligation [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	4,640
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	128,897	$ 128,942	$ 0
Defined Benefit Plan, Benefit Obligation, Business Combination	0	121,468
Defined Benefit Plan, Service Cost	1,650	961	0
Defined Benefit Plan, Interest Cost	3,434	1,659	0
Defined Benefit Plan, Actuarial Net (Gains) Losses	16,633	5,399
Defined Benefit Plan, Benefit Obligation, Benefits Paid	7,190	2,346
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	629	517
Defined Benefit Plan, Benefits Paid (Deprecated 2017-01-31)	(7,190)	(2,204)
Defined Benefit Plan, Plan Assets, Payment for Settlement	0	0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	629	517
Defined Benefit Plan, Fair Value of Plan Assets	101,663	104,353	0
Defined Benefit Plan, Plan Assets, Business Combination	0	99,511
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	11,910	2,989
Defined Benefit Plan, Plan Assets, Contributions by Employer	4,838	2,280
Defined Benefit Plan, Funded (Unfunded) Status of Plan	(27,234)	(24,589)
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	326
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	(12,877)	1,260
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	(15,201)	1,610
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	2,187
Defined Benefit Plan, Benefit Obligation	16,008	18,380	21,278
Defined Benefit Plan, Benefit Obligation, Business Combination	0	0
Defined Benefit Plan, Service Cost	0	0	0
Defined Benefit Plan, Interest Cost	554	593	691
Defined Benefit Plan, Actuarial Net (Gains) Losses	(531)	(673)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	2,395	2,818
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefits Paid (Deprecated 2017-01-31)	(2,395)	(2,818)
Defined Benefit Plan, Plan Assets, Payment for Settlement	0	0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Defined Benefit Plan, Fair Value of Plan Assets	0	0	0
Defined Benefit Plan, Plan Assets, Business Combination	0	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0	0
Defined Benefit Plan, Plan Assets, Contributions by Employer	2,395	2,818
Defined Benefit Plan, Funded (Unfunded) Status of Plan	(16,008)	(18,380)
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	0
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	0	0
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	0	0
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	0	0	56,612
Defined Benefit Plan, Benefit Obligation, Business Combination	0	0
Defined Benefit Plan, Service Cost	0	27	140
Defined Benefit Plan, Interest Cost	0	560	1,887
Defined Benefit Plan, Actuarial Net (Gains) Losses	0	(2,365)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	0	3,029
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefits Paid (Deprecated 2017-01-31)	0	(3,029)
Defined Benefit Plan, Plan Assets, Payment for Settlement	0	(51,805)
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Defined Benefit Plan, Fair Value of Plan Assets	0	0	$ 50,426
Defined Benefit Plan, Plan Assets, Business Combination	0	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0	(279)
Defined Benefit Plan, Plan Assets, Contributions by Employer	0	4,687
Defined Benefit Plan, Funded (Unfunded) Status of Plan	0	0
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	51,805
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	0	0
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	$ 0	$ 0

Benefit Plans (Amounts recognized in balance sheets) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Liability, Defined Benefit Plan, Current	$ 0	$ 0
Liability, Defined Benefit Plan, Noncurrent	(27,234)	(24,589)
Liability, Defined Benefit Pension Plan	(27,234)	(24,589)
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Liability, Defined Benefit Plan, Current	(2,187)	(2,463)
Liability, Defined Benefit Plan, Noncurrent	(13,821)	(15,917)
Liability, Defined Benefit Pension Plan	$ (16,008)	$ (18,380)

Benefit Plans (Amortize pre-tax amount AOCI) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax		$ 7,000
Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax		16,000
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Actuarial Net (Gains) Losses		0	$ (2,365)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		$ 0	$ 0	$ 0
Scenario, Forecast [Member] \| Other Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Actuarial Net (Gains) Losses	$ 739
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	$ (3,263)

Benefit Plans (Projected benefit obligation exceeding the fair value of plan assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2008
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation				$ 46,001
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	$ 0	$ 0	$ 56,612
Defined Benefit Plan, Fair Value of Plan Assets	0	0	50,426
Defined Benefit Plan, Benefit Obligation, Business Combination	0	0
Defined Benefit Plan, Service Cost	0	27	140
Defined Benefit Plan, Interest Cost	0	560	1,887
Defined Benefit Plan, Actuarial Net (Gains) Losses	0	(2,365)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	0	3,029
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	(51,805)
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	0	0
Defined Benefit Plan, Plan Assets, Business Combination	0	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0	(279)
Defined Benefit Plan, Plan Assets, Contributions by Employer	0	4,687
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Defined Benefit Plan, Plan Assets, Benefits Paid	0	3,029
Defined Benefit Plan, Funded (Unfunded) Status of Plan	0	0
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	128,897	128,942	0
Defined Benefit Plan, Fair Value of Plan Assets	101,663	104,353	0
Defined Benefit Plan, Benefit Obligation, Business Combination	0	121,468
Defined Benefit Plan, Service Cost	1,650	961	0
Defined Benefit Plan, Interest Cost	3,434	1,659	0
Defined Benefit Plan, Actuarial Net (Gains) Losses	16,633	5,399
Defined Benefit Plan, Benefit Obligation, Benefits Paid	7,190	2,346
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	629	517
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	(326)
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	(15,201)	1,610
Defined Benefit Plan, Plan Assets, Business Combination	0	99,511
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	11,910	2,989
Defined Benefit Plan, Plan Assets, Contributions by Employer	4,838	2,280
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	629	517
Defined Benefit Plan, Plan Assets, Benefits Paid	7,190	2,204
Defined Benefit Plan, Funded (Unfunded) Status of Plan	(27,234)	(24,589)
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	16,008	18,380	21,278
Defined Benefit Plan, Fair Value of Plan Assets	0	0	0
Defined Benefit Plan, Benefit Obligation, Business Combination	0	0
Defined Benefit Plan, Service Cost	0	0	0
Defined Benefit Plan, Interest Cost	554	593	$ 691
Defined Benefit Plan, Actuarial Net (Gains) Losses	(531)	(673)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	2,395	2,818
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	0
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	0	0
Defined Benefit Plan, Plan Assets, Business Combination	0	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0	0
Defined Benefit Plan, Plan Assets, Contributions by Employer	2,395	2,818
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Defined Benefit Plan, Plan Assets, Benefits Paid	2,395	2,818
Defined Benefit Plan, Funded (Unfunded) Status of Plan	$ (16,008)	$ (18,380)

Benefit Plans (Components of the annual net periodic benefit cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	$ 0	$ 0	$ 0
Defined Benefit Plan, Interest Cost	554	593	691
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	0	0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(3,263)	(3,263)	(3,263)
Defined Benefit Plan, Accumulated Benefit Obligation, (Increase) Decrease for Settlement and Curtailment	0	0	0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	(1,970)	(1,842)	(1,851)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	739	828	721
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold	531	673	2,327
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	3,263	3,263	3,263
Defined Benefit Plan, Amortization of Net Gains (Losses)	(739)	(721)	(721)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	3,055	3,215	4,869
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	1,085	1,373	3,018
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	0	27	140
Defined Benefit Plan, Interest Cost	0	560	1,887
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	0	(1,008)	(3,139)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0	0
Defined Benefit Plan, Accumulated Benefit Obligation, (Increase) Decrease for Settlement and Curtailment	0	26,470	0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	0	26,651	(6)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	0	602	1,106
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold	0	0	6,706
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	0	0	0
Defined Benefit Plan, Amortization of Net Gains (Losses)	0	(602)	(1,106)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	0	(602)	5,600
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	0	26,049	5,594
Other Defined Benefit Pension Plans [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	1,650	961	0
Defined Benefit Plan, Interest Cost	3,434	1,659	0
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	(2,853)	(1,324)	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	(142)	0
Defined Benefit Plan, Accumulated Benefit Obligation, (Increase) Decrease for Settlement and Curtailment	0	(326)	0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	2,231	828	0
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	0	0	0
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold	(7,553)	(3,733)	0
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	0	0	0
Defined Benefit Plan, Amortization of Net Gains (Losses)	0	0	0
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	(7,553)	(3,733)	0
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	$ (5,322)	$ (2,905)	$ 0

Benefit Plans (Assumptions used in calculating benefit obligations and net periodic benefit cost) (Details)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Synergy Health PLC Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	2.60%	3.50%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	4.87%	5.19%
Isotron [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.60%	1.60%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.60%	2.10%
Daniken [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	0.65%	0.40%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.40%	1.40%
Radeberg [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.50%	1.60%
Allershausen [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.50%	1.60%
Other Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	3.50%	3.25%

Benefit Plans (Significant assumptions used to determine the net periodic benefit costs) (Details)	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
UNITED STATES
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate			4.00%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets			6.75%
Synergy Health PLC Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	3.50%	3.20%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	4.87%	5.19%
Isotron [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	1.60%	2.10%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.60%	2.10%
Daniken [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	0.65%	0.40%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.40%	1.40%
Radeberg [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	1.50%	1.60%
Allershausen [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	1.50%	1.60%
Other Post-Retirement Benefit Plans, Net
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	3.50%	3.25%	3.00%

Benefit Plans (Assumed long-term healthcare cost trend rate) (Details)	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Postemployment Benefits [Abstract]
Healthcare cost trend rate medical	7.00%	7.00%	7.00%
Healthcare prescription drug	7.00%	7.00%	7.00%
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate	4.50%	4.50%	4.50%

Benefit Plans (Effect of one-percentage-point change in assumed healthcare cost trend rates) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2017 USD ($)
Postemployment Benefits [Abstract]
Defined Benefit Plan, Effect of One Percentage Point Increase on Service and Interest Cost Components	$ 1
Defined Benefit Plan, Effect of One Percentage Point Decrease on Service and Interest Cost Components	(1)
Defined Benefit Plan, Effect of One Percentage Point Increase on Accumulated Postretirement Benefit Obligation	32
Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation	$ (32)

Benefit Plans (Targeted asset allocation of plan assets and the actual allocation of plan assets) (Details)	Mar. 31, 2017
Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	75.00%
Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	25.00%

Benefit Plans (Fair value of our pension benefits plan assets) (Details) - USD ($)
$ in Thousands

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2015

Defined Benefit Plan Disclosure [Line Items]

Real Estate Investments, Net

$ 4,192

Other Investments

$ 3,959

Fair Value, Inputs, Level 1

Defined Benefit Plan Disclosure [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure

^[1]

282,918

225,090

Fair Value, Inputs, Level 2

Defined Benefit Plan Disclosure [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure

^[1]

Fair Value, Inputs, Level 3

Defined Benefit Plan Disclosure [Line Items]

Cash and Cash Equivalents, Fair Value Disclosure

Other Defined Benefit Pension Plans [Domain]

Defined Benefit Plan Disclosure [Line Items]

Real Estate Investments, Net

5,384

Insurance Contract

3,959

4,192

Cash and Cash Equivalents, Fair Value Disclosure

182

7,221

Other Investments

10,813

11,279

Marketable Securities, Equity Securities

64,922

50,125

Defined Benefit Plan, Fair Value of Plan Assets

101,663

104,353

$ 0

Marketable Securities, Fixed Maturities

21,787

26,152

Other Defined Benefit Pension Plans [Domain] | Fair Value, Inputs, Level 1

Defined Benefit Plan Disclosure [Line Items]

Insurance Contract

Cash and Cash Equivalents, Fair Value Disclosure

182

7,221

Other Investments

Defined Benefit Plan, Fair Value of Plan Assets

182

7,221

Other Defined Benefit Pension Plans [Domain] | Fair Value, Inputs, Level 2

Defined Benefit Plan Disclosure [Line Items]

Insurance Contract

Cash and Cash Equivalents, Fair Value Disclosure

Other Investments

10,813

11,279

Defined Benefit Plan, Fair Value of Plan Assets

10,813

11,279

Other Defined Benefit Pension Plans [Domain] | Fair Value, Inputs, Level 3

Defined Benefit Plan Disclosure [Line Items]

Insurance Contract

3,959

4,192

Cash and Cash Equivalents, Fair Value Disclosure

Other Investments

Defined Benefit Plan, Fair Value of Plan Assets

$ 3,959

$ 4,192

[1]

Money market fund holdings are valued at fair value using the net asset value per share practical expedient and are not included within the fair value hierarchy. These money market funds are being presented in the table above to permit a reconciliation of the fair value hierarchy to total cash and cash equivalents.

Benefit Plans (Expected payments to be made to plan participants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Gross Prescription Drug Subsidy Receipts Received (Deprecated 2017-01-31)	$ 326	$ 284
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	2,187
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	1,910
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	1,707
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	1,565
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	1,456
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	5,390
Foreign Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	3,498
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	3,472
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	3,915
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	3,706
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	4,121
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	$ 24,117

Benefit Plans (Details Textual) - USD ($)
$ in Thousands

12 Months Ended

Aug. 26, 2015

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2015

Nov. 02, 2015

DBP Purchase Price of Annuity Contract

$ 51,805

Defined Contribution Plan, Employer Discretionary Contribution Amount

$ 4,641

$ 15,069

13,354

$ 10,895

Unfunded Benefit Obligation - Synergy Plan

$ 23,507

Defined Contribution Plan, Fair Value of Plan Assets

$ 556,007

STERIS Corporation shares held in defined contribution plan

705,876

Fair value of STERIS Corporatio stock held in defined contribution plan

$ 49,030

Defined Contribution Plan, Dividends Paid

734

669

606

Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement

^[1]

26,470

$ 0

Deferred Compensation Plan Assets

$ 1,604

$ 1,696

Equity Securities [Member]

Defined Benefit Plan, Plan Assets, Target Allocation, Percentage

75.00%

Debt Securities

Defined Benefit Plan, Plan Assets, Target Allocation, Percentage

25.00%

[1]	See Note 9 titled, "Benefit Plans" for more information related to the settlement of the pension obligation.

Benefit Plans Benefit Plans (Rollforward of Level 3 assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Rollforward of Level 3 Assets [Abstract]
Real Estate Investments, Net		$ 4,192
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Period Increase (Decrease)	$ 116
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchases, Sales, and Settlements	(208)
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	(141)
Other Investments	$ 3,959

Contingencies (Details) - USD ($)
$ in Thousands

12 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Loss Contingencies [Line Items]

rebate program adjustment

^[1]

$ 0

Letters of credit as security for self insurance risk and retention policies

$ 7,694

7,050

Purchase Commitment, Remaining Minimum Amount Committed

85,154

long term construction contracts

1,703

Commercial commitments [Member]

Loss Contingencies [Line Items]

Commitments and Contingencies

$ 57,709

$ 56,649

[1]	{F\|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOmMxNGZkMGNiMTNhYzQ3MmNhOGNkM2M4NjRiZmQ4YzE3fFRleHRTZWxlY3Rpb246RTNGODU5MkNGRDYyQTlBNEYwODYxNjZDNUYwQUJEREMM}

Business Segment Information (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Mar. 31, 2017

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2015

Segment Reporting Information [Line Items]

Revenues

$ 681,189

$ 646,774

$ 646,415

$ 638,378

$ 690,277

$ 618,688

$ 489,897

$ 439,902

$ 2,612,756

$ 2,238,764

$ 1,850,263

Operating Income (Loss)

227,595

212,927

227,211

Goodwill, Impairment Loss

58,356

amortization of inventory and property step up to fair value

^[1]

4,743

9,907

1,330

amortization and impairment of acquired intangible assets

^[2]

66,398

47,704

28,317

acquisition and integration related charges

30,082

82,891

32,762

loss (gain) on fair value contingent consideration adjustments

2,569

(736)

2,271

Gain (Loss) on Disposition of Business

86,574

Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement

^[3]

26,470

rebate program adjustment

^[4]

Restructuring expenses

(5)

$ 18

$ 48

$ 154

156

$ (194)

$ (56)

$ (726)

215

^[5]

(501)

^[5]

(759)

^[5]

Assets

4,924,455

5,346,416

4,924,455

5,346,416

Payments to Acquire Productive Assets

172,901

126,407

85,255

Depreciation, Depletion and Amortization

188,142

143,740

91,541

Property, Plant and Equipment, Net

915,908

1,064,319

915,908

1,064,319

Applied Sterilization Technologies [Member]

Segment Reporting Information [Line Items]

Revenues

458,231

310,120

205,675

Operating Income (Loss)

156,010

99,224

59,458

Goodwill, Impairment Loss

Assets

2,770,366

1,494,638

2,770,366

1,494,638

Payments to Acquire Productive Assets

90,941

60,517

48,286

Depreciation, Depletion and Amortization

84,492

58,468

30,369

Life Science Member

Segment Reporting Information [Line Items]

Revenues

327,276

295,970

250,845

Operating Income (Loss)

96,983

85,466

56,072

Goodwill, Impairment Loss

Operating Segments [Member]

Segment Reporting Information [Line Items]

Assets

4,923,302

3,936,107

4,923,302

3,936,107

Payments to Acquire Productive Assets

171,801

126,393

85,237

Depreciation, Depletion and Amortization

188,009

143,661

91,504

OperatingSegmentAllExceptCorpandOther [Member]

Segment Reporting Information [Line Items]

Revenues

2,606,560

2,236,108

1,848,394

Operating Income (Loss)

490,965

390,150

298,674

OperatingSegmentCorpandOther [Member]

Segment Reporting Information [Line Items]

Revenues

6,196

2,656

1,869

Operating Income (Loss)

(14,433)

(11,488)

(7,542)

OperatingSegmentAll [Member]

Segment Reporting Information [Line Items]

Revenues

2,612,756

2,238,764

1,850,263

Operating Income (Loss)

476,532

378,662

291,132

Healthcare and Life Sciences [Member]

Segment Reporting Information [Line Items]

Assets

1,706,222

1,682,457

1,706,222

1,682,457

Payments to Acquire Productive Assets

38,613

34,567

34,174

Depreciation, Depletion and Amortization

46,627

49,063

41,201

Corporate and Other member [Member]

Segment Reporting Information [Line Items]

Assets

1,153

2,117

1,153

2,117

Payments to Acquire Productive Assets

1,100

Depreciation, Depletion and Amortization

133

Healthcare Specialty Services [Member]

Segment Reporting Information [Line Items]

Revenues

560,175

427,198

248,538

Operating Income (Loss)

13,450

25,197

16,629

Goodwill, Impairment Loss

58,356

Assets

446,714

759,012

446,714

759,012

Payments to Acquire Productive Assets

42,247

31,309

2,777

Depreciation, Depletion and Amortization

56,890

36,130

19,934

Healthcare Products [Member] [Member]

Segment Reporting Information [Line Items]

Revenues

1,260,878

1,202,820

1,143,336

Operating Income (Loss)

224,522

180,263

166,515

Goodwill, Impairment Loss

United Kingdom [Member]

Segment Reporting Information [Line Items]

Revenues

229,603

144,577

51,889

Property, Plant and Equipment, Net

38,535

121,853

38,535

121,853

UNITED STATES

Segment Reporting Information [Line Items]

Revenues

1,803,457

1,662,050

1,449,223

Property, Plant and Equipment, Net

499,760

505,169

499,760

505,169

Other Foreign Entities [Member] [Member]

Segment Reporting Information [Line Items]

Revenues

579,696

432,137

$ 349,151

Property, Plant and Equipment, Net

377,613

437,297

377,613

437,297

Synergy Health plc [Member]

Segment Reporting Information [Line Items]

Goodwill, Not Allocated, Amount

$ 0

$ 1,408,192

$ 0

$ 1,408,192

[1]	For more information regarding our goodwill impairment loss see Note 3 titled, "Goodwill and Intangible Assets".
[2]	Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions
[3]	See Note 9 titled, "Benefit Plans" for more information related to the settlement of the pension obligation.
[4]	{F\|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOmMxNGZkMGNiMTNhYzQ3MmNhOGNkM2M4NjRiZmQ4YzE3fFRleHRTZWxlY3Rpb246RTNGODU5MkNGRDYyQTlBNEYwODYxNjZDNUYwQUJEREMM}
[5]	{F\|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOmMxNGZkMGNiMTNhYzQ3MmNhOGNkM2M4NjRiZmQ4YzE3fFRleHRTZWxlY3Rpb246M0RFQjBFNDgwRkUwMzgxRDMzNTYxNjZDNUYwOTA5M0QM}

Common Shares (Details) $ in Thousands	3 Months Ended	12 Months Ended
Common Shares (Details) $ in Thousands	Mar. 31, 2017 £ / shares	Mar. 31, 2017 £ / shares shares	Mar. 31, 2016 £ / shares shares	Mar. 31, 2015 shares	Mar. 31, 2017 USD ($) shares	Mar. 31, 2016 USD ($) shares	Dec. 31, 2015 £ / shares	Dec. 31, 2015 USD ($) shares	Nov. 02, 2015 £ / shares shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Stock, Par or Stated Value Per Share \| £ / shares	£ 0.10	£ 0.10	£ 0.10
Ordinary shares, with £0.10 par value; £17,006 aggregate par amount authorized; 84,948 and 85,920 ordinary shares issued and outstanding, respectively \| $					$ 2,085,134	$ 2,151,719
Preferred Stock, Dividend Rate, Percentage	5.00%
Preferred Stock, Shares Issued \| shares					100,000	100,000		100,000
Preferred Stock, Par or Stated Value Per Share \| £ / shares	£ 0.10	£ 0.10	£ 0.10
Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding \| $					$ 15	$ 15
Preferred Stock, Redemption Price Per Share \| £ / shares							£ 0.10
Weighted Average Number of Shares Outstanding, Basic \| shares		85,473,000	70,698,000	59,413,000
Weighted Average Number Diluted Shares Outstanding Adjustment \| shares		621,000	486,000	632,000
Weighted Average Number of Shares Outstanding, Diluted \| shares		86,094,000	71,184,000	60,045,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount \| shares		576,000	263,000	342,000
United Kingdom, Pounds
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Par or Stated Value Per Share \| £ / shares							£ 0.10
United States of America, Dollars
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred shares, with £0.10 par value; 100 shares authorized; 100 issued and outstanding \| $								$ 15
Synergy Health plc [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Stock, Par or Stated Value Per Share \| £ / shares									£ 0.10
Total Shares Received by Synergy Shareholders for Combination \| shares									0.4308
Cash Value per share paid to Synergy Shareholders for Combination \| £ / shares									£ 439

Repurchases of Common Shares (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Aug. 09, 2016	Mar. 31, 2008
Schedule of Available-for-sale Securities [Line Items]
Stock Repurchase Program, Authorized Amount					$ 300,000
Stock Repurchased During Period, Shares	1,286,183
Ordinary Stock Repurchases Not Including Shares Withheld for Taxes	$ 90,475
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	168,906	267,696	541,700
Payments Related to Tax Withholding for Share-based Compensation	$ 7,034	$ 14,369	$ 30,687
Stock Repurchase Program Authorized Amt, 2016 Program				$ 300,000

Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	5,628,258
Weighted-average assumptions used for options granted:
Risk-free interest rate	1.29%	1.51%	1.89%
Expected life of options	5 years 7 months 28 days	5 years 7 months 28 days	5 years 9 months 28 days
Exptected dividend yield of stock	1.54%	1.40%	1.87%
Expected volatility of stock	22.92%	25.06%	29.86%
Estimated forfeiture rate	1.85%	1.55%	1.46%
Summary of share option activity:
Number of Options, Outstanding, Beginning of Period	1,729,517
Weighted Average Exercise Price, Outstanding, Beginning of Period	$ 0.00
Number of Options, Granted	402,141
Weighted Average Exercise Price, Granted	$ 69.85
Number of Options, Exercised	(163,563)
Weighted Average Exercise Price, Exercised	$ 30.36
Number of Options, Forfeited	(22,351)
Weighted Average Exercise Price, Forfeited	$ 62.81
Number of Options, Canceled	(470)
Weighted Average Exercise Price, Canceled	$ 25.98
Number of Options, Outstanding, End of Period	1,945,274	1,729,517
Weighted Average Exercise Price, Outstanding, End of Period	$ 50.28	$ 0.00
Average Remaining Contractual Term, Outstanding	6 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding	$ 37,462
Number of Options, Exercisable	1,126,875
Weighted Average Exercise Price, Exercisable	$ 40.34
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	4 years 10 months 12 days
Aggregate Intrinsic Value, Exercisable	$ 32,880
Non-vested stock options outstanding expected to vest	807,550
Common Stock, Fair Market Value Per Share	$ 69.46
Total intrinsic value of stock options exercised	$ 6,454	$ 13,000	$ 31,555
Net cash proceeds from the exercise of stock options	4,955	11,240	28,274
Tax benefit from stock option exercises	$ 5,058	$ 6,281	$ 11,526
Weighted average grant date fair value of stock option grants, per share	$ 13.42	$ 14.66	$ 13.41
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	41,641
Number of Restricted Shares, Granted	20,309
Number of Restricted Shares, Vested	(21,022)
Number of Restricted Shares, Canceled	(6,915)
Number of Restricted Shares, Non-vested at End of Period	34,013	41,641
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 33,082
Weighted average period for recognition of unrecognized compensation cost	2 years 16 days
Stock Appreciation Rights (SARs)
Summary of non-vested restricted share activity:
FairValueOfOutstandingStockAppreciationRights	$ 1,622	$ 2,165
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	872,972
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 51.98
Number of Restricted Shares, Granted	241,065
Weighted-Average Grant Date Fair Value, Granted	$ 69.96
Number of Restricted Shares, Vested	(270,062)
Weighted-Average Grant Date Fair Value, Vested	$ 40.41
Number of Restricted Shares, Canceled	(63,449)
Weighted-Average Grant Date Fair Value, Canceled	$ 63.80
Number of Restricted Shares, Non-vested at End of Period	780,526	872,972
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 60.87	$ 51.98
Fair Value, Share-based Payment Awards, Other than Options	$ 11,763

Financial and Other Guarantees (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Standard and Extended Product Warranty Accrual	$ 6,861	$ 5,909	$ 5,579	$ 7,765
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued	11,823	11,194	7,604
Standard Product Warranty Accrual, Decrease for Payments	(10,871)	(10,864)	(9,790)
Service Agreements [Member]
ERROR in label resolution.	$ 32,136	$ 33,416	$ 30,720

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

Forward and Swap Contracts (Details) $ in Thousands, MXN in Millions, CAD in Millions	12 Months Ended
	Mar. 31, 2017 USD ($) lbs	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Mar. 31, 2017 MXN lbs	Mar. 31, 2017 CAD lbs
Derivative [Line Items]
Non-derivative Net Investment Hedge	$ 59,510
Other Assets
Derivative [Line Items]
Derivative Assets	160	$ 145
Derivative Liabilities	0	0
Accrued Liabilities
Derivative [Line Items]
Derivative Assets	0	0
Derivative Liabilities	35	122
Selling, General and Administrative Expenses
Derivative [Line Items]
Foreign Currency Transaction Gain, before Tax	(1,886)	(683)	$ (1,457)
Cost of Sales
Derivative [Line Items]
Gain (Loss) on Sale of Commodity Contracts	$ 376	$ (461)	$ (373)
Mexico, Pesos
Derivative [Line Items]
Notional Amount of Foreign Currency Derivative Purchase Contracts (Deprecated 2013-01-31) \| MXN				MXN 110
Canada, Dollars
Derivative [Line Items]
Notional Amount of Foreign Currency Derivative Purchase Contracts (Deprecated 2013-01-31) \| CAD					CAD 10
212234 Copper Ore and Nickel Ore Mining [Member]
Derivative [Line Items]
Investment Contract Weight \| lbs	581,500			581,500	581,500

Fair Value Measurements (Details) - USD ($)
$ in Thousands

12 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2015

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities, Amortized Cost Basis

$ 12,128

$ 5,970

Unrealized Gain on AFS Securities

496

407

Unrealized Loss on AFS Securities

(72)

(185)

Investments, Fair Value Disclosure

12,552

6,192

Deferred Compensation Plan Assets

1,604

1,696

Business Acquisition, Contingent Consideration, at Fair Value

4,451

5,886

$ 2,500

Fair Value, Inputs, Level 1

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure

^[1]

12,552

6,192

Cash and Cash Equivalents, Fair Value Disclosure

^[2]

282,918

225,090

Foreign Currency Contract, Asset, Fair Value Disclosure

^[3]

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[3]

Deferred Compensation Plan Assets

^[1]

1,587

1,765

Long-term Debt, Fair Value

^[4]

Business Acquisition, Contingent Consideration, at Fair Value

^[5]

Fair Value, Inputs, Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure

^[1]

Cash and Cash Equivalents, Fair Value Disclosure

^[2]

Foreign Currency Contract, Asset, Fair Value Disclosure

^[3]

160

145

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[3]

122

Deferred Compensation Plan Assets

^[1]

Long-term Debt, Fair Value

^[4]

1,496,966

1,588,764

Business Acquisition, Contingent Consideration, at Fair Value

^[5]

Fair Value, Inputs, Level 3

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure

^[1]

Cash and Cash Equivalents, Fair Value Disclosure

Foreign Currency Contract, Asset, Fair Value Disclosure

^[3]

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[3]

Deferred Compensation Plan Assets

^[1]

Long-term Debt, Fair Value

^[4]

Business Acquisition, Contingent Consideration, at Fair Value

^[5]

4,451

5,886

Assets Measured at Net Asset Value [Domain]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure

^[1]

Cash and Cash Equivalents, Fair Value Disclosure

^[2]

23,751

Foreign Currency Contract, Asset, Fair Value Disclosure

^[3]

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[3]

Deferred Compensation Plan Assets

^[1]

Long-term Debt, Fair Value

^[4]

Business Acquisition, Contingent Consideration, at Fair Value

^[5]

Capital Additions

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Consideration Transferred

1,561

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

^[6]

3,592

2,730

Reductions and Payout [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

(5,416)

(858)

Foreign Currency Gain (Loss)

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

^[7]

389

(47)

Cost of Sales

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Gain (Loss) on Sale of Commodity Contracts

376

(461)

$ (373)

Mutual Funds [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities, Amortized Cost Basis

1,091

1,289

Unrealized Gain on AFS Securities

^[8]

496

407

Unrealized Loss on AFS Securities

^[8]

Investments, Fair Value Disclosure

1,587

1,696

Equity Securities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Available-for-sale Securities, Amortized Cost Basis

11,037

4,681

Unrealized Gain on AFS Securities

^[8]

Unrealized Loss on AFS Securities

(72)

^[8]

(185)

Investments, Fair Value Disclosure

10,965

4,496

Reported Value Measurement [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure

12,552

6,192

Cash and Cash Equivalents, Fair Value Disclosure

282,918

248,841

Foreign Currency Contract, Asset, Fair Value Disclosure

160

145

Foreign Currency Contracts, Liability, Fair Value Disclosure

122

Deferred Compensation Plan Assets

1,587

1,765

Long-term Debt, Fair Value

^[4]

1,478,361

1,567,796

Business Acquisition, Contingent Consideration, at Fair Value

$ 4,451

$ 5,886

[1]	We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Changes in the value of the investment accounts are recognized each period based on the fair value of the underlying investments. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the value of the investment are recognized each period based on the fair value of the investment.
[2]	Money market fund holdings are valued at fair value using the net asset value per share practical expedient and are not included within the fair value hierarchy. These money market funds are being presented in the table above to permit a reconciliation of the fair value hierarchy to total cash and cash equivalents.
[3]	The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[4]	We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
[5]	Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
[6]	{F\|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOmMxNGZkMGNiMTNhYzQ3MmNhOGNkM2M4NjRiZmQ4YzE3fFRleHRTZWxlY3Rpb246MERFQTlDMTU4QUFBOUE2MjY0QzcxNjZDNUYwQTk1REIM}
[7]	{F\|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOmMxNGZkMGNiMTNhYzQ3MmNhOGNkM2M4NjRiZmQ4YzE3fFRleHRTZWxlY3Rpb246RTg0QzRBNjg3M0YwOEMxNzAyNUYxNjZDNUYwQTg1M0EM}
[8]	(1) Our marketable equity securities have been in an unrealized loss position for less than 12 months.(2) Amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Accumulated Other Comprehensive Incom (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (238,525)	$ (72,594)	$ (58,848)
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	(2,355)	5,108	(8,889)
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	178	(673)	1,068
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (240,702)	$ (68,159)	$ (66,669)

Reclassifications out of AOCI (Details) - USD ($)
$ in Thousands

12 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2015

Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax

$ 178

$ (673)

$ 1,068

Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax

(2,355)

5,108

(8,889)

Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax

(238,525)

(72,594)

(58,848)

Accumulated Other Comprehensive Income (Loss), Net of Tax

(240,702)

(68,159)

(66,669)

Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax

851

(1,741)

507

Other Comprehensive Income (Loss), Net of Tax

(170,677)

(17,395)

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

1,866

(15,905)

Total other comprehensive loss attributable to shareholders

(172,543)

(1,490)

(71,150)

Accumulated Net Unrealized Investment Gain (Loss) [Member]

Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax

178

(673)

^[1]

1,068

^[1]

Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax

^[1]

745

(2,278)

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

^[1]

(106)

(537)

Total other comprehensive loss attributable to shareholders

851

(1,741)

Accumulated Defined Benefit Plans Adjustment [Member]

Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax

(2,355)

5,108

^[2]

(8,889)

^[2]

Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax

^[2]

(5,491)

(1,371)

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

^[2]

(1,972)

15,368

Total other comprehensive loss attributable to shareholders

7,463

(13,997)

Accumulated Translation Adjustment [Member]

Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax

(238,525)

(72,594)

^[3]

$ (58,848)

^[3]

Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax

^[3]

(165,931)

(13,746)

Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax

^[3]

Total other comprehensive loss attributable to shareholders

$ (165,931)

$ (13,746)

[1]	Realized gain (loss) on available for sale securities is reported in the Interest income and miscellaneous expense line of the ConsolidatedStatements of Income.
[2]	Amortization (gain) of defined benefit pension items is reported in the Selling, general, and administrative expense line of the ConsolidatedStatements of Incom
[3]	The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated other comprehensive income and is reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Related Party Transactions (Details) £ in Thousands, $ in Thousands	Dec. 31, 2015 GBP (£)	Dec. 31, 2015 USD ($)	Nov. 20, 2015 GBP (£)	Nov. 06, 2015 GBP (£)	Nov. 02, 2015 USD ($)	Oct. 26, 2015 GBP (£)
Related Party Transaction [Line Items]
Related party obligation to be remitted on employees behalf						£ 3,100
Related party remaining obligation	£ 1,860
Due to Related Parties			£ 3,100
Related Party Cash proceeds received in exchange for Synergy Holdings				£ 1,250
Related Party- Outstanding obligation after cash proceeds retained and applied to balance				£ 1,860
Notes Receivable, Related Parties \| $		$ 368			$ 5,152

Quarterly Results (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Mar. 31, 2017

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2015

Effect of Fourth Quarter Events [Line Items]

Sales Revenue, Goods, Net

$ 333,124

$ 302,260

$ 292,216

$ 271,750

$ 318,438

$ 305,156

$ 274,145

$ 232,307

$ 1,199,350

$ 1,130,046

$ 1,047,805

Sales Revenue, Services, Net

348,065

344,514

354,199

366,628

371,839

313,532

215,752

207,595

1,413,406

1,108,718

802,458

Revenues

681,189

646,774

646,415

638,378

690,277

618,688

489,897

439,902

2,612,756

2,238,764

1,850,263

Cost of Goods Sold

173,855

152,879

155,110

142,698

174,642

165,575

148,088

129,856

624,542

618,161

584,210

Cost of Services

227,209

236,286

243,397

255,690

251,746

214,932

132,488

125,956

962,582

725,122

491,752

Cost of Revenue

401,064

389,165

398,507

398,388

426,388

380,507

280,576

255,812

1,587,124

1,343,283

1,075,962

Gross Profit

$ 280,125

$ 257,609

$ 247,908

$ 239,990

$ 263,889

$ 238,181

$ 209,321

$ 184,090

1,025,632

895,481

774,301

Gross Profit Percentage

41.10%

39.80%

38.40%

37.60%

38.20%

38.50%

42.70%

41.80%

Restructuring expenses

$ (5)

$ 18

$ 48

$ 154

$ 156

$ (194)

$ (56)

$ (726)

215

^[1]

(501)

^[1]

(759)

^[1]

Net Income (Loss) Attributable to Parent

$ 26,143

$ (4,996)

$ 40,416

$ 48,401

$ 57,740

$ 20,045

$ 8,687

$ 24,291

$ 109,965

$ 110,763

$ 135,064

Earnings Per Share, Basic

$ 0.31

$ (0.06)

$ 0.47

$ 0.56

$ 0.67

$ 0.26

$ 0.15

$ 0.41

$ 1.29

$ 1.57

$ 2.27

Earnings Per Share, Diluted

$ 0.31

$ (0.06)

$ 0.47

$ 0.56

$ 0.67

$ 0.26

$ 0.14

$ 0.40

$ 1.28

$ 1.56

$ 2.25

[1]	{F\|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOmMxNGZkMGNiMTNhYzQ3MmNhOGNkM2M4NjRiZmQ4YzE3fFRleHRTZWxlY3Rpb246M0RFQjBFNDgwRkUwMzgxRDMzNTYxNjZDNUYwOTA5M0QM}

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)
$ in Thousands

12 Months Ended

Mar. 31, 2017

Mar. 31, 2016

Mar. 31, 2015

Mar. 31, 2014

Valuation and Qualifying Accounts Disclosure [Line Items]

Allowance for Doubtful Accounts Receivable, Current

$ 10,357

$ 11,185

^[1]

$ 9,415

^[1]

$ 10,922

^[1]

Provision for Doubtful Accounts

^[1]

1,248

3,362

1,415

Allowance for trade accounts receivable charges to other accounts

^[1],[2]

(100)

217

Allowance for trade accounts receivable deductions

^[1],[3]

(2,087)

(1,492)

(3,139)

Inventory Valuation Reserves

17,854

18,707

17,597

15,986

Inventory Write-down

^[4]

(171)

1,146

Foreign currency translation and other adjustments

^[2]

(682)

(36)

1,534

Deferred Tax Assets, Valuation Allowance

16,366

16,435

14,380

12,541

Valuation Allowances and Reserves, Additions for Adjustments

(214)

4,439

(1,867)

Valuation Allowances and Reserves, Deductions

(3,869)

(4,535)

(322)

Liability for Claims and Claims Adjustment Expense, Property Casualty Liability

22,718

20,222

18,078

14,444

Supplemental Information for Property, Casualty Insurance Underwriters, Paid Claims and Claims Adjustment Expense

5,000

4,141

3,600

Incurred Claims, Property, Casualty and Liability

768

1,187

2,112

Incurred Claims, Property, Casualty and Liability

(3,272)

(3,184)

(2,078)

Other Accrued Liabilities, Current

$ 8

rebate program adjustment

^[5]

Accrued Sys 1 Rebate and Class Action

^[5]

Accrued System Rebate Other Charges

Loss Contingency Accrual, Carrying Value, Provision

(16)

(10)

Valuation Allowance of Deferred Tax Assets [Member]

Valuation and Qualifying Accounts Disclosure [Line Items]

Valuation Allowances and Reserves, Additions for Charges to Cost and Expense

$ 4,014

$ 2,151

$ 4,028

[1]	Net allowance for doubtful accounts and allowance for sales and returns.
[2]	Change in foreign currency exchange rates and acquired reserves.
[3]	Uncollectible accounts written off, net of recoveries.
[4]	Provision for excess and obsolete inventory, net of inventory written off.
[5]	{F\|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOmMxNGZkMGNiMTNhYzQ3MmNhOGNkM2M4NjRiZmQ4YzE3fFRleHRTZWxlY3Rpb246RTNGODU5MkNGRDYyQTlBNEYwODYxNjZDNUYwQUJEREMM}